<SEC-DOCUMENT>0001193125-23-039833.txt : 20230215
<SEC-HEADER>0001193125-23-039833.hdr.sgml : 20230215
<ACCEPTANCE-DATETIME>20230215092059
ACCESSION NUMBER:		0001193125-23-039833
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230215
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230215
DATE AS OF CHANGE:		20230215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		23633837

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 633-0300

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d644968d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ibrx="http://www.immunitybio.com/20230215" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-02-15_to_2023-02-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-02-15_to_2023-02-15">0001326110</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ibrx-20230215.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-02-15_to_2023-02-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-15</xbrli:startDate> <xbrli:endDate>2023-02-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-02-15_to_2023-02-15">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported):</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt:datemonthdayyearen">February&#160;15, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-02-15_to_2023-02-15">ImmunityBio, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-02-15_to_2023-02-15">001-37507</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-02-15_to_2023-02-15">43-1979754</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-02-15_to_2023-02-15">3530 John Hopkins Court</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-02-15_to_2023-02-15">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-02-15_to_2023-02-15">92121</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-02-15_to_2023-02-15">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-02-15_to_2023-02-15">633-0300</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-02-15_to_2023-02-15">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-02-15_to_2023-02-15">IBRX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-02-15_to_2023-02-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registered Direct Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, ImmunityBio,&#160;Inc. (the &#8220;Company&#8221;) entered into a stock purchase agreement (the &#8220;SPA&#8221;) with certain institutional investors (the &#8220;Investors&#8221;) for the purchase and sale of 14,072,615 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and warrants to purchase an additional 14,072,615 shares of Common Stock at an exercise price of $4.2636&#160;per share, for a purchase price of $3.5530 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0&#160;million before deducting placement agent fees and other estimated offering expenses. The warrants will become immediately exercisable after the issuance date and expire two&#160;years after the initial issuance date. The closing of the offering is expected to occur on or about February&#160;17, 2023, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, the Company also entered into a placement agency agreement (the &#8220;PAA&#8221;) with Jefferies LLC (the &#8220;Placement Agent&#8221;). Pursuant to the terms of the PAA, the Placement Agent has agreed to serve as our exclusive Placement Agent on a reasonable best efforts basis to arrange for the sale of the securities described above and the Company has agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds generated from the sale of such securities, less certain Company expenses to be reimbursed by the Placement Agent. The Placement Agent will not receive any fees for the exercise of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities are being offered and sold by the Company pursuant to a prospectus supplement and an accompanying prospectus forming part of a &#8220;shelf&#8221; registration statement <span style="white-space:nowrap">on&#160;Form&#160;S-3&#160;(Registration</span> <span style="white-space:nowrap">No.&#160;333-269608),&#160;including</span> a base prospectus, previously filed with the Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) on February&#160;7, 2023 and declared effective by the SEC on February&#160;9, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SPA and PAA contain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, the Placement Agent and the Investors, other obligations of the parties and termination provisions. The representations, warranties and covenants contined in the SPA and PAA were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is only a brief description of the material terms of the PAA, the Form of Common Stock Purchase Warrant and the SPA, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the PAA, the Form of Common Stock Purchase Warrant, and the SPA that are filed as Exhibits&#160;1.1, 4.1 and 10.1, respectively, to this Current Report on Form&#160;8-K and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legal opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. relating to the legality of the issuance and sale of the securities in the offering is filed as Exhibit&#160;5.1 to this Current&#160;Report <span style="white-space:nowrap">on&#160;Form&#160;8-K.</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;contains</span> forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;that</span> do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including our Quarterly Report on <span style="white-space:nowrap">Form&#160;10-Q&#160;for</span> the quarter ended September&#160;30, 2022, filed with the SEC on November&#160;9, 2022, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking information presented in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;is</span> not a guarantee of future events, and that actual events may differ materially from those described in or suggested by the forward-looking information contained in this Current Report on <span style="white-space:nowrap">Form&#160;8-K.&#160;In</span> addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of such terms and other similar terminology. Any forward-looking information presented herein is made only as of the date of this Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K,&#160;and</span> we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d)</span>&#160;&#160;&#160;&#160;<span style="font-style:italic">Exhibits</span>. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description of Exhibit</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex11.htm">Placement Agency Agreement by and between the Company and Jefferies, LLC, dated as of February&#160;15, 2023.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex41.htm">Form of Common Stock Purchase Warrant.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex51.htm">Legal Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex101.htm">Securities Purchase Agreement dated as of February&#160;15, 2023.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex51.htm">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit&#160;5.1).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d644968dex991.htm">Press Release dated February&#160;15, 2023.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Furnished herewith. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">IMMUNITYBIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: February&#160;15, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Sachs</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Sachs</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d644968dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLACEMENT AGENCY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;15, 2023 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc., a
Delaware corporation (the &#147;Company&#148;), proposes, subject to the terms and conditions of this Placement Agency Agreement (this &#147;Agreement&#148;) and the Securities Purchase Agreement (as defined below), to issue and sell to the
purchasers identified on the signature pages to the Securities Purchase Agreement (the &#147;Investors&#148;) (i) an aggregate of 14,072,615 shares (the &#147;Shares&#148;) of the Company&#146;s common stock, par value $0.0001 per share (the
&#147;Common Stock&#148;), and (ii)&nbsp;warrants to purchase up to an additional 14,072,615 shares of Common Stock (the &#147;Warrants&#148;), in an offering under its registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> as
amended (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-269608).</FONT> The Shares and Warrants will be issued separately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock issuable upon exercise of the Warrants are referred to herein as the &#147;Warrant Shares.&#148; The Shares, the Warrants and
the Warrant Shares are referred to herein, collectively, as the &#147;Securities.&#148; The Securities are more fully described in the Disclosure Package and the Prospectus. The Company desires to engage Jefferies LLC as the placement agent in
connection with such issuance and sale of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference herein to the Registration Statement, the Base Prospectus or the
Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> which were filed under the Exchange Act on or before the Effective Date of the
Registration Statement or the issue date of the Base Prospectus or the Prospectus, as the case may be; and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration
Statement, the Base Prospectus or the Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus or the
Prospectus, as the case may be, deemed to be incorporated therein by reference. Any reference herein to &#147;Registration Statement&#148; shall be deemed to include any abbreviated registration statement to register additional securities of the
Company under Rule 462(b) under the Securities Act. Certain terms used herein are defined in Section&nbsp;18 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby
confirms its agreement with you as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. Agreement to Act as Placement Agent</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement Jefferies LLC shall be the Company&#146;s exclusive placement agent (in such capacity, the &#147;Placement Agent&#148;), acting on a reasonable best efforts basis, in connection with the issuance and sale by the Company of the
Securities to the Investors in a proposed offering pursuant to the Registration Statement, with the terms of the offering to be subject to market conditions and negotiations among the Company, the Placement Agent and the prospective Investors (such
offering shall be referred to herein as the &#147;Offering&#148;). As compensation for services rendered, and provided that any of the Securities are sold to the Investors in the Offering, on the Closing Date (as defined in Section&nbsp;1(c) hereof)
of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offering, the Company shall pay to the Placement Agent an amount in the aggregate equal to 6.00% of the gross proceeds received by the Company from the sale of the Shares and the Warrants (the
&#147;Placement Fee&#148;). The Placement Agent will not receive any fees in connection with the exercise of the Warrants. The sale of the Securities shall be made pursuant to the securities purchase agreement in the form included as Exhibit A
hereto (the &#147;Securities Purchase Agreement&#148;) on the terms described on Exhibit B hereto. The Company shall have the sole right to accept offers to purchase the Securities and may reject any such offer in whole or in part. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Agreement shall not give rise to any commitment by the Placement Agent to purchase any of the Securities, and the Placement Agent
shall have no authority to bind the Company to accept offers to purchase the Securities. The Placement Agent shall act on a reasonable best efforts basis and does not guarantee that it will be able to raise new capital in the Offering. Prior to the
earlier of (i)&nbsp;the date on which this Agreement is terminated and (ii)&nbsp;the Closing Date, the Company shall not, without the prior written consent of the Placement Agent, solicit or accept offers to purchase Securities (other than pursuant
to the exercise of options to purchase Common Stock or vesting of restricted stock units (&#147;RSUs&#148;) that are outstanding under existing equity incentive plans at the date hereof) otherwise than through the Placement Agent in accordance
herewith. The Company acknowledges and agrees that the Placement Agent shall have no liability (in tort, contract or otherwise) to the Company, its affiliates or any other person for any losses, claims, damages and liabilities (including legal or
other expenses reasonably incurred in connection with investigating or defending the same) (each a &#147;Loss&#148; and, collectively, the &#147;Losses&#148;) arising from its own acts or omissions in performing its obligations as Placement Agent in
connection with the Offering, except for any such Losses that are finally judicially determined to have resulted primarily from its bad faith, gross negligence or willful misconduct in performing its services hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment of the purchase price for, and delivery of, the Securities shall be made at a closing (the &#147;Closing&#148;) remotely at 10:00
A.M. New York City time on February&nbsp;17, 2023, or at such time on such other date as may be agreed upon in writing by the Placement Agent and the Company (such date of payment and delivery being herein called the &#147;Closing Date&#148;). All
such actions taken at the Closing shall be deemed to have occurred simultaneously. No Shares and Warrants which the Company has agreed to sell pursuant to this Agreement and the Securities Purchase Agreement shall be deemed to have been purchased
and paid for, or sold by the Company, until such Shares and Warrants shall have been delivered to the Investors against payment therefor by the Investors. If the Company shall default in its obligations to deliver the Shares and Warrants to the
Investors whose offer it has accepted, the Company shall indemnify and hold the Placement Agent harmless against any loss, claim or damage incurred by the Placement Agent arising from or as a result of such default by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On the Closing and on each closing date of the purchase and sale of Warrant Shares, (i)&nbsp;the Company shall deliver, or cause to be
delivered, the Securities to the Investors or their designee, and the Investors shall deliver, or cause to be delivered, the purchase price for the Securities to the Company pursuant to the terms of the Securities Purchase Agreement and
(ii)&nbsp;the Company will wire the amounts owed to the Placement Agent as provided in this Agreement. Delivery of the Shares and Warrant Shares shall be made &#147;delivery versus payment&#148; through the facilities of The Depository Trust Company
(&#147;DTC&#148;) unless the Placement Agent shall otherwise instruct. The Warrants shall be delivered to the Investors in definitive form, registered in such names and in such denominations as the Investors shall request in writing not later than
the Closing Date. The Warrants will be made available for inspection by the Placement Agent on the business day prior to the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Securities shall be registered in such names and in such denominations as the
Investors, unless otherwise instructed by the Placement Agent, shall request by written notice to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.
Representations, Warranties and Agreements of the</B><B> </B><B>Company</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents, warrants and covenants to the
Placement Agent as of the date hereof, and as of the closing date, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Disclosure Package. The Disclosure Package as of the
Execution Time did not, and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the Placement Agent furnished to the Company
in writing by the Placement Agent expressly for use in such Disclosure Package, it being understood and agreed that the only such information furnished by the Placement Agent consists of the Placement Agent Information. No statement of material fact
included in the Prospectus has been omitted from the Disclosure Package and no statement of material fact included in the Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. There are no contracts or
other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Issuer Free Writing Prospectus. Other than the Registration Statement and the Prospectus, the Company (including its agents and
representatives, other than the Placement Agent in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as
defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives an &#147;Issuer Free Writing
Prospectus&#148;) other than any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act, each electronic road show and any other written communications approved in
writing in advance by the Placement Agent. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433 under the Securities Act) filed in
accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Disclosure Package, and did not, and as of the Closing, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or
warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to the Placement Agent furnished to the Company in writing by the Placement Agent
expressly for use in such Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished by the Placement Agent consists of the Placement Agent Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Registration Statement and Prospectus. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act. Each of the Registration Statement and any post-effective amendment thereto has become effective under the Securities Act. The Company has complied with each request (if any) from the Commission for additional information. No
stop order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offering of the Securities has been initiated or threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the
Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing, the Prospectus will comply in all material
respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the Placement Agent furnished to the Company in writing by the
Placement Agent expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by the Placement Agent consists of the Placement
Agent Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Incorporated Documents. The documents incorporated by reference in the Registration Statement, the Prospectus and
the Disclosure Package, when they were filed with the Commission, conformed or will conform, as the case may be, in all material respects to the requirements of the Exchange Act and such documents did not and will not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters.</FONT></FONT> The Company (i)&nbsp;has not alone
engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Due Authorization of Placement Agency Agreement. This Agreement has been duly authorized, executed and delivered by the Company. The
Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the consummation by it of the transactions contemplated hereby has been duly and validly taken. This Agreement constitutes a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Due Authorization of Securities Purchase Agreement. The Securities Purchase Agreement has been duly authorized, executed and delivered by
the Company. The Company has full right, power and authority to execute and deliver the Securities Purchase Agreement and to perform its obligations thereunder; and all action required to be taken for the due and proper authorization, execution and
delivery by it of the Securities Purchase Agreement and the consummation by it of the transactions contemplated thereby has been duly and validly taken. The Securities Purchase Agreement constitutes a valid and legally binding agreement of the
Company enforceable against the Company in accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Due Authorization of Securities. (i)&nbsp;The Shares have been
duly and validly authorized, and, when issued and delivered to and paid for by the Investors pursuant to the Securities Purchase Agreement, will be validly issued, fully paid and nonassessable and conform to the description thereof contained in the
Registration Statement, the Disclosure Package and the Prospectus; (ii)&nbsp;The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants have been duly and validly authorized and, when executed and delivered by the Company in accordance with the Securities Purchase Agreement, will constitute valid and legally binding
agreements of the Company enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by equitable
principles relating to enforceability, and will conform to the description thereof contained in the Registration Statement, the Disclosure Package and Prospectus; (iii)&nbsp;The Warrant Shares have been duly authorized and reserved for issuance and,
when issued and delivered to and paid for by the Investor upon valid exercise of the Warrants and subject to the terms and conditions set forth in the applicable Securities Purchase Agreement, will be validly issued, fully paid and nonassessable,
and will not be subject to preemptive or similar rights. The Warrant Shares, when so issued, will conform in all material respects to the description thereof contained in the Registration Statement, the Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Ineligible Issuer Status. The Company is not an &#147;ineligible issuer&#148; in connection with the offering of the Securities pursuant to
Rules 164, 405 and 433 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Statistical and Market-Related Data. Nothing has come to the attention of the Company
that has caused the Company to believe that the statistical and market-related data included in the Registration Statement, Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material
respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has
established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;comply with the requirements
of the Exchange Act; (ii)&nbsp;have been designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and principal financial officer
by others within those entities; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. The Company maintains a system of internal control over financial reporting (as such term is defined in
Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that complies with the requirements of the Exchange Act applicable to the Company and has been designed by the Company&#146;s principal executive officer and principal
financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles in the United States (&#147;GAAP&#148;). Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial
reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial
reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) No Applicable Registration or Other Similar Rights. There are no persons with registration
or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement and any Securities Purchase Agreement, except for such rights as have been
duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) No Material Adverse Change. Except as otherwise disclosed in the Registration Statement, Disclosure Package and the
Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, Disclosure Package and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that could be expected to
result in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets or liabilities, whether or not arising
from transactions in the ordinary course of business, of the Company and its subsidiaries (the &#147;Subsidiaries&#148;), considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement
or perform its obligations hereunder (any such change being referred to herein as a &#147;Material Adverse Change&#148;); (ii) the Company and the Subsidiaries, considered as one entity, have not incurred any material liability or obligation,
indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute
or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business;
and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or the Subsidiaries and there has been no dividend or distribution of any kind declared,
paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of the Subsidiaries of any class of
capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Independent Accountants. Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial
statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, Disclosure Package and the Prospectus, is (i)&nbsp;an independent registered public accounting
firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;PCAOB&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule
<FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or
revoked and who has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Financial Statements. The financial statements filed with the
Commission as a part of the Registration Statement, Disclosure Package and the Prospectus present fairly the consolidated financial position of the Company and the Subsidiaries (including NantCell, Inc.) as of the dates indicated and the results of
their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity GAAP applied on a consistent basis throughout the periods involved, except as may be
expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and
has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement, Disclosure Package or the
Prospectus. The combined consolidated financial statements of the Company and the Subsidiaries and the related notes thereto included in the Registration Statement, Disclosure Package or the Prospectus present fairly the information contained
therein, have been prepared in all material respects in accordance with the Commission&#146;s rules and guidelines and have been properly presented on the bases described therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)
Company&#146;s Accounting System. The Company and each of the Subsidiaries make and keep books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access
to assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals
and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, Disclosure Package and the Prospectus
fairly presents the information called for in all material respects and is prepared in all material respects in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) Incorporation and Good Standing of the Company. Each of the Company and each of the Subsidiaries has been (i)&nbsp;duly organized and is
validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Registration Statement, Disclosure Package
and the Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to
require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change, and each subsidiary
of the Company required to be listed in the Registration Statement has been so listed in the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Capitalization
and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, Disclosure Package and the Prospectus (other than for subsequent issuances, if any, pursuant to
employee benefit plans described in the Base Prospectus or the Prospectus or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, Disclosure Package and the Prospectus). The Common Stock
(including the Shares) conform in all material respects to the description thereof contained in the Base Prospectus and the Prospectus. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and
nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or
purchase securities of the Company, except for such rights as have been duly waived. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities
convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Registration Statement, Disclosure Package and the Prospectus and except for such rights as have been duly waived. The
descriptions of the Company&#146;s stock option, stock bonus, stock purchase and other stock or equity incentive plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, Disclosure Package
and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights. Except as described in the Registration Statement, Disclosure Package and the Prospectus, all of the
issued and outstanding capital stock of, or other equity interests in, each Subsidiary has been duly authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and is owned by the Company, directly or
through other subsidiaries of the Company, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) Stock Exchange Listing. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and is listed on the
Nasdaq Global Select Market (&#147;Nasdaq&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq,
nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects with all applicable listing
requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments.
Neither the Company nor any of the Subsidiaries is (i)&nbsp;in violation of its certificate of incorporation or bylaws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any
court or governmental agency or body having jurisdiction over the Company or any of the Subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained
in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such
defaults as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) No Further
Authorizations or Approvals Required. The Company&#146;s execution, delivery and performance of this Agreement, the Securities Purchase Agreement, and the Warrants, and the consummation of the transactions contemplated hereby, by the Warrants, and
by the Registration Statement, Disclosure Package and the Prospectus and the issuance and sale of the Securities (including the use of proceeds from the sale of the Securities as described in the Registration Statement, Disclosure Package and the
Prospectus under the caption &#147;Use of Proceeds&#148;) will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A)&nbsp;any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which the Company or any of the Subsidiaries is bound or to which any of the property or assets of the Company or any of the Subsidiaries is subject,
(B)&nbsp;the certificate of incorporation or bylaws (or other applicable organizational document) of the Company or any of the Subsidiaries, or (C)&nbsp;any statute or any judgment, order, rule or regulation of any court or governmental agency or
body having jurisdiction over the Company or any of the Subsidiaries or any of their properties, except, in the case of clauses (A)&nbsp;and (C), for such defaults, breaches, or violations that would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) No Conflicts. No consent, approval, authorization or other order of, or registration,
qualification or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by
the Registration Statement, Disclosure Package and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or
blue sky laws or FINRA (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) No Material Actions or Proceedings. Other than as set forth in the Registration Statement,
Disclosure Package and the Prospectus, there are no legal or governmental proceedings pending to which the Company or any of the Subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is a party or of which any
property or assets of the Company or any of the Subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is the subject which, if determined adversely to the Company or any of the Subsidiaries (or such officer or
director), would individually or in the aggregate have a Material Adverse Change; and, to the Company&#146;s knowledge, no such proceedings are threatened by governmental authorities or others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Intellectual Property Rights. The Company and the Subsidiaries own, possess or license
adequate rights to use all material trademarks, service marks, trade names, domain names and other source identifiers, and all goodwill associated with the foregoing, inventions, patents, copyrights and copyrightable works, licenses, approvals,
technology, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures, and other intellectual property rights (including all registrations
and applications for registration of the foregoing, as applicable) (collectively, &#147;Intellectual Property Rights&#148;) used in, held for use in or necessary for the conduct of their respective businesses as currently conducted and as proposed
in the Registration Statement, Disclosure Package or the Prospectus to be conducted. To the knowledge of the Company: (1)&nbsp;neither the Company nor any of the Subsidiaries has materially infringed, misappropriated or otherwise violated the
Intellectual Property Rights of any third party, and (2)&nbsp;neither the manufacture of, nor the use or sale of, any of the Company&#146;s or the Subsidiaries&#146; product candidates described in the Registration Statement, Disclosure Package or
the Prospectus materially infringe, misappropriate or otherwise violate the Intellectual Property Rights of any third party. Except as disclosed in the Registration Statement, Disclosure Package and the Prospectus, to the knowledge of the Company,
there are no rights of third parties (including any liens or encumbrances) to any of the Intellectual Property Rights owned or purported to be owned by the Company or any of the Subsidiaries. Except as disclosed in the Registration Statement,
Disclosure Package and the Prospectus, there is no pending or threatened in writing action, suit, proceeding or claim by any third party (i)&nbsp;challenging the Company&#146;s or any of the Subsidiaries&#146; rights in or to, or alleging a
violation of any of the terms of, any of their owned or licensed Intellectual Property Rights; (ii)&nbsp;alleging that the Company or any of the Subsidiaries has infringed, misappropriated or otherwise violated any Intellectual Property Rights of
any third party; or (iii)&nbsp;challenging the validity, scope or enforceability of any Intellectual Property Rights owned by or exclusively licensed to the Company or any of the Subsidiaries, and in the case of each of (i), (ii) and (iii), the
Company is unaware of any facts that would form a reasonable basis for any such action, suit, proceeding or claim. Except as disclosed in the Registration Statement, Disclosure Package and the Prospectus to the Company&#146;s knowledge, there is no
material infringement, misappropriation, breach or default, or other violation by others of any Intellectual Property Rights owned by or exclusively licensed to the Company or any of the Subsidiaries. The Company and the Subsidiaries have at all
times taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property Rights, the value of which to the Company or any of the Subsidiaries is contingent upon maintaining the
confidentiality thereof, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. All founders, current and former employees, consultants, and other parties involved in the development of
Intellectual Property Rights for the Company and the Subsidiaries have signed confidentiality and invention assignment agreements with the Company or a Subsidiary pursuant to which the Company or any of the Subsidiaries either (x)&nbsp;has obtained
ownership of and is the exclusive owner of such Intellectual Property Rights, or (y)&nbsp;has obtained a valid and unrestricted right to exploit such Intellectual Property Rights, sufficient for the conduct of the business as currently conducted and
as proposed in the Registration Statement, Disclosure Package and the Prospectus to be conducted, except where the failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) All Necessary Permits, etc. Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the
Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in
the Registration Statement, Disclosure Package or the Prospectus (&#147;Permits&#148;). Neither the Company nor any of the Subsidiaries is in violation of, or in default under, any of the Permits, or has received any notice of violation of or
default under or proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate, authorization or permit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) Title to Properties. The Company and the Subsidiaries have good and marketable title in
fee simple to all real property and good and marketable title to all personal property owned by them (other than with respect to Intellectual Property Rights (as defined above), which for the avoidance of doubt is addressed exclusively in
Section&nbsp;2(y)), in each case free and clear of all liens, encumbrances and defects except such as are described in the Registration Statement, Disclosure Package and Prospectus or such as do not materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries; any real property and buildings held under lease by the Company and the Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) Tax Law Compliance. (i)&nbsp;The Company and each of the Subsidiaries have filed all federal, state, local and foreign tax returns
required to be filed or have requested extensions thereof and have paid all taxes required to be paid thereon (except for cases in which the failure to file such tax returns or pay such taxes would not reasonably be expected to have a Material
Adverse Change), (ii) the Company and each of the Subsidiaries have no liability for unpaid taxes, except as currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company
or where such liability would not reasonably be expected to have a Material Adverse Change and (iii)&nbsp;no tax deficiency has been determined adversely to the Company or any of the Subsidiaries, and neither the Company nor any of the Subsidiaries
has received written notice of, or has knowledge of, any tax deficiency that could reasonably be expected to be determined adversely to the Company or the Subsidiaries, in each case which could reasonably be expected to have a Material Adverse
Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) Company Not an &#147;Investment Company.&#148; The Company is not, and will not be, either after receipt of payment for the
Securities or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, Disclosure Package or the Prospectus, required to register as an &#147;investment company&#148; under the
Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) Insurance. Except as otherwise disclosed in the
Registration Statement, Disclosure Package or Prospectus, each of the Company and the Subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such
risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and the Subsidiaries against theft, damage, destruction, acts of
vandalism and earthquakes and policies covering the Company and the Subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of the Subsidiaries will not be able (i)&nbsp;to
renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not be
expected to result, individually or in the aggregate, in a Material Adverse Change. Neither the Company nor any of the Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied except as would not be
expected to result, individually or in the aggregate, in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) No Price Stabilization or Manipulation;
Compliance with Regulation M. Neither the Company nor any of the Subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Common Stock or of any
&#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;Regulation M&#148;)) with respect to the Common Stock, whether to facilitate the sale or resale of the Shares, the Warrant Shares or otherwise, and
has taken no action which would directly or indirectly violate Regulation M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) Related Party Transactions. No relationship, direct or indirect, exists between the
Company, on the one hand, and the directors, officers, or stockholders of the Company, on the other, that is required by the Act to be described in the Registration Statement, Disclosure Package and the Prospectus and that is not so described in
such documents. There are no related-party transactions involving the Company or any of the Subsidiaries or any other person required to be described in the Registration Statement, Disclosure Package or the Prospectus which have not been described
as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) FINRA Matters. All of the information provided to the Placement Agent or to counsel for the Placement Agent by the
Company, its counsel, its officers and directors in connection with the offering of the Securities is true, complete, correct and compliant with Financial Industry Regulatory Authority, Inc.&#146;s (&#147;FINRA&#148;) rules and any letters, filings
or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act
specified in FINRA Rule 5110(h)(1)(C). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) No Unlawful Contributions or Other Payments. Except as otherwise disclosed in the Registration
Statement, Disclosure Package or Prospectus, neither the Company nor any of the Subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any
official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) Compliance with Environmental Laws. The Company and the Subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;Environmental Laws&#148;), (ii) have received all
permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably
be expected to have a Material Adverse Change. There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT>
closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, reasonably be
expected to have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) ERISA Compliance. Each employee benefit plan, within the meaning of Section&nbsp;3(3) of
the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;) that the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is under common control with the Company within the meaning of
Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) sponsors or maintains (each, a &#147;Plan&#148;) has been maintained, in all material respects, in compliance with its terms and the requirements of any
applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) Brokers. Except as described in the Registration Statement, Disclosure Package and
Prospectus, the Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any underwriter for a brokerage commission, finder&#146;s fee
or like payment in connection with the offering and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) No Outstanding Loans or Other Extensions of Credit. The
Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by
Section&nbsp;13(k) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Compliance with Laws. The Company and the Subsidiaries have been and are in compliance with
all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Dividend Restrictions. Except as disclosed in the Registration Statement, Disclosure Package and Prospectus, no subsidiary of the Company
is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the
Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Anti-Corruption and Anti-Bribery Laws. None of the Company or any of the Subsidiaries nor, to the knowledge of the Company, any director,
officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company or any of the Subsidiaries has (i)&nbsp;made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful
expense or taken any act in furtherance thereof; (ii)&nbsp;made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977 (the
&#147;FCPA&#148;), the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law. The Company and the Subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates, have conducted their
respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Money Laundering Laws. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with the
requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the applicable anti-money
laundering laws of the various jurisdictions in which the Company and the Subsidiaries conduct business (collectively, the &#147;Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any of the Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) Except as disclosed in the Registration Statement, Disclosure Package and Prospectus, the Company and each of the Subsidiaries possess all
licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations (collectively, &#147;Authorizations&#148;) issued by, and have made all declarations and filings with, the appropriate federal, state,
local or foreign governmental or regulatory authorities that are required for the ownership or lease of its property or the conduct of their respective businesses as currently conducted and described in the Registration Statement, Base
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus, Disclosure Package or Prospectus, including, without limitation, from the U.S. Food and Drug Administration (the &#147;FDA&#148;), the European Medicines Agency (the &#147;EMA&#148;)
or similar foreign, state, and local governmental or regulatory authorities, including any government medical device regulatory agency or institutional review board (collectively, the &#147;Regulatory Authorities&#148;), such Authorizations are
valid and in full force and effect, and the Company is not in violation of any such Authorizations, except, in each case, as would not, individually or in the aggregate, have a Material Adverse Change; and the Company has not received notice of any
revocation of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Except as
disclosed in the Registration Statement, Disclosure Package and Prospectus, the Company and each of the Subsidiaries (i)&nbsp;have operated and currently operate their respective businesses in compliance with all statutes, rules and regulations
applicable to them and their respective businesses, including, without limitation, (A)&nbsp;requirements governing investigational drugs and biologics under the U.S. Federal Food, Drug and Cosmetic Act and rules and regulations thereunder, including
regulations relating to Good Clinical Practices and Good Laboratory Practices for studies and tests that are submitted to regulatory authorities to support regulatory approvals, (B)&nbsp;the U.S. Animal Welfare Act and rules and regulations
thereunder, (C)&nbsp;the U.S. Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the U.S. Civil
False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C.
Section&nbsp;1320d et seq.), the exclusion laws, the statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; (D)&nbsp;the Standards for Privacy
of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section&nbsp;17921 et seq.), and the regulations promulgated thereunder and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or any other law or regulation the purpose of which is to protect the privacy of
individuals or prescribers; (E)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; (F)&nbsp;the U.S. Controlled Substances Act
(21 U.S.C. Section&nbsp;801 et seq.); and (G)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company and the ownership, testing, development, registration, licensure, manufacture,
packaging, processing, use, recordkeeping, filing of reports, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product or product candidate under development, manufactured or distributed
by or on behalf of the Company or such subsidiary (collectively, &#147;Applicable Laws&#148;), except where the failure to so operate or be in compliance would not reasonably be expected to have a Material Adverse Change; (ii)&nbsp;have not received
any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice alleging or asserting material noncompliance with any Applicable Laws or Authorizations or otherwise providing notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Regulatory Authority, any court or arbitrator or other governmental authority or agency; (iii)&nbsp;have not received any recalls, field
notifications, field corrections, market withdrawals, &#147;dear doctor&#148; letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company&#146;s
products or product candidates; (iv)&nbsp;have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws,
that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission) and no material deficiencies regarding compliance
with applicable law have been asserted by any applicable Regulatory Authority with respect to any such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments; and (v)&nbsp;are not a party to any
corporate integrity agreements, monitoring agreements, consent decrees, settlement orders or similar agreements with or imposed by any governmental or regulatory authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;(i) Except as disclosed in the Registration Statement, Disclosure Package and Prospectus, any preclinical studies and clinical trials
conducted by the Company or any of the Subsidiaries and, to the knowledge of the Company, any preclinical studies and clinical trials conducted on behalf of the Company or the Subsidiaries or in which the Company or the Subsidiaries have
participated for the purposes of supporting a regulatory filing or application submitted to a Regulatory Authority, were, and if still pending, are, being conducted in all material respects in accordance with approved study protocols and Applicable
Laws, including those of the FDA and other regulatory authorities, to which the Company and the Subsidiaries are subject; (ii)&nbsp;the descriptions of the results of such studies, tests and trials contained in the Registration Statement, Disclosure
Package and Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trial; (iii)&nbsp;neither the Company nor any of the Subsidiaries have received any notices or correspondence
from the FDA, any other Regulatory Authority or any other governmental agency, institutional review board, ethics committee or other similar entity requiring, or would reasonably be expected to result in a requirement for, the termination,
suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of the Subsidiaries, nor is the Company aware of any facts that would form a reasonable basis for any such
termination, suspension or modification; and (iv)&nbsp;except to the extent disclosed in the Registration Statement, Disclosure Package or Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company
believes reasonably call into question the study, test or trial results described or referred to in the Registration Statement, Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) Neither the Company nor any of the Subsidiaries, nor, to the knowledge of the Company, any of its or any of the Subsidiaries&#146;
officers, directors or managing employees (as defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-5(b)),</FONT> is or has been excluded, suspended or debarred from participation in any Federal Health Care Program, (as defined at 42
U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7(b)(f)),</FONT> debarred by FDA or comparable authorities pursuant to 21 U.S.C. &#167; 335a or similar laws, or made subject to any pending or, to the knowledge of the Company, threatened action
which could reasonably be expected to result in such exclusion, suspension or debarment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) The Company&#146;s manufacturing facilities
and operations and, to the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers, are operated in compliance in all material respects with all Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) Sanctions. None of the Company or any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or
affiliate of the Company or any of the Subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department
of the Treasury (&#147;OFAC&#148;), or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, His Majesty&#146;s Treasury, the
United Nations Security Council, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company or any of the Subsidiaries located, organized or resident in a country or territory that is the subject or target of
Sanctions (including, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic or
any other regions of Ukraine as may be identified by the Secretary of the Treasury, in consultation with the Secretary of State, pursuant to Executive Order 14065, Crimea, Cuba, Iran, North Korea and Syria), and the Company will not directly or
indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or
business with any person, or in any country or territory, that, at the time of such funding, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating
in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; and for the past five years, the Company and the Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or target of Sanctions or with any sanctioned country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) Sarbanes-Oxley. The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002
and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) Duties, Transfer Taxes, Etc. No stamp or other issuance or transfer taxes or
duties and no capital gains, income, withholding or other taxes are payable by the Placement Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of
this Agreement by the Company or the sale and delivery by the Company of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) Cybersecurity. (i)&nbsp;Except as disclosed in
the Registration Statement, Disclosure Package and the Prospectus, (x)&nbsp;to the Company&#146;s knowledge, there has been no material security breach or other material compromise of any of the Company&#146;s or the Subsidiaries&#146; information
technology and computer systems, networks, hardware, software, or confidential, personally identifiable, or personal data (including any such data of their respective customers, employees, suppliers, vendors or other third parties collected,
processed, stored, maintained or otherwise used by or on behalf of the Company or the Subsidiaries) (collectively, &#147;IT Systems and Data&#148;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and have no knowledge of any
event or condition that would reasonably be expected to result in, any material security breach or other material compromise to their IT Systems and Data; and (ii)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery
technology consistent with industry standards and practices, except as would not, in the case of clauses (i)&nbsp;or (ii), individually or in the aggregate, have a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) Compliance with Data Privacy Laws. The Company and the Subsidiaries are, and at all prior times were, in material compliance with all
applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, relating to the use, processing, privacy and security of IT Systems and Data and to the protection of
such IT Systems and Data from unauthorized use, access, misappropriation or modification, including without limitation HIPAA, and the Company and the Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since
May&nbsp;25, 2018, have been and currently are in compliance with, the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679) (collectively, the &#147;Privacy Laws&#148;). To ensure compliance with the Privacy Laws, the
Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection,
storage, use, disclosure, handling, processing, and analysis of its IT Systems and Data (the &#147;Policies&#148;). The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the
Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any
obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) Other Underwriting Agreements. The Company is not a party to any agreement with an
agent or underwriter for any &#147;at the market&#148; or continuous equity transaction other than that certain Open Market Sale Agreement, dated as of April&nbsp;30, 2021, by and between the Company and Jefferies LLC, and no sales of Common Stock
are pending thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) The statements set forth, or incorporated by reference, in the Registration Statement, Disclosure Package
and the Prospectus under the caption &#147;Description of our Capital Stock,&#148; insofar as they purport to constitute a summary of the terms of the Common Stock, and under the captions &#147;Risk Factors&#151;Risks Related to Government
Regulation,&#148; &#147;Risk Factors&#151;Risks Related to Intellectual Property,&#148; &#147;Business of ImmunityBio&#151;Intellectual Property,&#148; &#147;Business of ImmunityBio&#151;Government Regulation,&#148; &#147;Business of
ImmunityBio&#151;Intellectual Property&#148; and &#147;Plan of Distribution,&#148; insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. Covenants</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Placement Agent as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Required Filings. The Company will file the Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A,
430B or 430C under the Securities Act, as applicable, and will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or
information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is
required in connection with the offering or sale of the Securities and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Placement Agent in New York City prior
to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Placement Agent may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Delivery of Copies. The Company will deliver, without charge, or make available (i)&nbsp;to the Placement Agent, two signed copies of the
Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to the Placement Agent (A)&nbsp;a conformed copy
of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto
and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Placement Agent may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of
the public offering of the Securities as in the opinion of counsel for the Placement Agent a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act or a similar
rule) in connection with sales of the Securities by the Placement Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before making, preparing,
using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Disclosure Package or the Prospectus, the Company will furnish to the
Placement Agent and counsel for the Placement Agent a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing
Prospectus or file any such proposed amendment or supplement to which the Placement Agent reasonably objects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notice to the Placement
Agent. The Company will advise the Placement Agent promptly, and confirm such advice in writing, (i)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Prospectus
if such post-effective amendment is filed prior to the Closing Date; (ii)&nbsp;of the time and date when any post-effective amendment to the Registration Statement becomes effective if such post-effective amendment is filed prior to the Closing
Date; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other
request by the Commission for any additional information including, but not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication;
(iv)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any of the Disclosure Package or the
Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (v)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which
the Prospectus, any of the Disclosure Package or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing when the Prospectus, the Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; (vi)&nbsp;of the receipt by the Company of any notice of
objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any
suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such
order suspending the effectiveness of the Registration Statement, preventing or suspending the use of the Disclosure Package or the Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will obtain as
soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Ongoing Compliance. (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or
development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will immediately notify the
Placement Agent thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Placement Agent and to such dealers as the Placement Agent may designate such amendments or supplements to the
Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and
incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing
(i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Disclosure Package is delivered to a purchaser, not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misleading or (ii)&nbsp;it is necessary to amend or supplement the Disclosure Package to comply with law, the Company will immediately notify the Placement Agent thereof and forthwith prepare
and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Placement Agent and to such dealers as the Placement Agent may designate such amendments or supplements to the Disclosure Package (or any
document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the
Disclosure Package is delivered to a purchaser, be misleading or so that the Disclosure Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Blue Sky
Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Placement Agent shall reasonably request and will continue such qualifications in effect so long as required
for distribution of the Securities; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to
so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Earning Statement. The Company will make generally available to its security holders and the Placement Agent as soon as practicable an
earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company
occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Use of Proceeds. The Company
will apply the net proceeds from the sale of the Securities as described in each of the Registration Statement, the Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No Stabilization. Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any action designed to or that
could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities and will not take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities
contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Exchange Listing. The Company will use its reasonable best efforts to list for quotation the Shares and Warrant
Shares on Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Reports. So long as the Securities are outstanding, the Company will furnish to the Placement Agent, as soon as they
are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities
exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Placement Agent to the extent they are filed on the Commission&#146;s Electronic Data Gathering,
Analysis, and Retrieval system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Record Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain
copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. Costs and Expenses.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay all costs and
expenses incident to the Company&#146;s obligations under this Agreement and in connection with the transactions contemplated hereby, including but not limited to costs and expenses of or relating to (i)&nbsp;the preparation, printing, filing,
delivery and shipping of the Registration Statement, any issuer free writing prospectus and the Prospectus, and any amendment or supplement to any of the foregoing and the printing and furnishing of copies of each thereof to the Placement Agent and
dealers (including costs of mailing and shipment), (ii) the registration, issue, sale and delivery of the Securities including any stock or transfer taxes and stamp or similar duties payable upon the sale, issuance or delivery of the Securities and
the printing, delivery, shipping of the certificates representing the Securities, (iii)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (iv)&nbsp;fees, disbursements and other charges of counsel to the Company,
(v)&nbsp;listing fees, if any, for the listing or quotation of the Shares and Warrant Shares on the Nasdaq, (vi)&nbsp;fees and disbursements of the Company&#146;s auditor incurred in delivering the letters described in Section&nbsp;5(i) hereof, and
(viii)&nbsp;the costs and expenses of the Company in connection with the marketing of the Offering and the sale of the Securities to prospective investors including, but not limited to, those related to any presentations or meetings undertaken in
connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. Conditions of Placement Agent</B><B> </B><B>Obligations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Placement Agent hereunder are subject to the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No Stop Orders. Prior to the Closing: (i)&nbsp;no stop order suspending the effectiveness of the Registration Statement shall have been
issued under the Securities Act and no proceedings initiated under Section&nbsp;8(d) or 8(e) of the Securities Act for that purpose shall be pending or threatened by the Commission, and (ii)&nbsp;any request for additional information on the part of
the Commission (to be included in the Registration Statement, the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Placement Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No Section&nbsp;8A Proceedings. No stop order suspending the qualification of the Registration Statement shall have been issued by the
Commission and no proceedings for that purpose or pursuant to Section&nbsp;8A of the Securities Act shall be pending or, to the knowledge of the Company, shall be threatened or contemplated by the Commission at or prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Action Preventing Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or
issued by any governmental agency or body which would, as of the Closing Date, prevent the issuance or sale of the Securities; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction
shall have been issued as of the Closing Date which would prevent the issuance or sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Objection of Placement
Agent. No prospectus or amendment or supplement to the Registration Statement shall have been filed to which the Placement Agent shall have objected in writing, which objection shall not be unreasonable. The Placement Agent shall not have advised
the Company that the Registration Statement or the Prospectus, or any amendment thereof or supplement thereto, contains, in the reasonable opinion of counsel for the Placement Agent, an untrue statement of fact which, in their reasonable opinion, is
material, or omits to state a fact which, in their reasonable opinion, is material and is required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Prior to the Closing, there shall not have occurred any material adverse
change in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations of the Company and its subsidiaries taken as a whole from that set forth in the Prospectus that makes it, in the
Placement Agent judgment, impracticable to market the Securities on the terms and in the manner contemplated in the Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) There shall not have occurred any of the following: (i)&nbsp;trading generally shall have been suspended or materially
limited on or by any of the New York Stock Exchange or the Nasdaq; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak
or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Placement Agent, is material and adverse and makes it impracticable or inadvisable to
proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms and in the manner contemplated by this Agreement and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Representations and Warranties. Each of the representations and warranties of the Company contained herein shall be true and correct when
made and on and as of the Execution Time and the Closing Date, as if made on such date (except that those representations and warranties that address matters only as of a particular date shall remain true and correct as of such date), and all
covenants and agreements herein contained to be performed on the part of the Company and all conditions herein contained to be fulfilled or complied with by the Company at or prior to the Closing Date shall have been duly performed, fulfilled or
complied with. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of U.S. Counsel to the Company. The Placement Agent
shall have received from Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., counsel to the Company, such counsel&#146;s written opinion and negative assurance letter, each addressed to the Placement Agent and dated the Closing Date in form and
substance reasonably satisfactory to the Placement Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Opinions of Intellectual Property Counsel for the Company. The Placement
Agent shall have received from Kilpatrick Townsend&nbsp;&amp; Stockton LLP, Leydig, Voit&nbsp;&amp; Mayer, Ltd., Lucas&nbsp;&amp; Mercanti LLP, Newport IP, LLC, Sheridan Ross P.C., Umberg/Zipser LLP and Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
P.C., each intellectual property counsel for the Company, such counsel&#146;s written opinion, each addressed to the Placement Agent and dated the Closing Date in form and substance reasonably satisfactory to the Placement Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of U.S. Counsel to the Placement Agent. The Placement Agent shall have
received from Goodwin Procter LLP, counsel to the Placement Agent, such counsel&#146;s written opinion and negative assurance letter, each addressed to the Placement Agent and dated the Closing Date, in form and substance reasonably satisfactory to
the Placement Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Comfort Letter. The Placement Agent shall have received, from Ernst&nbsp;&amp; Young LLP, letters dated,
respectively, the date of the Securities Purchase Agreement and the Closing Date, and addressed to the Placement Agent in customary forms reasonably satisfactory to the Placement Agent, which letters shall cover, without limitation, the various
financial disclosures contained in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) CFO Certificate. On the date of this Agreement and on the Closing Date, the Company
shall have furnished to the Placement Agent a certificate, dated the respective dates of delivery thereof and addressed to the Placement Agent, of its chief financial officer with respect to certain financial data contained in the Disclosure Package
and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Placement Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Officers&#146; Certificate. The Placement Agent shall have received on the Closing Date a certificate of the Company, addressed to the
Placement Agent and dated the Closing Date, signed by the Chief Executive Officer and the principal financial or accounting officer of the Company to the effect that the signers of such certificate have carefully examined the Registration Statement,
Disclosure Package and Prospectus and any supplements or amendments thereto, as well as each electronic road show used in connection with the offering of the Securities, and this Agreement and that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) each of the representations, warranties and agreements of the Company in this Agreement were true and correct when
originally made and are true and correct as of the Execution Time and the Closing Date (except that those representations and warranties that address matters only as of a particular date shall remain true and correct as of such date); and the
Company has complied with all agreements and satisfied all the conditions on its part required under this Agreement to be performed or satisfied at or prior to the Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no stop order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof or
the qualification of the Securities for offering or sale, nor suspending or preventing the use of the Prospectus shall have been issued, and no proceedings for that purpose shall be pending or to their knowledge, threatened by the Commission or any
state or regulatory body; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) since the date of the most recent financial statements included in the Prospectus
(exclusive of any supplement thereto), there has been no material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations of the Company and its subsidiaries taken as
a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Prospectus (exclusive of any supplement thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Other Filings with the Commission. The Company shall have prepared and filed with the Commission a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> with respect to the transactions contemplated hereby meeting all of the requirements of the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Exchange Listing. The Company shall have submitted a Listing of Additional Shares Notification Form to Nasdaq with respect to the Shares
and Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Additional Documents. Prior to the Closing Date, the Company shall have furnished to the Placement Agent such
further information, certificates and documents as the Placement Agent may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Securities Purchase Agreement. On or
prior to the Closing, the Company shall have furnished to the Placement Agent executed copies of the Securities Purchase Agreement entered into by the Company and Investors for the sale of the Placement Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents required to be delivered by this Section&nbsp;5 shall be delivered through the
electronic exchange of documents and signatures or as otherwise agreed between the parties to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters,
evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Placement Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. Indemnification and Contribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Indemnification of the Placement Agent. The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates, directors,
officers and employees, and agents who have or who are alleged to have participated in the distribution of the Securities as Placement Agent and each person who controls the Placement Agent within the meaning of either the Securities Act or the
Exchange Act against any and all losses, claims, damages, liabilities or actions, joint or several, to which they or any of them may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at
common law or otherwise (i)&nbsp;relating to, arising out of or in connection with the services performed pursuant to this Agreement, the transaction contemplated hereby or the Placement Agent role in connection therewith; provided, however, that
the Company will not be responsible for any losses, claims, damages or liabilities (or expenses relating thereto) under this clause (i)&nbsp;that are finally judicially determined to have resulted from the willful misconduct, bad faith or gross
negligence of the Placement Agent or (ii)&nbsp;insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement as originally filed or in any amendment thereof, or in the Base Prospectus, the Prospectus, any Issuer Free Writing Prospectus, any Disclosure Package, any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, any electronic road show used in connection with the offering of the Securities or in any amendment thereof or supplement thereto or
arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees to reimburse each such indemnified party, as
incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action under clauses (i)&nbsp;or (ii); provided, however, that the Company will not be
liable in any such case pursuant to clause (ii)&nbsp;to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with the Placement Agent Information (as defined below). This indemnity agreement will be in addition to any liability which the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Indemnification of the Company. The Placement Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its
officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of either the Securities Act or the Exchange Act, against any and all losses, claims, damages, liabilities or actions that arise out
of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to the Placement Agent furnished to the Company in writing by the Placement Agent
expressly for use in and contained in the Registration Statement as originally filed or in any amendment thereof, or in the Base Prospectus, the Prospectus, any Issuer Free Writing Prospectus, any Disclosure Package, any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, any electronic road show used in connection with the offering of the Securities or in any amendment thereof or supplement, and agrees to
reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the parties
hereto hereby agree that such information provided by the Placement Agent consists solely of the name of the Placement Agent on the cover of the Prospectus (collectively, the &#147;Placement Agent Information&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notice and Procedures. Promptly after receipt by an indemnified party under this
Section&nbsp;6 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;6, notify the indemnifying party in writing of the
commencement thereof; but the failure so to notify the indemnifying party (i)&nbsp;will not relieve it from liability under paragraph (a)&nbsp;or (b) above unless and to the extent it did not otherwise learn of such action and such failure results
in the forfeiture by the indemnifying party of substantial rights and defenses and (ii)&nbsp;will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in
paragraph (a)&nbsp;or (b) above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party&#146;s choice at the indemnifying party&#146;s expense to represent the indemnified party in any action for which indemnification
is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); provided, however, that such counsel shall
be satisfactory to the indemnified party. Notwithstanding the indemnifying party&#146;s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including
local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i)&nbsp;the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with
a conflict of interest, (ii)&nbsp;the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal
defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (iii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of the institution of such action or (iv)&nbsp;the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party;
provided, however, that an indemnifying party shall not be liable for the fees and expenses of more than one such separate counsel (in addition to local counsel) in connection with any proceeding or related proceeding in the same jurisdiction. An
indemnifying party shall not be liable for any settlement of any proceeding effected without its consent (which consent shall not be unreasonably withheld). Notwithstanding the foregoing sentence, if at any time an indemnified party shall have
requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;6(a) or (b)&nbsp;hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding
effected without its written consent if (i)&nbsp;such settlement is entered into more than 60 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such
settlement at least 30 days before such settlement is entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request or disputed in good faith the indemnified party&#146;s
entitlement to such reimbursement prior to the date of such settlement. An indemnifying party will not, without the prior written consent (which consent shall not be unreasonably withheld) of the indemnified parties, settle or compromise or consent
to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential
parties to such claim or action) unless such settlement, compromise or consent: (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or proceeding and (ii)&nbsp;does not
include an admission of fault. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Contribution. In the event that the indemnity provided in paragraph (a)&nbsp;or (b) of
this Section&nbsp;6 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company and the Placement Agent severally agree to contribute to the aggregate Losses to which the Company and the Placement Agent may be
subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Placement Agent on the other from the offering of the Securities. If the allocation provided by the immediately
preceding sentence is unavailable for any reason, the Company and the Placement Agent severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one
hand and of the Placement Agent on the other in connection with the actions, statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal
to the total net proceeds from the Offering (before deducting expenses) received by it, and benefits received by the Placement Agent shall be deemed to be equal to the Placement Fee, in each case as set forth on the cover page of the Prospectus.
Relative fault shall be determined (i)&nbsp;in the case of any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact by reference to, among other things, whether such statement or
omission relates to information provided by the Company on the one hand or the Placement Agent on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or
omission; and (ii)&nbsp;in the case of any other action or omission, shall be determined by reference to, among other things, whether such action or omission was taken or omitted to be taken by the Company or by the Placement Agent and the
parties&#146; relative intent, relative knowledge, access to information and opportunity to correct or prevent such action or omission. The Company and the Placement Agent agree that it would not be just and equitable if contribution were determined
by pro rata allocation (even if the Placement Agent were treated as one entity for such purpose) or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this
paragraph (d), in no event shall a Placement Agent be required to contribute any amount in excess of the amount by which the Placement Fee received by such Placement Agent with respect to the offering of the Securities exceeds the amount of any
damages that such Placement Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this paragraph (d), in no event shall a Placement Agent be
required to contribute any amount in excess of the amount by which the total Placement Fee received by such Placement Agent exceeds the amount of any damages that such Placement Agent has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. For purposes of this Section&nbsp;6, each person who controls the Placement Agent within the meaning of either the Securities Act or the Exchange Act and each director, officer, employee, affiliate and agent of the
Placement Agent shall have the same rights to contribution as the Placement Agent, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, each officer of the Company who shall have signed the
Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph (d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Representations and Agreements to Survive Delivery. The obligations of the Company under this Section&nbsp;6 shall be in addition to any
liability which the Company may otherwise have. The indemnity and contribution agreements of the parties contained in this Section&nbsp;6 and the covenants, warranties and representations of the Company contained in this Agreement shall remain
operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of the Placement Agent, their affiliates, directors, officers and employees, and agents who have or who
are alleged to have participated in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the distribution of the Securities as Placement Agent and each person who controls the Placement Agent within the meaning of either the Securities Act or the Exchange Act, or by or on behalf of
the Company, its directors or officers or any person who controls the Company within the meaning of either the Securities Act or the Exchange Act, and (iii)&nbsp;the issuance and delivery of the Securities. The Company and the Placement Agent agree
promptly to notify each other of the commencement of any proceeding against it and, in the case of the Company, against any of the Company&#146;s officers or directors in connection with the issuance and sale of the Securities, or in connection with
the Registration Statement or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. Termination</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Placement Agent services hereunder may be terminated with or without cause by the Placement Agent at any time and without liability or
continuing obligation to the Placement Agent or the Company, except for any compensation earned by the Placement Agent to the date of termination and as otherwise provided in this Section&nbsp;7. If this Agreement shall be terminated by the
Placement Agent pursuant to Section&nbsp;5 hereof or the sale of the Securities to the Investors is not consummated because of any failure, refusal or inability on the part of the Company to comply with the terms or perform any agreement or
obligation of this Agreement or the Securities Purchase Agreement, other than by reason of a default by the Placement Agent, the Company will, in addition to paying the amounts described in Section&nbsp;4 hereof, and, if applicable, the preceding
sentence, reimburse the Placement Agent for all of its reasonable, documented and actual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements (including, but not limited to, the reasonable and
documented fees and disbursements of its outside counsel). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any termination of this Agreement, Sections 1(b), 4, 6, and 8
through 18 hereof shall at all times be effective and shall survive such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. Notices</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing or by facsimile, and: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) if to the Placement Agent, shall be delivered or sent by mail, telex or facsimile transmission to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to the Company shall be delivered or sent by mail, telex or facsimile transmission to:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3530 John Hopkins Court </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San
Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jason Liljestrom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: Jason.Liljestrom@Immunitybio.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">12235 El Camino Real </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego,
CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Martin J. Waters and Thomas Hornish </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: mwaters@wsgr.com; thornish@wsgr.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such notice shall be effective only upon receipt. Any party to this Agreement may change such address for notices by sending to the
parties to this Agreement written notice of a new address for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. Persons Entitled to Benefit of</B><B>
</B><B>Agreement</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall inure to the benefit of and shall be binding upon the Placement Agent, the Company and their
respective successors and assigns and the controlling persons, officers and directors and other parties referred to in Section&nbsp;6 hereof. Nothing in this Agreement is intended or shall be construed to give to any other person, firm or
corporation, other than the persons, firms or corporations mentioned in the preceding sentence, any legal or equitable remedy or claim under or in respect of this Agreement, or any provision herein contained. The term &#147;successors and
assigns&#148; as herein used shall not include any purchaser of the Securities by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.
Governing Law</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York, without giving effect to the conflicts of laws provisions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. No Fiduciary Relationship</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges and agrees that the Placement Agent shall act as an independent contractor, and not as a fiduciary, and any duties of
the Placement Agent with respect to providing investment banking services to the Company, including the offering of the Securities contemplated hereby (including in connection with determining the terms of the Offering), shall be contractual in
nature, as expressly set forth herein, and shall be owed solely to the Company. Each party hereto disclaims any intention to impose any fiduciary or similar duty on any other party hereto. Additionally, the Placement Agent has not acted as a
financial advisor, nor has advised or is advising, the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction with respect to the transactions contemplated hereby. The Company shall consult
with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Placement Agent shall have no responsibility or liability to the
Company with respect thereto. Any review by the Placement Agent of the Company, the transactions contemplated hereby or other matters relating to such transactions has been and will be performed solely for the benefit of the Placement Agent and has
not been and shall not be performed on behalf of the Company or any other person. It is understood that the Placement Agent has not and will not be rendering an opinion to the Company as to the fairness of the terms of the Offering. Notwithstanding
anything in this Agreement to the contrary, the Company acknowledges that the Placement Agent may have financial interests in the success of the Offering contemplated hereby that are not limited to the Placement Fee. The Company hereby waives and
releases, to the fullest extent permitted by law, any claims that the Company may have against the Placement Agent with respect to any breach or alleged breach of fiduciary duty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12. Headings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Section headings in this Agreement have been inserted as a matter of convenience of reference and are not a part of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. Amendments and</B><B> </B><B>Waivers</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The
failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provision hereof (regardless of whether similar), nor shall any such waiver constitute a continuing waiver unless otherwise expressly provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. Submission to</B><B> </B><B>Jurisdiction; Waiver of Jury Trial</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Submission to Jurisdiction. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the
Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of venue
of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the jurisdiction
of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Waiver of Jury Trial. Each of the parties hereto hereby waives any right to
trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. Patriot Act</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into
law October&nbsp;26, 2001)), the Placement Agent is required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as
well as other information that will allow the Placement Agent to properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16. Limitation
on Damages</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No party hereto shall be responsible or have any liability to any other party for any indirect, special or consequential
damages incurred by the other party arising out of or in connection with this Agreement or the transactions contemplated hereby, even if advised of the possibility thereof; provided that nothing in this Section shall be deemed to relieve the Company
of any obligation it may otherwise have under Section&nbsp;6 to indemnify any person referred to in Section&nbsp;6(a) for any such damages asserted by an unaffiliated third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17. Counterparts</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each
be deemed to be an original and all such counterparts shall together constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission, electronic mail, or otherwise by electronic transmission
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) evidencing an intent to sign this Agreement, such facsimile transmission, electronic
mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of this Agreement by facsimile transmission, electronic
mail or other electronic transmission is legal, valid and binding for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18. Definitions. </B>The terms that
follow, when used in this Agreement, shall have the meanings indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Base Prospectus&#148; shall mean the base prospectus
referred contained in the Registration Statement at the Execution Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;business day&#148; shall mean any day other than a
Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Commission&#148; shall mean the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Disclosure Package&#148; shall mean (i)&nbsp;the Base Prospectus, including documents incorporated by reference therein, (ii)&nbsp;the
information included on Exhibit B hereto, and (iii)&nbsp;any other Free Writing Prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective Date&#148; shall mean each date and time that the Registration Statement and any post-effective amendment or amendments
thereto became or becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Exchange Act&#148; shall mean the Securities Exchange Act of 1934, as amended, and the rules
and regulations of the Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Execution Time&#148; shall mean the date and time that this Agreement is
executed and delivered by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Free Writing Prospectus&#148; shall mean a free writing prospectus, as defined in
Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Prospectus&#148; shall mean the final prospectus supplement to the Base Prospectus relating to
the Securities that will be filed pursuant to Rule 424(b) after the Execution Time, together with the Base Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Registration
Statement&#148; shall mean the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-269608,</FONT> including exhibits and financial statements and any
prospectus supplement relating to the Securities that is filed with the Commission pursuant to Rule 424(b) under the Securities Act and deemed part of such registration statement pursuant to Rule 430B under the Securities Act, as amended on each
Effective Date and, in the event any post-effective amendment thereto becomes effective prior to the Closing Date, shall also mean such registration statement as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Securities Act&#148; shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any
communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages
Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of the agreement between the
Company and the Placement Agent, kindly indicate your acceptance in the space provided for that purpose below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;&nbsp;&nbsp;IMMUNITYBIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David C. Sachs</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David C. Sachs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Placement Agency Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Brinkman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Placement Agency Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Securities Purchase Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B Pricing Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Shares: 14,072,615 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering Price per Share and
accompanying Warrant: $3.5530 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock Underlying Warrants: 14,072,615 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exercise Price of Warrant: $4.2636 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d644968dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUNITYBIO, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date: February __, 2023</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS COMMON STOCK PURCHASE WARRANT (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
_______________________ or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00
p.m. (New York City time) on February __, 202_ (the &#147;<U>Termination Date</U>&#148;) but not thereafter, to subscribe for and purchase from ImmunityBio, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), up to ________________ shares
(as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the &#147;<U>Purchase Agreement</U>&#148;), dated December&nbsp;February 15, 2023, among the Company and the purchasers signatory thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at
any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or <FONT STYLE="white-space:nowrap">e-mail</FONT>
attachment) of the Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as
defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#146;s check
drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise.<B> </B>No <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the
outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The exercise price per share of Common Stock under
this Warrant shall be <B>$4</B>.2636, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may
also be exercised, in whole or in part, at such time by means of a &#147;cashless exercise&#148; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
<FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(A) = as applicable: (i)&nbsp;the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to
Section&nbsp;2(a) hereof on a Trading Day prior to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the
Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the
Holder&#146;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours
after the close of &#147;regular trading hours&#148; on a Trading Day) pursuant to Section&nbsp;2(a) hereof, which Bid Price shall be shown on supporting documents provided by the Holder to the Company within two Trading Days of delivery of the
Notice of Exercise, or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a) hereof after
the close of &#147;regular trading hours&#148; on such Trading Day; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise,
the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section&nbsp;2(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if the Company is
then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless
exercise, and otherwise by physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to
the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of
the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the
Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date applicable to such exercise,
the Holder may upon written demand to the Company require the Company to pay (and the Company shall pay) to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the
VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the
Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:30 a.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the
Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the
following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is
then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by
an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common
Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by
Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent Bid Price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the
request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If the Company fails to cause the Transfer
Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company at any time prior to the
Company delivering such Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure
to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of
Section&nbsp;2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver, but did not timely deliver, to
the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise
of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
the Company written notice indicating the amounts payable to the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a
Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares
or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in
the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Transfer Agent fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for <FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Holder&#146;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a
Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder
(together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below).&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of
Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion
of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;Except as set forth in the
preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in
compliance with the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied upon by
the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no
obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the number
of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied upon by the Holder). For purposes of this Section&nbsp;2(e), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public
announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;Upon the written or oral request of a Holder, the Company shall within one
Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise
of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#147;<U>Beneficial Ownership
Limitation</U>&#148; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrant Shares, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e) shall continue to
apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or
<FONT STYLE="white-space:nowrap">re-classification.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any
adjustments pursuant to Section&nbsp;3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of
shares of Common Stock (the &#147;<U>Purchase Rights</U>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a merger or consolidation in which the Company is the continuing corporation and that does not
result in any reclassification or reorganization of the outstanding shares of Common Stock), (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of the Company&#146;s assets in one or a series of related transactions,(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50% of the outstanding Common Stock or more than 50% of the voting power of the
common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section&nbsp;2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate
Consideration</U>&#148;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any
limitation in Section&nbsp;2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the
Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder&#146;s option, exercisable at </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the Trading Day of the Holder&#146;s request ;
<U>provided</U>,<I> </I><U>however</U>, that, if the Fundamental Transaction is not within the Company&#146;s control, including not approved by the Company&#146;s Board of Directors, the Holder shall only be entitled to receive from the Company or
any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in
connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in
connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to
have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#147;<U>Black Scholes Value</U>&#148; means the value of this Warrant based on the
Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the Trading Day of the Holder&#146;s request pursuant to this Section&nbsp;3(d) and the Termination Date, (B)&nbsp;an expected volatility equal to the <FONT
STYLE="white-space:nowrap">one-hundred</FONT> (100)&nbsp;day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the
applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the value of any <FONT
STYLE="white-space:nowrap">non-cash</FONT> consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable
Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#146;s request pursuant to this Section&nbsp;3(c) and D) a remaining option time equal to the time
between the Trading Day of the Holder&#146;s request pursuant to this Section&nbsp;3(d) and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
(or such other consideration) within the later of (i)&nbsp;five Business Days of the Holder&#146;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &#147;<U>Successor Entity</U>&#148;) to assume in writing all of the obligations of the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&nbsp;3(d) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the
&#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same
effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt, if, at any time while this Warrant is outstanding, a Fundamental Transaction occurs, pursuant to the terms of this Section&nbsp;3(d), the Holder
shall not be entitled to receive more than one of (i)&nbsp;the Black Scholes Value of the unexercised portion of this Warrant, (ii)&nbsp;the consideration receivable as a result of such Fundamental Transaction by a holder of the number of shares of
Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction or (iii)&nbsp;the assumption by the Successor Entity of all of the obligations of the Company under this Warrant and the other Transaction Documents
and the option to receive a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding
treasury shares, if any) issued and outstanding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice to Holder</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of the Company&#146;s assets, or any compulsory share exchange whereby the Common Stock
is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be
delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Voluntary Adjustment By Company</U>. Subject to the rules and
regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or, in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer, provided, however, that any such transfer for less than 1,000,000 shares issuable upon exercise of a portion of the Warrant
shall be subject to the Company&#146;s prior written consent. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant
Shares on a &#147;cashless exercise&#148; basis pursuant to Section&nbsp;2(c) or to receive cash payments pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of
this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authorized Shares</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be,
necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before taking any action which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction,
validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to
comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable
attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Remedies</U>. The Holder, in addition to being entitled to exercise
all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a
breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>IMMUNITYBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: IMMUNITYBIO, INC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Payment shall take the form of (check applicable box): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#9744; in lawful money of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#9744; the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of
Investing Entity: ________________________________________________________________________ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Investing Entity</I>:
_________________________________________________ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: ___________________________________________________________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: ____________________________________________________________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: ____________________________________________________________________________________ </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>(Please Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;______________ _ __, ______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature: &nbsp;&nbsp;____________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address:&nbsp;&nbsp;______________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d644968dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g644968g54n21.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Wilson Sonsini Goodrich&nbsp;&amp; Rosati<BR>Professional Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">12235 El Camino Real<BR>San Diego, California 92130-3002</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">o: <FONT STYLE="white-space:nowrap">650.350-2300</FONT><BR>f: 650.493.6811</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;15, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3530 John Hopkins Court </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel
to ImmunityBio, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the registration of the offer and sale of (a) 14,072,615 shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common stock,
$0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), (b) warrants to purchase 14,072,615 shares of Common Stock (the &#147;<B><I>Warrants</I></B>&#148;) and (c)&nbsp;the shares of Common Stock issuable upon exercise of the Warrants
(the &#147;<B><I>Warrant Shares</I></B>&#148; and, together with the Shares and the Warrants, the &#147;<B><I>Securities</I></B>&#148;), pursuant to the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-269608),</FONT> which was declared effective by the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on February&nbsp;9, 2023 (the &#147;<B><I>Registration
Statement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering and sale of the Securities are being made pursuant to the Securities Purchase Agreement (the
&#147;<B><I>Securities Purchase Agreement</I></B>&#148;, dated as of February&nbsp;14, 2022, by and among the Company and the purchasers identifies in the signature pages thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have examined copies of the Securities Purchase Agreement, the form of Warrant, the Registration Statement, the base prospectus that forms
a part thereof (the &#147;<B><I>Base Prospectus</I></B>&#148;) as supplemented by the prospectus supplement dated February&nbsp;15, 2023, in the form filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations, together with the
documents or portions thereof incorporated by reference therein, as modified or superseded as described therein (the &#147;<B><I>Prospectus Supplement</I></B>&#148; and, together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;).
We have also examined instruments, documents and records that we deemed relevant and necessary for the basis of our opinion hereinafter expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such examination, we have assumed (i)&nbsp;the authenticity of original documents and the genuineness of all signatures, (ii)&nbsp;the
conformity to the originals of all documents submitted to us as copies, (iii)&nbsp;the truth, accuracy, and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have
reviewed; and (iv)&nbsp;the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of
officers and other representatives of the Company. In making our examination of documents executed or to be executed, we have assumed that the counterparties thereto, excluding the Company, have been duly incorporated or organized and are, and will
continue to be, validly existing and in good standing, and have or will have the requisite legal status and legal capacity under the laws of their respective jurisdictions of incorporation or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 15, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organization and had or will have the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action,
corporate or other, and execution and delivery by such parties of such documents and, except as expressly set forth in the paragraphs below, the validity and binding effect thereof on such parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set out below, we are of the
opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares have been duly authorized by the Company and, when issued and delivered by the Company against
payment therefor in accordance with the terms of and in the manner contemplated by the Securities Purchase Agreement, will be validly issued, fully paid and nonassessable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Warrants have been duly authorized by the Company and, when issued and delivered by the Company against
payment therefor in accordance with the terms of the Securities Purchase Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Warrant Shares have been duly authorized by the Company and, when issued and delivered by the Company
against payment of the exercise price therefor in accordance with the terms of the Warrants,&nbsp;will have been validly issued, fully paid and nonassessable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General
Corporation Law of the State of Delaware and, solely as to the Warrants constituting valid and binding obligations of the Company, the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion that any document is legal, valid, binding and enforceable is qualified as to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent transfer, moratorium or
other similar laws relating to or affecting the rights of creditors generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effect of general principles of equity, including without limitation concepts of materiality,
reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief and limitation of rights of acceleration, regardless of whether such enforceability is considered in a proceeding in equity or
at law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we express no opinion as to whether a state court outside of the State of New York or a federal
court of the United States would give effect to the choice of New York law provided for in the Warrants. For purposes of our opinion in paragraph 2, we have assumed the Exercise Price (as defined in the Warrants) will not be adjusted to an amount
below the par value per share of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Company&#146;s
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on or about the date hereof, for incorporation by reference into the Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;15, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional Corporation</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d644968dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Securities Purchase Agreement (this &#147;<U>Agreement</U>&#148;) is dated as of February&nbsp;15, 2023, by and among ImmunityBio, Inc.,
a Delaware corporation (the &#147;<U>Company</U>&#148;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#147;<U>Purchaser</U>&#148; and collectively the &#147;<U>Purchasers</U>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the
Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. In addition
to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section&nbsp;1.1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquiring Person</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Base Prospectus</U>&#148; shall mean the base prospectus contained in the Registration Statement at the Execution
Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of Directors</U>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The City of
New York are authorized or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the Trading Day on which all of the
Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&#146; obligations to pay the Subscription Amount and (ii)&nbsp;the Company&#146;s obligations to
deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) Trading Day following the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the common stock of the Company, par value $0.0001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock
Equivalents</U>&#148; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Counsel</U>&#148; means Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., with offices located at 12235 El
Camino Real, San Diego,&nbsp;CA&nbsp;92130. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Package</U>&#148; shall mean the Base Prospectus,
including documents incorporated by reference therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Time</U>&#148; means, (i)&nbsp;if this
Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City
time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange
Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Execution Time</U>&#148; shall mean the date and time that this Agreement is executed and delivered by the parties
hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FCPA</U>&#148; means the Foreign Corrupt Practices Act of 1977, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(m). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(x). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right
or other restriction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Change</U>&#148; shall have the meaning assigned
to such term in Section&nbsp;3.1(o). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Per Share Purchase Price</U>&#148; equals $3.5530, subject to adjustment for
reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agent</U>&#148; means Jefferies, LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agency Agreement</U>&#148; means that certain Placement Agency Agreement, dated as of the date hereof, by
and between the Company and the Placement Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agent Counsel</U>&#148; means Goodwin Procter LLP,
counsel to the Placement Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agent Information</U>&#148; means the name of the Placement Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means an action, claim, suit, arbitration, hearing, investigation or proceeding (including,
without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that will
be filed with the Commission and delivered by the Company to each Purchaser at or prior to the Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser
Party</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration
Statement</U>&#148; means the effective registration statement filed with the Commission on February&nbsp;7, 2023, as amended (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269608),</FONT> and all exhibits filed with or incorporated by
reference into such registration statement, and includes any Rule 462(b) Registration Statement which registered the sale of the Shares, the Warrants and the Warrant Shares to the Purchasers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Approvals</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 144</U>&#148; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 424</U>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 462(b) Registration Statement</U>&#148; means any registration
statement prepared by the Company registering additional Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the
Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means, collectively, the Shares, the Warrants and the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; means the shares of Common Stock issued or issuable to each Purchaser pursuant to
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as defined in Rule 200 of Regulation SHO
under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subscription Amount</U>&#148; means, as to each Purchaser, the aggregate amount to be paid for the Shares and the
Warrants purchased hereunder as specified below such Purchaser&#146;s name on the signature page of this Agreement and next to the heading &#147;Subscription Amount,&#148; in United States dollars and in immediately available funds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(o). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which the principal Trading Market is open for trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Agreement and the Warrants, all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of
the Company, and any successor transfer agent of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrants</U>&#148; means, collectively, the Common
Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section&nbsp;2.2(a)(iv) hereof, which Warrants shall have a term of exercise equal to two (2)&nbsp;years from the Closing Date, in the form of
<U>Exhibit&nbsp;A</U> attached hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Shares</U>&#148; means the shares of Common Stock issuable
upon exercise of the Warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURCHASE AND SALE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 <U>Closing</U>. On the
Closing Date, upon the terms and subject to the conditions set forth herein the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $ 50,000,001.10 of Shares and Warrants. Each
Purchaser&#146;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#147;Delivery Versus Payment&#148; settlement with the Company or its designee. The Company shall deliver to each
Purchaser its respective Shares and a Warrant as determined pursuant to Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the
covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise agreed by the Company and the Purchasers, on the Closing Date, the Company shall
issue the Shares registered in the Purchasers&#146; names and addresses and released by the Transfer Agent directly to the account(s) identified by each Purchaser. Notwithstanding anything herein to the contrary, if at any time on or after the time
of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Period</U>&#148;), such Purchaser sells
to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares</U>&#148;), such Purchaser shall, automatically
hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares to such Purchaser at the Closing; provided,
that the Company shall not be required to deliver any <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares to such Purchaser prior to the Company&#146;s receipt of the purchase price of such
<FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not
during the <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the
time such Purchaser elects to effect any such sale, if any. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 <U>Deliveries</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each
Purchaser the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) subject to the fifth sentence of Section&nbsp;2.1, the Company shall have provided each Purchaser with the Company&#146;s
wire instructions, on Company letterhead and executed by an officer of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) subject to the fifth sentence of
Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system Shares equal to such
Purchaser&#146;s Subscription Amount divided by the Per Share Purchase Price, rounded down to the nearest whole share, registered in the name of such Purchaser; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a Warrant registered in the name of such Purchaser to purchase up to a
number of shares of Common Stock equal to 100% of such Purchaser&#146;s Shares, with an exercise price equal to $4.2636, subject to adjustment therein (for the avoidance of doubt, the original Warrant may be delivered within five (5)&nbsp;Trading
Days of the Closing Date); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the Base Prospectus and the Prospectus (which may be delivered in accordance with Rule
172 under the Securities Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered
to the Company the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by such Purchaser; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) such Purchaser&#146;s Subscription Amount, which shall be made available for &#147;Delivery Versus Payment&#148;
settlement with the Company or its designee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing Conditions</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or
warranties are qualified by materiality, in all respects) as of such date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements
of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b) of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations
of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Change, in all respects) when made and on the Closing Date of the representations and warranties of the Company
contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Change, in all respects) as of such
date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing Date shall have been performed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Company of the items set
forth in Section&nbsp;2.2(a) of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) there shall have been no Material Adverse Change with respect to the
Company since the date hereof; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) all of the conditions set forth in Section&nbsp;5 of the Placement Agency Agreement
shall have been duly satisfied or waived; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the Shares shall be freely tradable on the Nasdaq Global Select Market;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the
Commission or the Company&#146;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been
established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material
outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the Closing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1
<U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Disclosure Package</U>. The Disclosure Package as of the Execution Time did not, and as of the Closing Date, will not,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no
representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the Placement Agent furnished to the Company in writing by the Placement Agent expressly for use in such
Disclosure Package, it being understood and agreed that the only such information furnished by the Placement Agent consists of the Placement Agent Information. No statement of material fact included in the Disclosure Package that is required to be
included in the Prospectus has been omitted therefrom. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuer Free Writing Prospectuses</U>. Other than the Registration
Statement and the Prospectus, the Company (including its agents and representatives, other than the Placement Agent in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use,
authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its
agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;<U>Issuer Free Writing Prospectus</U>&#148;) other than any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the
Securities Act or Rule 134 under the Securities Act, each electronic road show and any other written communications approved in writing in advance by the Placement Agent. Each such Issuer Free Writing Prospectus complies in all material respects
with the Securities Act, has been or will be (within the time period specified in Rule 433 under the Securities Act) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in
the Registration Statement or the Disclosure Package, and did not, and as of the Closing, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in
conformity with information relating to the Placement Agent furnished to the Company in writing by the Placement Agent expressly for use in such Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished
by the Placement Agent consists of the Placement Agent Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Registration Statement and Prospectus</U>. The
Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. Each of the Registration Statement and any post-effective amendment thereto has become effective under the Securities Act. The
Company has complied with each request (if any) from the Commission for additional information. No stop order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or
pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Securities has been initiated or threatened by the Commission; as of the applicable effective date of the Registration Statement and any
post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing, the Prospectus will
comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the Placement Agent furnished to the
Company in writing by the Placement Agent expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by the Placement Agent
consists of the Placement Agent Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Incorporated Documents</U>. The documents incorporated by reference
in the Registration Statement, the Prospectus and the Disclosure Package, when they were filed with the Commission, conformed or will conform, as the case may be, in all material respects to the requirements of the Exchange Act and such documents
did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT></U>. The Company
(i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Organization and Qualification</U>. Each of the Company and each of the Subsidiaries has been (i)&nbsp;duly organized
and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Registration Statement, Disclosure
Package and the Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as
to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change, and each
subsidiary of the Company required to be listed in the Registration Statement has been so listed in the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each
of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the
Company, the Board of Directors or the Company&#146;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon
delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by
laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>No Conflicts</U>. The execution, delivery and performance by the
Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;conflict with
or violate any provision of the Company&#146;s or any Subsidiary&#146;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice
or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company
or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction
Documents, other than: (i)&nbsp;the filings required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus, (iii)&nbsp;the notice and/or application(s) to the principal Trading Market for the
listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv)&nbsp;such filings as are required to be made under applicable state securities laws and (v)&nbsp;such consents, waivers and authorizations
that shall be obtained prior to the Closing (collectively, the &#147;<U>Required Approvals</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Issuance of
the Securities; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company. The Warrants are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will constitute valid and legally binding obligations of the Company, enforceable against the Company in
accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization, fraudulent transfer, fraudulent conveyance, moratorium or other laws now or hereafter in effect relating to or affecting enforcement of creditors&#146;
rights generally and by general principles of equity (including without limitation concepts of materiality, reasonableness, good faith and fair dealing), regardless of whether such enforcement is considered in a proceeding at law or in equity. The
Warrant Shares are duly authorized and, when issued in accordance with the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective
on&nbsp;May 18, 2022 after a post-effective amendment, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act
and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the
knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the
Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any
amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the time of
the filing of the Registration Statement eligible to use Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The Company is eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act pursuant to General Instruction I.B.1
of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Ineligible Issuer Status</U>. The Company is not an
&#147;ineligible issuer&#148; in connection with the offering of the Securities pursuant to Rules 164, 405 and 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Statistical and Market-Related Data</U>. Nothing has come to the attention of the Company that has caused the Company to
believe that the statistical and market-related data included in the Registration Statement, Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. The
Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;comply with the
requirements of the Exchange Act; (ii)&nbsp;have been designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and principal
financial officer by others within those entities; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. The Company maintains a system of internal control over financial reporting (as such
term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that complies with the requirements of the Exchange Act applicable to the Company and has been designed by the Company&#146;s principal executive
officer and principal financial officer, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles in the United States (&#147;<U>GAAP</U>&#148;). Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s
internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s
internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>No Applicable Registration or
Other Similar Rights</U>. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement and any
Securities Purchase Agreement, except for such rights as have been duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>No Material Adverse Change</U>.
Except as otherwise disclosed in the Registration Statement, Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, Disclosure Package and the Prospectus:
(i)&nbsp;there has been no material adverse change, or any development that could be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating
results, assets or liabilities, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries (the &#147;<U>Subsidiaries</U>&#148;), considered as one entity or (B)&nbsp;the ability of the Company
to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<U>Material Adverse Change</U>&#148;); (ii) the Company and the Subsidiaries, considered as one
entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether
or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered
into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or the Subsidiaries and
there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Subsidiaries on any class of capital stock, or any repurchase or
redemption by the Company or any of the Subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Independent Accountants</U>.
Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement,
Disclosure Package and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<U>PCAOB</U>&#148;), (ii)
in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a
registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Financial Statements</U>. The financial statements filed with the
Commission as a part of the Registration Statement, Disclosure Package and the Prospectus present fairly the consolidated financial position of the Company and the Subsidiaries (including NantCell, Inc.) as of the dates indicated and the results of
their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity GAAP applied on a consistent basis throughout the periods involved, except as may be
expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and
has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement, Disclosure Package or the
Prospectus. The combined consolidated financial statements of the Company and the Subsidiaries and the related notes thereto included in the Registration Statement, Disclosure Package or the Prospectus present fairly the information contained
therein, have been prepared in all material respects in accordance with the Commission&#146;s rules and guidelines and have been properly presented on the bases described therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Company</U><U>&#146;</U><U>s Accounting System</U>. The Company and each of the Subsidiaries make and keep books and
records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in all material respects in accordance
with the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Capitalization and Other Capital Stock
Matters</U>. The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, Disclosure Package and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans
described in the Base Prospectus or the Prospectus or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, Disclosure Package and the Prospectus). The Common Stock (including the Shares) conform
in all material respects to the description thereof contained in the Base Prospectus and the Prospectus. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been
issued in compliance with all federal and state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the
Company, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
except for such rights as have been duly waived. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or
debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Registration Statement, Disclosure Package and the Prospectus and except for such rights as have been duly
waived. The descriptions of the Company&#146;s stock option, stock bonus, stock purchase and other stock or equity incentive plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement,
Disclosure Package and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights. Except as described in the Registration Statement, Disclosure Package and the
Prospectus, all of the issued and outstanding capital stock of, or other equity interests in, each Subsidiary has been duly authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and is owned by the
Company, directly or through other subsidiaries of the Company, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Stock Exchange Listing</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act
and are listed on the Nasdaq Global Select Market (&#147;Nasdaq&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common
Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects with all
applicable listing requirements of Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing
Instruments</U>. Neither the Company nor any of the Subsidiaries is (i)&nbsp;in violation of its certificate of incorporation or bylaws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or
regulation of any court or governmental agency or body having jurisdiction over the Company or any of the Subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or
condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses
(ii)&nbsp;and (iii), for such defaults as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>No Further Authorizations or Approvals Required</U>. The Company&#146;s execution, delivery and performance of this
Agreement, the Securities Purchase Agreement, and the Warrants, and the consummation of the transactions contemplated hereby, by the Warrants, and by the Registration Statement, Disclosure Package and the Prospectus and the issuance and sale of the
Securities (including the use of proceeds from the sale of the Securities as described in the Registration Statement, Disclosure Package and the Prospectus under the caption &#147;Use of Proceeds&#148;) will not conflict with or result in a breach
or violation of any of the terms or provisions of, or constitute a default under, (A)&nbsp;any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which
the Company or any of the Subsidiaries is bound or to which any of the property or assets of the Company or any of the Subsidiaries is subject, (B)&nbsp;the certificate of incorporation or bylaws (or other applicable organizational document) of the
Company or any of the Subsidiaries, or (C)&nbsp;any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of the Subsidiaries or any of their properties, except, in
the case of clauses (A)&nbsp;and (C), for such defaults, breaches, or violations that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>No Material Actions or Proceedings</U>. Other than as set forth in
the Registration Statement, Disclosure Package and the Prospectus, there are no legal or governmental proceedings pending to which the Company or any of the Subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is
a party or of which any property or assets of the Company or any of the Subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is the subject which, if determined adversely to the Company or any of the Subsidiaries
(or such officer or director), would individually or in the aggregate have a Material Adverse Change; and, to the Company&#146;s knowledge, no such proceedings are threatened by governmental authorities or others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Intellectual Property Rights</U>. The Company and the Subsidiaries own, possess or license adequate rights to use all
material trademarks, service marks, trade names, domain names and other source identifiers, and all goodwill associated with the foregoing, inventions, patents, copyrights and copyrightable works, licenses, approvals, technology, <FONT
STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures, and other intellectual property rights (including all registrations and applications
for registration of the foregoing, as applicable) (collectively, &#147;<U>Intellectual Property Rights</U>&#148;) used in, held for use in or necessary for the conduct of their respective businesses as currently conducted and as proposed in the
Registration Statement, Disclosure Package or the Prospectus to be conducted. To the knowledge of the Company: (1)&nbsp;neither the Company nor any of the Subsidiaries has materially infringed, misappropriated or otherwise violated the Intellectual
Property Rights of any third party, and (2)&nbsp;neither the manufacture of, nor the use or sale of, any of the Company&#146;s or the Subsidiaries&#146; product candidates described in the Registration Statement, Disclosure Package or the Prospectus
materially infringe, misappropriate or otherwise violate the Intellectual Property Rights of any third party. Except as disclosed in the Registration Statement, Disclosure Package and the Prospectus, to the knowledge of the Company, there are no
rights of third parties (including any Liens or encumbrances) to any of the Intellectual Property Rights owned or purported to be owned by the Company or any of the Subsidiaries. Except as disclosed in the Registration Statement, Disclosure Package
and the Prospectus, there is no pending or threatened in writing action, suit, proceeding or claim by any third party (i)&nbsp;challenging the Company&#146;s or any of the Subsidiaries&#146; rights in or to, or alleging a violation of any of the
terms of, any of their owned or licensed Intellectual Property Rights; (ii)&nbsp;alleging that the Company or any of the Subsidiaries has infringed, misappropriated or otherwise violated any Intellectual Property Rights of any third party; or
(iii)&nbsp;challenging the validity, scope or enforceability of any Intellectual Property Rights owned by or exclusively licensed to the Company or any of the Subsidiaries, and in the case of each of (i), (ii) and (iii), the Company is unaware of
any facts that would form a reasonable basis for any such action, suit, proceeding or claim. Except as disclosed in the Registration Statement, Disclosure Package and the Prospectus to the Company&#146;s knowledge, there is no material infringement,
misappropriation, breach or default, or other violation by others of any Intellectual Property Rights owned by or exclusively licensed to the Company or any of the Subsidiaries. The Company and the Subsidiaries have at all times taken reasonable
steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property Rights, the value of which to the Company or any of the Subsidiaries is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
contingent upon maintaining the confidentiality thereof, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. All founders, current and
former employees, consultants, and other parties involved in the development of Intellectual Property Rights for the Company and the Subsidiaries have signed confidentiality and invention assignment agreements with the Company or a Subsidiary
pursuant to which the Company or any of the Subsidiaries either (x)&nbsp;has obtained ownership of and is the exclusive owner of such Intellectual Property Rights, or (y)&nbsp;has obtained a valid and unrestricted right to exploit such Intellectual
Property Rights, sufficient for the conduct of the business as currently conducted and as proposed in the Registration Statement, Disclosure Package and the Prospectus to be conducted, except where the failure to do so would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>All Necessary Permits, etc</U><U>.</U>
Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign
regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, Disclosure Package or the Prospectus (&#147;Permits&#148;). Neither the Company nor any of the Subsidiaries
is in violation of, or in default under, any of the Permits, or has received any notice of violation of or default under or proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with,
any such certificate, authorization or permit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Title to Properties</U>. The Company and the Subsidiaries have good
and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them (other than with respect to Intellectual Property Rights (as defined above), which for the avoidance of doubt is addressed
exclusively in Section&nbsp;3.1(x)), in each case free and clear of all Liens, encumbrances and defects except such as are described in the Registration Statement, Disclosure Package and Prospectus or such as do not materially affect the value of
such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries; any real property and buildings held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Tax Law Compliance</U>. (i)&nbsp;The Company and each of the Subsidiaries have filed all federal, state, local and
foreign tax returns required to be filed or have requested extensions thereof and have paid all taxes required to be paid thereon (except for cases in which the failure to file such tax returns or pay such taxes would not reasonably be expected to
have a Material Adverse Change), (ii) the Company and each of the Subsidiaries have no liability for unpaid taxes, except as currently being contested in good faith and for which reserves required by GAAP have been created in the financial
statements of the Company or where such liability would not reasonably be expected to have a Material Adverse Change and (iii)&nbsp;no tax deficiency has been determined adversely to the Company or any of the Subsidiaries, and neither the Company
nor any of the Subsidiaries has received written notice of, or has knowledge of, any tax deficiency that could reasonably be expected to be determined adversely to the Company or the Subsidiaries, in each case which could reasonably be expected to
have a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Company Not an &#147;Investment Company.&#148;</U> The Company is
not, and will not be, either after receipt of payment for the Securities or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, Disclosure Package or the Prospectus, required
to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Insurance</U>. Except as otherwise disclosed in the Registration Statement, Disclosure Package or Prospectus, each of
the Company and the Subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their
businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and the Subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and
the Subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of the Subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies
expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not be expected to result, individually or in the aggregate, in a
Material Adverse Change. Neither the Company nor any of the Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied except as would not be expected to result, individually or in the aggregate, in a
Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Related Party Transactions</U>. No relationship, direct or indirect, exists between the
Company, on the one hand, and the directors, officers, or stockholders of the Company, on the other, that is required by the Act to be described in the Registration Statement, Disclosure Package and the Prospectus and that is not so described in
such documents. There are no related-party transactions involving the Company or any of the Subsidiaries or any other person required to be described in the Registration Statement, Disclosure Package or the Prospectus which have not been described
as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>FINRA Matters</U>. All of the information provided to the Placement Agent or to counsel for the
Placement Agent by the Company, its counsel, its officers and directors in connection with the offering of the Securities is true, complete, correct and compliant with Financial Industry Regulatory Authority, Inc.&#146;s (&#147;FINRA&#148;) rules
and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT>
under the Securities Act specified in FINRA Rule 5110(h)(1)(C). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>No Unlawful Contributions or Other Payments</U>.
Neither the Company nor any of the Subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal,
state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>Compliance with Environmental Laws</U>. The Company and the
Subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (&#147;Environmental Laws&#148;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms
and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits,
licenses or approvals would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Change. There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating
expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities
to third parties) which would, singly or in the aggregate, reasonably be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)
<U>ERISA Compliance</U>. Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;) that the Company or any member of its &#147;Controlled Group&#148;
(defined as any organization which is under common control with the Company within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) sponsors or maintains (each, a &#147;Plan&#148;) has been
maintained, in all material respects, in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Brokers</U>. Except as described in the Registration Statement, Disclosure Package and Prospectus, the Company is not a
party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection
with the offering and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>No Outstanding Loans or Other Extensions of Credit</U>. The Company does
not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of
the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Compliance with Laws</U>. The Company and the Subsidiaries have been and are in compliance with
all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>Dividend Restrictions</U>. Except as disclosed in the Registration Statement, Disclosure Package and Prospectus, no
subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or
any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Anti-Corruption and Anti-Bribery Laws</U>. None of the Company or
any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company or any of the Subsidiaries has (i)&nbsp;made, offered, promised or
authorized any unlawful contribution, gift, entertainment or other unlawful expense or taken any act in furtherance thereof; (ii)&nbsp;made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in
violation of any provision of the Foreign Corrupt Practices Act of 1977 (the &#147;<U>FCPA</U>&#148;), the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law. The Company and the Subsidiaries and, to
the knowledge of the Company, the Company&#146;s affiliates, have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to
continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Money Laundering Laws</U>. The operations of the Company and
the Subsidiaries are and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the
rules and regulations promulgated thereunder, and the applicable anti-money laundering laws of the various jurisdictions in which the Company and the Subsidiaries conduct business (collectively, the &#147;<U>Money Laundering Laws</U>&#148;) and no
action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of the Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>Regulatory Matters</U>. Except as disclosed in the Registration Statement, Disclosure Package and
Prospectus, the Company and each of the Subsidiaries possess all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations (collectively, &#147;<U>Authorizations</U>&#148;) issued by, and have
made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are required for the ownership or lease of its property or the conduct of their respective businesses as currently
conducted and described in the Registration Statement, Base Prospectus, Disclosure Package or Prospectus, including, without limitation, from the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;), the European Medicines Agency (the
&#147;<U>EMA</U>&#148;) or similar foreign, state, and local governmental or regulatory authorities, including any government medical device regulatory agency or institutional review board (collectively, the &#147;<U>Regulatory
Authorities</U>&#148;), such Authorizations are valid and in full force and effect, and the Company is not in violation of any such Authorizations, except, in each case, as would not, individually or in the aggregate, have a Material Adverse Change;
and the Company has not received notice of any revocation of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>Health Care Laws</U>. Except as disclosed in the Registration Statement, Disclosure Package and Prospectus, the Company
and each of the Subsidiaries (i)&nbsp;have operated and currently operate their respective businesses in compliance with all statutes, rules and regulations applicable to them and their respective businesses, including, without limitation,
(A)&nbsp;requirements governing investigational drugs and biologics under the U.S. Federal Food, Drug and Cosmetic Act and rules and regulations thereunder, including regulations relating to Good Clinical Practices and Good Laboratory Practices for
studies and tests that are submitted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
regulatory authorities to support regulatory approvals, (B)&nbsp;the U.S. Animal Welfare Act and rules and regulations thereunder, (C)&nbsp;the U.S. Anti-Kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), all applicable
federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections
286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws, the statutes, regulations and
directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; (D)&nbsp;the Standards for Privacy of Individually Identifiable Health Information, the Security Standards, and
the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated thereunder and any state
or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or any other law or regulation the purpose of which is to protect the privacy of individuals or prescribers; (E)&nbsp;the Patient Protection and Affordable Care Act of 2010, as
amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; (F)&nbsp;the U.S. Controlled Substances Act (21 U.S.C. Section&nbsp;801 et seq.); and (G)&nbsp;all other local, state, federal, national,
supranational and foreign laws, relating to the regulation of the Company and the ownership, testing, development, registration, licensure, manufacture, packaging, processing, use, recordkeeping, filing of reports, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product or product candidate under development, manufactured or distributed by or on behalf of the Company or such subsidiary (collectively, <U>&#147;Applicable
Laws</U>&#148;), except where the failure to so operate or be in compliance would not reasonably be expected to have a Material Adverse Change; (ii)&nbsp;have not received any FDA Form 483, written notice of adverse finding, warning letter, untitled
letter or other correspondence or written notice alleging or asserting material noncompliance with any Applicable Laws or Authorizations or otherwise providing notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any Regulatory Authority, any court or arbitrator or other governmental authority or agency; (iii)&nbsp;have not received any recalls, field notifications, field corrections, market withdrawals, &#147;dear
doctor&#148; letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company&#146;s products or product candidates; (iv)&nbsp;have filed, obtained,
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws, that all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission) and no material deficiencies regarding compliance with
applicable law have been asserted by any applicable Regulatory Authority with respect to any such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments; and (v)&nbsp;are not a party to any
corporate integrity agreements, monitoring agreements, consent decrees, settlement orders or similar agreements with or imposed by any governmental or regulatory authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>Clinical Trials</U>. (i)&nbsp;Except as disclosed in the
Registration Statement, Disclosure Package and Prospectus, any preclinical studies and clinical trials conducted by the Company or any of the Subsidiaries and, to the knowledge of the Company, any preclinical studies and clinical trials conducted on
behalf of the Company or the Subsidiaries or in which the Company or the Subsidiaries have participated for the purposes of supporting a regulatory filing or application submitted to a Regulatory Authority, were, and if still pending, are, being
conducted in all material respects in accordance with approved study protocols and Applicable Laws, including those of the FDA and other regulatory authorities, to which the Company and the Subsidiaries are subject; (ii)&nbsp;the descriptions of the
results of such studies, tests and trials contained in the Registration Statement, Disclosure Package and Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trial;
(iii)&nbsp;neither the Company nor any of the Subsidiaries have received any notices or correspondence from the FDA, any other Regulatory Authority or any other governmental agency, institutional review board, ethics committee or other similar
entity requiring, or would reasonably be expected to result in a requirement for, the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of the
Subsidiaries, nor is the Company aware of any facts that would form a reasonable basis for any such termination, suspension or modification; and (iv)&nbsp;except to the extent disclosed in the Registration Statement, Disclosure Package or
Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test or trial results described or referred to in the Registration Statement, Disclosure Package
and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>Certain FDA Matters</U>. Neither the Company nor any of the Subsidiaries, nor, to the
knowledge of the Company, any of its or any of the Subsidiaries&#146; officers, directors or managing employees (as defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-5(b)),</FONT> is or has been excluded, suspended or debarred from
participation in any Federal Health Care Program, (as defined at 42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7(b)(f)),</FONT> debarred by FDA or comparable authorities pursuant to 21 U.S.C. &#167; 335a or similar laws, or made subject to
any pending or, to the knowledge of the Company, threatened action which could reasonably be expected to result in such exclusion, suspension or debarment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Manufacturing. </U>The Company&#146;s manufacturing facilities and operations and, to the Company&#146;s knowledge, the
manufacturing facilities and operations of its suppliers, are operated in compliance in all material respects with all Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Sanctions</U>. None of the Company or any of the Subsidiaries nor, to the knowledge of the Company, any director,
officer, agent, employee or affiliate of the Company or any of the Subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets
Control of the U.S. Department of the Treasury (&#147;<U>OFAC</U>&#148;), or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the European
Union, Her Majesty&#146;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#147;<U>Sanctions</U>&#148;), nor is the Company or any of the Subsidiaries located, organized or resident in a country or
territory that is the subject or target of Sanctions (including, without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s
Republic or any other regions of Ukraine as may be identified by the Secretary of the Treasury, in consultation with the Secretary of State, pursuant to Executive Order 14065, Crimea, Cuba, Iran, North Korea and Syria), and the Company will not
directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any
activities of or business with any person, or in any country or territory, that, at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
time of such funding, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; and for the past five years, the Company and the Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any
person that at the time of the dealing or transaction is or was the subject or target of Sanctions or with any sanctioned country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Sarbanes-Oxley</U>. The Company is in compliance, in all material respects, with all applicable provisions of the
Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Duties, Transfer Taxes, Etc.</U>
No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the Placement Agent in the United States or any political subdivision or taxing authority thereof or therein in connection
with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <U>Cybersecurity</U>. (i)&nbsp;Except as disclosed in the Registration Statement, Disclosure Package and the Prospectus,
(x)&nbsp;to the Company&#146;s knowledge, there has been no material security breach or other material compromise of any of the Company&#146;s or the Subsidiaries&#146; information technology and computer systems, networks, hardware, software, or
confidential, personally identifiable, or personal data (including any such data of their respective customers, employees, suppliers, vendors or other third parties collected, processed, stored, maintained or otherwise used by or on behalf of the
Company or the Subsidiaries) (collectively, &#147;IT Systems and Data&#148;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any
material security breach or other material compromise to their IT Systems and Data; and (ii)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices, except as
would not, in the case of clauses (i)&nbsp;or (ii), individually or in the aggregate, have a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)
<U>Compliance with Data Privacy Laws</U>. The Company and the Subsidiaries are, and at all prior times were, in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority, relating to the use, processing, privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, including without
limitation HIPAA, and the Company and the Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in compliance with, the European Union General Data Protection
Regulation (&#147;<U>GDPR</U>&#148;) (EU 2016/679) (collectively, the &#147;<U>Privacy Laws</U>&#148;). To ensure compliance with the Privacy Laws, the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably
designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, processing, and analysis of its IT Systems and Data (the
&#147;<U>Policies</U>&#148;). The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or
liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <U>Disclosure</U>. The statements set forth, or incorporated by
reference, in the Registration Statement, Disclosure Package and the Prospectus under the caption &#147;Description of our Capital Stock,&#148; insofar as they purport to constitute a summary of the terms of the Common Stock, and under the captions
&#147;Risk Factors&#151;Risks Related to Government Regulation,&#148; &#147;Risk Factors&#151;Risks Related to Intellectual Property,&#148; &#147;Business of ImmunityBio&#151;Intellectual Property,&#148; &#147;Business of ImmunityBio&#151;Government
Regulation,&#148; &#147;Business of ImmunityBio&#151;Intellectual Property&#148; and &#147;Plan of Distribution,&#148; insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair
in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby
represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the
Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has
no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#146;s right to sell the Securities pursuant to
the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is,
and on each date on which it exercises any Warrants, it will be an &#147;accredited investor&#148; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Experience of Such Purchaser</U>. Such Purchaser, either alone or
together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the
merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction
Documents (including all exhibits and schedules thereto) and the Company&#146;s public filings with the Commission and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition, results of
operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser
with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp;Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the
Securities and the Placement Agent and any Affiliate may have acquired <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp;In connection with the
issuance of the Securities to such Purchaser, neither the Placement Agent nor any of their Affiliates has acted as a financial advisor or fiduciary to such Purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such
Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period
commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending
immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#146;s representatives, including, without limitation,
its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of
this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short
Sales or similar transactions in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not
modify, amend or affect such Purchaser&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or
instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OTHER
AGREEMENTS OF THE PARTIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 <U>Warrant Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration
statement to cover the issuance or resale of the Warrant Shares, or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date
hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall promptly
notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall immediately notify such holders when the registration statement is effective again and available for the sale or resale of the
Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company
shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective for as long as any Warrants remain outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 <U>Furnishing of Information</U>. Until the earlier of the time that (i)&nbsp;no Purchaser owns Securities or (ii)&nbsp;the Warrants have expired, the
Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act, even if the Company is not the
subject to the reporting requirements thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.3 <U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of applicable rules and regulations of any Trading Market such that it would
require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.4 <U>Securities Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a
press release disclosing the material terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the Transaction Documents required to be filed as exhibits
thereto, with the Commission within the time required by the Exchange Act (the &#147;<U>Form <FONT STYLE="white-space:nowrap">8-K</FONT></U>&#148;). From and after the issuance of such press release, the Company represents to the Purchasers that it
shall have publicly disclosed all material, <FONT STYLE="white-space:nowrap">non-public</FONT> information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and
agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including,
without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each
Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with
prior notice of such public statement or communication, or if such disclosure is consistent with the Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection with the
filing of final Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure
permitted under this clause (b)&nbsp;and reasonably cooperate with such Purchaser regarding such disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.5 <U>Shareholder Rights Plan</U>. No claim
will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#147;<U>Acquiring Person</U>&#148; under any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of
receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6 <U><FONT
STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company
covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The
Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to a Purchaser
without such Purchaser&#146;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement
Agent, not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any
Transaction Document constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.7 <U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and
shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of the Company&#146;s debt (other than payment of trade payables and other liabilities arising in the ordinary course of the Company&#146;s business and prior practices), (b)
for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation or (d)&nbsp;in violation of FCPA or OFAC regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.8 <U>Indemnification of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
such Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#147;<U>Purchaser Party</U>&#148;) harmless from any and all losses, liabilities, obligations, claims,
contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#146; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon
a material breach of such Purchaser Party&#146;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser
Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in
respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser
Party except to the extent that (i)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or
(iii)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the
reasonable and documented fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)&nbsp;for any settlement by a Purchaser Party effected without the Company&#146;s
prior written consent, which shall not be unreasonably withheld or delayed; or (z)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#146;s breach of any of the representations,
warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The Company shall not, without the prior written consent of the Purchaser Party, consent to entry of any judgment or enter into
any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Purchaser Party of a release from all liability in respect to such Covered action, and such settlement shall
not include any admission as to fault on the part of the Purchaser Party. The indemnification required by this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when
bills are received or are incurred; <U>provided</U>, <U>however</U>, that if it is subsequently determined by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction that a Purchaser was not
entitled to receive such periodic payments, such Purchaser shall promptly (but in no event later than five (5)&nbsp;Business Days) return such payments to the Company. The indemnity agreements contained herein shall be in addition to any cause of
action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose
of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.<U> </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.10
<U>L</U><U>isting of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock on the principal Trading Market on which it is currently listed, and concurrently with the
Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company
applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be
listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the
Company&#146;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another
established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.11 <U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction
Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For
clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be
construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.12
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any
purchases or sales, including Short Sales of any of the Company&#146;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly
announced pursuant to the initial press release as described in Section&nbsp;4.4.&nbsp;Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are
publicly disclosed by the Company pursuant to the initial press release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other
representatives).&nbsp;Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant
hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section&nbsp;4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company,
any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agents, including, without limitation, the Placement Agent, after the issuance of the initial press release as described in
Section&nbsp;4.4.&nbsp;Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the portfolio managers have
no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.13 <U>Exercise Procedures</U>. The form of Notice of
Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise
their Warrants. Without limiting the preceding sentences, no <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 <U>Termination</U>.&nbsp;This
Agreement may be terminated by (i)&nbsp;any Purchaser, as to such Purchaser&#146;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties
or (ii)&nbsp;by the Company by written notice to the Purchasers, in either case if the Closing has not been consummated on or before the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Trading Day following the date hereof;
<U>provided</U>, <U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such
party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any
Securities to the Purchasers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 <U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and
the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via email attachment at the email address
as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at
the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>)
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Trnasaction Document constitutes, or contains, material <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the
Company or any Subsidiary, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or
amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the
Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or
group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be
a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof except to the extent expressly stated in such waiver, nor shall any delay or omission of any party to
exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and
obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities and the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or
affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and
their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights
under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents
that apply to the &#147;Purchasers.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.8 <U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the
representations and warranties of the Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and
permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any action or Proceeding, any claim that it is not personally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the jurisdiction of any such court, that such action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If
any party shall commence an action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section&nbsp;4.8, the prevailing party in such action or Proceeding shall be
reimbursed by the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or Proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.10 <U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.11 <U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission, electronic mail, or otherwise by electronic transmission (including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,www.docusign.com) evidencing an intent to sign this Agreement, such
facsimile transmission, electronic mail or other electronic transmission shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#147;.pdf&#148;
signature page were an original thereof. Execution and delivery of this Agreement by facsimile transmission, electronic mail or other electronic transmission is legal, valid and binding for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.12 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.13 <U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the
other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>,
that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the
aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#146;s right to acquire such shares pursuant to such Purchaser&#146;s Warrant (including, issuance of a replacement warrant certificate evidencing
such restored right). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.14 <U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.15 <U>Remedies</U>. In addition to being entitled to exercise all
rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate
compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at
law would be adequate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.16 <U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any
Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or
preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.17 <U>Independent Nature of Purchasers&#146; Obligations and Rights</U>. The obligations of
each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of
the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any
other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative
convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through Placement Agent Counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Placement Agent Counsel does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document
is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.18
<U>Liquidated Damages</U>. The Company&#146;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial
liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.19 <U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are
to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction
Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.21 <B><U>WAIVER OF JURY TRIAL</U></B><B>. </B><B><U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Pages Follow) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IMMUNITYBIO, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Address for Notice:</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3530 John Hopkins
Court <BR>San Diego, CA 92121</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U>&nbsp;/s/&nbsp;Richard&nbsp;Adcock&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Richard Adcock</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Executive Officer</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-Mail:</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard.Adcock@immunitybio.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12235 El Camino Real</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego,&nbsp;CA&nbsp;92130</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>mwaters@wsgr.com;thornish@wsgr.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Martin J. Waters and Thomas Hornish</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOR PURCHASER FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[PURCHASER SIGNATURE PAGES TO IBRX SECURITIES PURCHASE AGREEMENT] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Purchaser: CVI Investments Inc., </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: Heights Capital Management, Inc., its authorized agent </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of
Purchaser</I>: /s/ Martin Kobinger </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: Martin Kobinger </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: President </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address of
Authorized Signatory: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Notice to Purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Delivery of Warrants to Purchaser (if not same as address for notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscription Amount: $ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant Shares: Beneficial Ownership Blocker &#9746;4.99% or &#9744; 9.99% </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EIN Number: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Notwithstanding anything contained in this
Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such
securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the second (2nd) Trading Day following the date of this Agreement and (iii) any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be
a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[PURCHASER SIGNATURE PAGES TO IBRX SECURITIES PURCHASE AGREEMENT] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Purchaser: Armistice Capital Master Fund </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Purchaser</I>: /s/ Steven Boyd </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: Steven Boyd </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized
Signatory: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address of Authorized Signatory: CIO of Armistice Capital, LLC, the Investment Manager </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Notice to Purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Delivery of
Warrants to Purchaser (if not same as address for notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscription Amount: $ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant Shares: Beneficial Ownership Blocker &#9745;
4.99% or &#9744; 9.99% </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EIN Number: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Notwithstanding
anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the Closing shall occur on the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) Trading
Day following the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the above-signed of any agreement,
instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A</B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Form of Warrant</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d644968dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g644968snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CULVER CITY, Calif., February&nbsp;15, 2023 &#151; ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that
it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors, providing for
the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $50&nbsp;million before deducting any
offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to $60&nbsp;million. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC is acting as the exclusive placement agent for the registered direct offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities to be sold by the Company are offered under its shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT
STYLE="white-space:nowrap">No.&nbsp;333-269608).</FONT> A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be on the SEC&#146;s website at www.sec.gov. Electronic copies
of the prospectus supplement may be obtained for free by contacting Jefferies, LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388,</FONT> or
by email at Prospectus_Department@Jefferies.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before investing in this offering, interested parties should read the prospectus supplement, the
accompanying prospectus, and the other documents that are incorporated by reference in such prospectus supplement and the accompanying prospectus in their entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ImmunityBio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio is a
vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company&#146;s range of immunotherapy and cell
therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. These platforms and their associated product candidates are designed to be more effective,
accessible, and easily administered than current standards of care in oncology and infectious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">N-803</FONT>
(Anktiva<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), ImmunityBio&#146;s lead cytokine fusion protein, is a novel <FONT STYLE="white-space:nowrap">IL-15</FONT> superagonist complex and has received Breakthrough Therapy and Fast Track
Designations from the U.S. Food and Drug Administration (FDA) for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> CIS <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer (NMIBC).
<FONT STYLE="white-space:nowrap">N-803</FONT> is currently under review by the FDA for this indication with a Prescription Drug User Fee Act (PDUFA) target date of May&nbsp;23, 2023. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has established GMP manufacturing capacity at scale with cutting-edge cell therapy manufacturing
expertise and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-scale</FONT></FONT> facilities, as well as extensive and seasoned R&amp;D, clinical trial, and regulatory operations, and development teams. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the anticipated closing of the equity financing described herein and use of proceeds to be received from such
financing, the development of therapeutics for cancers and infectious diseases, data from the clinical trials for certain of ImmunityBio&#146;s product candidates, clinical trial enrollment and results, the regulatory review process and timing
thereof, timing of regulatory submissions, timing of meetings with regulators, potential implications to be drawn from clinical trials, potential commercialization of product candidates, ImmunityBio&#146;s product candidates as compared to existing
treatment options, and intellectual property protection and patent life, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of
words such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;continues,&#148; &#147;goal,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;scheduled,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148;
&#147;potential,&#148; &#147;predicts,&#148; &#147;indicate,&#148; &#147;projects,&#148; &#147;seeks,&#148; &#147;should,&#148; &#147;will,&#148; &#147;strategy,&#148; and variations of such words or similar expressions. Statements of past
performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements
are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio&#146;s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete,
and ImmunityBio&#146;s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to
future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i)&nbsp;whether the equity
financing transaction described herein will close on the timeline anticipated, if at all, (ii)&nbsp;whether the FDA will approve ImmunityBio&#146;s filed BLA and the risks and uncertainties associated with the regulatory approval process,
(iii)&nbsp;the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions,
(iv)&nbsp;ImmunityBio&#146;s ability to retain and hire key personnel, (v)&nbsp;ImmunityBio&#146;s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates,
(vi)&nbsp;ImmunityBio&#146;s ability to successfully commercialize its product candidates and uncertainties around regulatory reviews and approvals, (vii)&nbsp;ImmunityBio&#146;s ability to scale its manufacturing and commercial supply operations
for its product candidates and future approved products, (viii)&nbsp;ImmunityBio&#146;s ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies, and (ix)&nbsp;the
unknown future impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on certain clinical trials or their milestones and/or ImmunityBio&#146;s business operations or operating expenses. More details about these and other risks that
may impact ImmunityBio&#146;s business are described under the heading &#147;Risk Factors&#148; in the Company&#146;s Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) on
March&nbsp;1, 2022 and the Company&#146;s Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;9, 2022, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC&#146;s website at
www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this
press release, except to the extent required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Singleton </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">844-696-5235,</FONT></FONT> Option 5 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah.Singleton@immunitybio.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Katie Dodge </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salutem </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">978-360-3151</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Katie.Dodge@salutemcomms.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ibrx-20230215.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/15/2023 5:49:53 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:ibrx="http://www.immunitybio.com/20230215"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.immunitybio.com/20230215"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230215_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230215_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ibrx-20230215_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/15/2023 5:49:53 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ibrx-20230215_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/15/2023 5:49:53 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ibrx-20230215.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g644968g54n21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644968g54n21.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8T*J45HDE3DDDELEL?FO_P $DP1\)OBB2Q8GXB6/7   \)Z-C KU,VTEA_\
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MU46WKI;<_2S6M6L?#>AZMKM^3#IN@Z5?ZM>F) 6BL=+M);RX,:9496W@?"Y
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MSTMM9KST^3P&3K#8)9A23=>DZCFN\4XU(M*[5XM.^]TUHN5WPI/VA+_]HO\
M:-_8Z\3Z]:&V\6^&/$/PJ\'>+;A%@CL]8U?3_BE->Q:Y81P-MC2^T[4+*>:)
M4C2*Z:ZCB7R4C+:+#+#9=B(Q=XU'*:7:]*S7I=:>6G2[X8X^699W@*DX\L\,
MJ=&3O\3AB;J72S:DDUW3:T:1^Q'_  4"X_9#^+W;]SX)]O\ FI'@\5\Y@_\
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F;5PGM!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g644968snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644968snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $4 S@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@!"=H/!..PY]NPHV!?=8R=3UO3M%MY;W5KNSTO3
M[=6DN=0U"[AL;&VC39N>:[N2D,?S/@!G!.TXS@X2O>RCL-VBM[6/D'QQ^W#\
M,/#5W]D\,&V\;".9H+B>SOM6TVWC*%06AG?PQ<Q7B988:"1U(^8$J":Z:>'<
MMY<ORO\ JCFE74'91YK>?_ /;OA3\<_ _P 7+"2;PU?HVHVD8DO]*:'5(I+4
M A6\J?4M)LEO44Y!>W5UXK*K'V/7FM\O\RH5>;[-OG_P#V93D ],@'TQD5FG
M=)[71LON%I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!BZ
M]K6F>'M&U36]8O(;#2])LY[[4+N9PD=O:VL;2S.QP3PB-A0"2>!R14TVW-QL
M]&_P9G4ER1OM;[S\,_VA/C[K_P :O$US%'/=V7@;3+R2/PUX<8-&'A@=X(M6
MU:TBN)$NM9N!,V1&'6W2>.WB8LDDMQZ,(1IPNX_@<+J.H[*37+WT^[N?8W[-
M?['NC6^E:=XW^+NE+J^JZM:BZTSP=?1N=.TJTN%2>&Z\16K[3=:U(I)^R/F"
M&.0"1'G+>1A4Q/*G&/N]M#>&'>DGK;_AC]$K'3['3+2WL=.M+>PL;2%+>UL[
M.%+6UMH(QB.&"W@"I#$@X544 #@ 5RN3GW^9TP@H]+6+H& !Z #UZ>YJDK)+
ML5M\A: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!K,$'0G S
MP,] 3T[GC&/<4 ?F9^VI\4K_ ,1:O8_ SP>+B^=9K75/&8T^SU"_F24%;C2M
M)E33K:>7[)"CP:A<QQP2L6DM!D>4R2=-.'(E/;L<>(ES-06EK+[BA^S?^R)+
M)K&E?$'QSJUK?:;HM]]KTGPT-"\7:7/>ZC"I:*XUB/Q?H>AW-M:VMT8YHX8K
M"YANB$S,(HVCN*GB5%<MQ?5F^25MEW/U!12N.<X ]LX'7%<+5YJ71?Y6.R*Y
M8J/8?5C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!C$@X!Q@9
M^F*:6GH2W9\J^+H1[SG (X..,<>V*S?/>R2A'^:ZT^6N^WS'&-1-<RT^7R.&
M^(WC2#P'X3U/Q))$;VYMDCM-&TN(%[G6/$&HSQ:?H6C6L*.K2S7FJW-I!E2#
M&':1CM1JVA#FE!7M'J_ZV)DW3C)S?*EM^A\O?#']DC2TO9_''QHU"^\8^/O$
MK2ZKKEA#?7%GX>L=1NK@74L._26MWU-XY!$/WDD5H#&%@M-D:R5I4JM7A!^[
M'1:=%HMU<RA2C)J<ES7UO?\ R9]GV%A9Z596UA8PI:V=G!%;6T"%BL,,"+%%
M&&=BQVHJC+$DXY)-<G(Y2]Z5DME_78Z7?2,%HE_6Y>4\CG([=!P![544X7BW
M?^4GE<;7=FNA)5#"@ H * "@ H * "@ H C9B.AQ@^W;./UQ4*Z=F^5-M+^O
M1":=X\KM9Z^FHT,V#SCTX QC@_R-5)JFGKS<N_Z#47&I*[O#3E7;17_$<A/0
MGI]!T^E3":J*Z7+;H.5E:VB)*L0E3:7< ^A''T/^>*+276P?@(#[CY>O3BFK
MKT0E===AW_ZOR_\ U4QA0 9 ]L?AC'_ZJ #^GZ8H Y'QMXU\-_#[PWK'B[Q9
MJ,.DZ#H5A+?7U[</&BA8P1%:VZO(IN+^XFV06]M'F2>::**,-)(JGIPF"Q6.
MKT<+A:;JU*\U!1CNM+N3[05O>:O9:M<J;7-B\3A\!AYXW$34(4VH[-N[V27_
M  3\Z;?]I+]JGX\3ZM=?L\?##2] \"6U[)#IOBOQK''%J%_!%*Z(R_VCJ,5A
M]I=0QFL[*VU0PL5C-V,@M]RLBX:R.+H\08Z53&1BU*C14ZD(SMS+7W)>[:U[
M\M^G5?'U<US[,:D9Y51E#"2DN64W3@Y1VNK.6G76SLN]D?10\9D+9^,?C1KN
M@Z#HOP6TS2K?QG<V:7,OA>Z^+^NV%E'=2:?)+"TM\FA:?J]O:6RVZS WOBFX
M "SZ>NSXIT'C<;+"Y13E*G5<W14N6$E3C=I-RE9-17\SVMS-VO\ 4*HZ&%YL
MSDH^P454:NTY.VJLE=:KHO0^G-%US2/$.DZ=K.A:A:ZII&JV=M?Z9J-C*MS9
M7EE<1I+!/;SH=LL+QLO(.>2#AE('%4HUL)6JX?$0<:U!RC.+:;O%V>J=G9]4
M[/=7.VA5H5Z-.>&ES4Y13@_[MM//;_@GSAXK^,GB[1/VJ/AK\%;.#1&\)^,?
M!.M>(M3NI[2\;7(;S3H?%<L$5E>1Z@EO%;D:/:Y$EI*WS. PX:OHL+E>'Q'#
MV89I)M5<+4I1@D_LSE"+^=Y+K:U^MCQ*^9SHYM0P$;QYHR<KI<KMM;=[/JD?
M48E12,\ ' .Y!GG83C=_>..E?.6M&]G[MNC;U5_/9;GO24?=ES*\;:7[JW6R
MZDGG1C'./3D''7@X)QTZ].1SS2YXJ/-JE_AE\NGD-:[->[NKK3[@$Z$9&3QG
M;P'&!GE"<@XQP0*<7=7LTEM=/_(ER2:2=WV37Y70&95SPPV@GH.BY[9ST4G!
MYHNE;HGL[-K\+E:;)IR71;K[[+\1/M$8XY!&!C*Y!/&,;NN>*OE=K[+6SL^F
MKZ=$C/VL5.5-:RIVNE;36*VO?[2 7$><#)[ @H1QCON]_P!#6:G%JZ?,DKZ*
M6WW%.5JGL[6:5[W5M+=+WZ]A1.F 0&P1D?=7(P,8#,.N0/J?>DIQ;A&-Y.2;
M6CT2[WLUMV+TBE[R2?F'G+Z-@ G/RD<9[AO;^7K5-J*>MN5VM9WWMV!I)?$O
MZ^0&=%SPPVD X ."1QT/T'UI<R4W#6\8\VSVT_S_ #!)6TDK+^NP>?&.,XQV
MRHX!QG&[IQ1&49)N-[1W]V73Y?D3>*:7/%75TVRC?3W L[QK&-9+U;><VD<A
M'EO<B)V@20B9,1LX52=Z  \LO4.DZ,YTG5DXPA-<RLU+E=UHFM[.^Q,N:5.K
M[+248Z7:2>VS5]^FQX/X-\;?%3P[\&_%GCGXZ>&M'T?Q5X3LO$_B"XT3PK=V
M<EI<>']"TI]4M_(F.L:A"MW,D%W&2]SU0$A17I5J& KYK#"X"=Z>(=./OQJ7
MC-J,?>5GM_=OOH>=2Q%>C@:E7%0DG3NT[P=TG]FTOSL=?\%/B%/\4?AGX1^(
M5YIL6D3>*+"?4#IL%Q)=QV$<>H7MG% +N2&(W!$4$3%S''N9W*HJ[16>9X/^
MS<?5R_24Z'Q2@I<C]V,M'*,7=<VS2V[FV!Q4,3A88E*483T2ER\RLVM4I25M
M.C>Z/6@X]", 'L,9SQUZ\5P<VD=&E+3IIOOKY=+G=MULNAY!\=O'VL_#;X3>
M,?&WAV'3Y]8T"VT^6RBU>*2?3RUSKFFZ;-]HAM[RWE?;;W<Q0)*OSHA^8#:V
MD(\THPC%R;;5EIM?O;30QE4Y.>_NJ'72WRL[_>D?.WA+QO\ MF^+_#>B^*]$
M\/\ P4?2==TZVU;3A=/K]M=/:7,0>!9X5U\"&79M!&YL$=<"M)Q5&HZ4HVE'
M?L9J<ZL(U*4TXM;:IJSMU7ET9V7PL^.OCN^^)L_P;^,G@ZP\*>-7TF76]#O?
M#]Q<7&@ZY9V\;S7*0BYNKEXSY,=R\4B7$@86-U'(L4D0#4Z+5-U%:RMIUWL.
ME*I[2,)>?Y,];@U#XKM\5[K3I]"T)/A&/#:RVNO+/&-??Q&/(?['+;MK#2BT
MP]V,MIX'R#Y^><>6RO=>FO\ E;\3H3][E['K(D1% P0% '10!C@  $<\=%'T
MI695K=5H5YQ'<1R1$R1B6-HF:-A',BNK1Y4@[HV42,<@97&3BE:P6MU6A1T'
M1DT.TEMH[_5-06>Y>Z$NK7TFH7$0>**);>&60#R[5$A3;&. 2YS\U&WR%L?F
MS_P4"\5:AJVN?#3X*[9+/0_%'B/P+JFI:I"Q1G74]6\6>'9=/E/"F%$6&[P>
M0T"L,%01^C\#X1T\/F.<4VE6PE.O3AM>+Y</[R33L[5&N:VS9\1Q9B*DJN%R
M^I#FP565*<K;\_-525E[UK17D?>6J_V3\+_A\+'PIH4,5IH6F66@^$O#6FV5
MS+!-?W#IIGA_2Q!:+)*(9-2N;<37+$"..2>YG=5CDD'Y_7KU<;BJE;%3=>O7
MJ3G4J3UUO*_Z1LHZ+;0^MPL(8+"T:6'BZ=.A3AR*,7VBNS?4YC5/A/HNI_!G
M5OAEXH>+Q#!J&@:D=<U;48(A<:CXCO7N-:O?$Y5"%AO?^$AEDU&-HMOE2)'Y
M>WRU"]&7XN6%S' UJ%X\E:,/=T]W522VTDDUZNZ[DX^C#$X.O3K)3]K3YG?1
M)JS5]DK6V\CYE_X)P^+-5\0? _5-'U*YDN;?PAXSOM(T:1VW+%I=]I^F:V;2
M/(!\N*_U&_<;BQ N0 0BHJ_2<=X6E0SCZU3CR_6\/2DXK=2E1I.3:ULW)MMW
M=]SP>%*D_JLJ;;<,/4J4XK=6A.<$EZ*-D:'Q#P/^"@GP)_V?A3XH_2P^(A_F
MH_*GED8T^!LYB_XCQ6'2?9<]-OTZ?<3BO92XFP<7&U1TZEM'LH_\ X_XGW7Q
M7\7?MBR_";P?\3_$O@GPWKGPWT^[UF?3;NZD;1-/MYI;^_N?#FGRW*VMGKMY
M+8V-I]N$8DBCOY9 7 ,<G=@HY/E_",,UQ6#AB\9'$0A"+CS*4FZT(\SORV2C
M=W32MM<Y<3+'8GB*OET,3.AAU&]XR:Y5&G":M;57>FG?L><_%/P[\4OV7?BA
M\+=&^&?Q>\=^)8/C1=:KX2:R^(VLMXDM+'7;R[TC0[776BVP1O+:7'B6RU"$
MB,2F33FCFEEBE9#U99BLJS_*L:\=E-'"5\L2JT_90C'GA&:]V3@[>]%^\GNM
M=);9XVEF658RA&CCIU(XY^S2E)Z-QO>TEII'[^YL_'[X5>.?V=/!\7QL\*_'
MKXM:_P"*='UW0X-:M/%.N&YT+6H=2GCM9(8])ACCBM+3[28A]EF%X@BD8+CR
M\CFR+'83/,:LHQ64T*-.I1KRIRA"":]E&4XZPL_ACY.^YMFN QF5TL+CZ>85
M&XU80JQYWRWES1E9:JW,M+:6VTL=[^U]\0OB%I'BG]F ?#?Q)JOAR_\ 'VI:
M[IZV$>HW<&F7-]K7_"#:?HAUO3K.ZBBU1-/O-8$R1W'FQ[FD4J8W93R<+Y?E
MT<3G]',J,<72R^G6MS1:490JJ"<=8\N[M9Z?<7G5;'\N5U,NK.E/$SI\[YDM
M'3DWNGIHNFIPOQ^^$_CS]G?P9%\;_#?QX^*_B;Q?H_B+0/[=M/$^NM/X=UR"
M_O4MYX%T2)%%G9_:3;?Z--)=J(6<(R,JLO;DF8X#.,3+)<3E5"AAZ]*K[.I&
M$.:FZ<?:*TE:7O*,HMV6]FFFVL,UPF89906987&RGC%5A&<)3]R2FW&7Q>Y:
M.DH^<5;6U^M\3? WXE>+OAIJ'QL\0?''XF:+\23X3OOB!IN@^'-;GTSP%X8_
MXEDFN6_A;2=*@!N190VS"R-U]L\]_)\QUG+%Y<,-G&7X+,*>34LEPT\)AJSP
MM2I*%-U*MVX^TDW9[K9;::Q5D;5,'C*F#GF<\PJPQ,J:ER*4E!72NE9<O32W
M_!,;Q]\7?B!JW[ OA?XF)XHUG2?&]U<:/87?B'1[R32=6NGT[QC>^'I[M[O3
M'A9)+JUT_P#?F(JDC3-QAJ5'*LOH\<ULM6'4L,E7J0I\KFHQ=#VL(]?AYE;5
MO3=V"MC,13X<P>+=24JLI4H2E?5OFE%N_GRGZ(^&I9KCP7X?NYYII[N7PUI4
M\MU++))<RS/ID$KS23NQ>25W&YG9B6/))S7R6,5*GG&+PU*DE2I8NI3Y>5*,
M8J<K*S[))6Z>J/H</*I/+XU9-IO#J5WH[V3^\_.;]G+Q]XYUS]BKX]^*]6\9
M>)=2\3:(/B4VC^(;W7;^XUC2AIOP^T:^L?[.U&XN&ELUM[J666(1.@5G)3!.
M:^HQ^!H87B;+L-+"TXT:E/#.45%-24Z<&TTN[U\FKGS^'Q^)EDV.Q,9RYZ3D
MHN^UJG)HWIL:/P>^!_Q#^/\ \*?"7CSXD?'CXIZ;)J&E_P#%,:)X0UY].L=-
ML=.>;3+75=<GNUNKC7M>O)[.6^GE:6)P;P1I*$157HS?-LMR/-\9A,!DV'J4
M*4XQFIPB[MQBVES-\J4GNKVUM$,KP.(S7*L+B:V.J4IRC+X923LI36T;=CT/
M]EGQ=\07L?C_ /#7QWXMU#QEJ'P=\4:CH&C>*M0D9M6NM/>#6(;=I[DL\SRI
M/HAN(V>::2/[84,K>2A'+Q-@<L6-R+&8#"PHTLSAAZU2DERQ3J4J<Y046W&R
ME-JRTTTV-\KQ&(A3S3"UJ\Y1P$9TJ<U>3:I-4XO3WKM1UOKJ[ZGBGPWB\6?%
MO]AGQMK'B7XD_$%=8T"Z^)/B"75+;Q)>2ZAKUIH7A2^2+PMKMW?&YEN_#-T+
MG$UJ&4'RU((YSU5JF$RKC"@J&5T)4YK#QE&4864Y0I^^KM^\EJO[R6QQ4HU\
M;D$Y3QE23@Y23;DFHQG)<KT5O1]&:GPO^%'C1OV-K[Q1X(^*_P 3K3Q+K/@V
M#Q)H.C+XFN(M(\/S^%]4U6]N-&\,06!@N-/MM6LQ>VLD9F</)/%(V?+7;OFF
M9X"7&$J&.RVC'#J;C.480;?-0487U5^6<HMVO91=KVLUA*&(AP_/$X7$SE/E
M7)&[TY:JOIT]V,OO\SZT^"/QGM?%'[-^@?%;7=0CN;C1O!]]<^,;E6C6X;5/
M"%K<1:]<3J>([BX;3Y;L)M4$7T)4*K"OE,RRFI0XAQ&!HI+#XBLGAU'5>SJM
M.G9?RJ^NME9ZZ7/?RS'JIDM+'8B6M"BW4N]>>-XV>NDFUMOY'R-87GQ!\4?L
M:_&+XH_$37]5U*]^)NO0^(]#TF[U&]OM/\,^'(/&FD6NGZ9HUA>3F/3;-KM-
M1EBBA5%^S_8^&88KMS^GA\%F-'+\#3A2G@Z5.G5G&VM54HJHW+6[YD[OJV[I
M-'#EDZ^+RZ>.G4E*&)FYPA*Z:ISJ2<59[)1M;R2.F^%?[27Q1\,_#7P5X?TG
M]F/X@>)-.TCPUI=E9>(;/_A((].UB&WM$":C:B'P-<(+>5]Q&)W^N,5X$J/O
MSG*KSRD[O7;I;7R['N4JD:5"G&-)QM'HNOR+OP=\<O\ %C]IF#Q;\3+63X=>
M,?#GAB\T7P+\.=0TO5[6\N;6>#4FU&]N=5U2WMDNKN.'5-3V0QV\$DRM*RQ(
MEDS3DGRTW!:)VO\ )K_)$PK\U:,;-/6VGDSUJP\5>(A^V;K7A-_$&L'PK!\,
M4U&+PZVJ7IT2&^"Z9F[CTHS?94N,22GS1%NY;GDYEI*DM+6*C-JLUKIT/-_!
MT7BS]K#Q!X\\17?Q$\7>#/A/H'B*3PUX7T#P1>?V/>:S]F3[0^I:I>.DBR$V
ML]A<2>=!<#=J!C4PI;[YIC4C%)<NL44U-MV>E]$C0@O_ !E^S/\ %SX=>#]3
M\<>)_'?PJ^)TLN@Z5%XJN5U75_#6M+<V5I"T5_Y4;&".ZU6P^5(XHY+>XN"T
M7F01M5M1G2G-)1<&E;_@$QE*%6$&W:2?X?D??Z'Y5Z_=7KG/3OG!S7*MD=>S
M:['R'^V/\%=6^+WPTD7P='''X_\ "NI:5XG\/3+,MI<WW]C_ -IQ7&DQ79CD
M$<S66K:A/;HR!7NH;>-GC60R1_6<(YTLHS+EQ>N68FE5HU5:]IU%'EERZ.R<
M(7:V1\_Q%E57'8)5L)+EQF'J4Y15[7A#F;7;[3^X\L^$'[=WP]O=(LO#_P ;
MKB\^'/Q*T0-I>OP:GH>I)IEY?6D:QR74?V2WGDT2>;<LDEG>QP".3S(XGD54
MV]^9<%9DJ]2OD\88[+<;-U,/&-:"G",_?47&I*,DXKF6LI/>[UUX<#Q5A(0>
M%S*=7#8K"Q4)KV<G&3@XIM.%T[[]/T.>^.G[:?AKQ;H=U\,_V>!K'C_Q_P",
M%N/#D&H:;H6HQZ;I=K?PO:WUU:&^A@GO-06*4)"ZVYM8PTES+,5M-DG1E'!V
M.P-?^T\^IT\%EN _>6E6A.;DK*'NTY2?Q.^]M-=&89KQ%2QM%X3)U4G4Q'NN
M7(XJV[UEZ=CZC_9@^##? SX1Z!X0NUM6\07)N=?\77%K.;B*7Q%J?E":&&8Q
M+]HAM;&"SLA-\N\:<KA3YI-?+\0YO_:V<U\12<OJOP44]+4H)1INVMFXI:=-
M%=GO9!@)9;EV'I5$E6DN>I9W]^;<Y:^LF>&?$,[?^"@7P+;&%7X5>)E[#DV/
MQ&4#!//W6Z9X!KW<"D^"<]2Y7..(P[Y6];<]+;[E?L>+C'R<4X*K-RBE3J15
MK]8V_0BMV4_\%$[D#/'P23&58#"R1*2#C!&>A!HJ*'_$/\'[L8N.-AS)6O\
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0>5C4* "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139646051445968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ImmunityBio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">633-0300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d644968d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ibrx-20230215.xsd" xlink:type="simple"/>
    <context id="duration_2023-02-15_to_2023-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-02-15_to_2023-02-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-02-15_to_2023-02-15"
      id="Hidden_dei_EntityCentralIndexKey">0001326110</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-02-15_to_2023-02-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-02-15_to_2023-02-15">2023-02-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-02-15_to_2023-02-15">ImmunityBio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-02-15_to_2023-02-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-02-15_to_2023-02-15">001-37507</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-02-15_to_2023-02-15">43-1979754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-02-15_to_2023-02-15">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-02-15_to_2023-02-15">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-02-15_to_2023-02-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-02-15_to_2023-02-15">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-02-15_to_2023-02-15">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-02-15_to_2023-02-15">633-0300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-02-15_to_2023-02-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-02-15_to_2023-02-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-02-15_to_2023-02-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-02-15_to_2023-02-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-02-15_to_2023-02-15">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-02-15_to_2023-02-15">IBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-02-15_to_2023-02-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-02-15_to_2023-02-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )Q*3U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "<2D]6!KNH!^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>.FTIAZCK98@32$A, G&+$F^+:/XH,6KW]K1AZX3@ 3C&_N7S
M9\F="D+YB,_1!XQD,-U,=G!)J+!A1Z(@ )(ZHI6IG!-N;NY]M)+F9SQ D.I#
M'A!JSN_ (DDM2<("+,)*9'VGE5 1)?EXQFNUXL-G'#),*\ !+3I*4)45L'Z9
M&$[3T,$5L, (HTW?!=0K,5?_Q.8.L'-R2F9-C>-8CDW.S3M4\/;T^)+7+8Q+
M))W"^5<R@DX!-^PR^;79WN\>6%_SNBEX753MKKH5-1=M^[ZX_O"["ENOS=[\
M8^.+8-_!K[OHOP!02P,$%     @ G$I/5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MO[%_'_?J[\@66A= U@78(=L)V+B_CUOUBH>%LM./^FOR*$S2.OTZ1&P/RVV
M#)_.2,X4>69)P<D[[\)N'$D.7=4Q4RCRP>8?M^Q'Q2);>JO7="U;"Z]#8'']
M\"=&TMB]CUMSG;S;ES!FV98?W:AU"-W/5C>SWS"FQN?]DWS^-N5J:[/T'A1,
M;(LP9UGKSK]#\&BMN0<G3'M:_\SL%S5)^ :$O(LA>+:J#L!5P\B\/'2NI8$C
M;'D9<P;SP+X SS=2FK>&/<?6_X:8?@-02P,$%     @ G$I/5I^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ G$I/5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "<2D]6!KNH!^\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "<2D]6F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )Q*
M3U;0LHW$3@0  )(0   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "<2D]6GZ ;\+$"  #B#   #0
M        @ &2#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )Q*3U:7BKL<
MP    !,"   +              "  6X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )Q*3U8<.&7J/P$  #P"   /              "  5<0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "<2D]6)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "<2D]699!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d644968d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d644968d8k.htm">d644968d8k.htm</File>
    <File>d644968dex101.htm</File>
    <File>d644968dex11.htm</File>
    <File>d644968dex41.htm</File>
    <File>d644968dex51.htm</File>
    <File>d644968dex991.htm</File>
    <File>ibrx-20230215.xsd</File>
    <File>ibrx-20230215_lab.xml</File>
    <File>ibrx-20230215_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d644968d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d644968d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ibrx-20230215_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibrx-20230215_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ibrx-20230215.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ibrx",
   "nsuri": "http://www.immunitybio.com/20230215",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d644968d8k.htm",
      "contextRef": "duration_2023-02-15_to_2023-02-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d644968d8k.htm",
      "contextRef": "duration_2023-02-15_to_2023-02-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com//20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-23-039833-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-039833-xbrl.zip
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M$\-I-'XTI.LV#)K=ADTQ$;%(__'RF6NK_2,6'6*O</>>13%WJ6^(JQ=<.M+
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M*I-0*'\@Q=+D<79(2MD*FT'J\..LE]H64;1DQB K:!YS?8J,1-OCJDC3<!)
MS#]ZH!_=CB!"3*5P!KNF*A^HFC.G$3$@H03@>M^Y8K7&TBTUPK(@JY6LYTD]
M#@JN\4.J!L'&P>S(T:R_M1AKE1M<:][2P*YB H$20"CN%F<TYSS0<\YZ8[59
M6;9>%^QJH&((I)4MX\4%.DY BX%9'MB: $4/+!"H;BBDCM247<Q03A%2W]&O
M2'!5P("S(R"P!,Q P8GZ8' '/"ZN#'U.'JX.)\=@YL&L9L($GX^Y69]U!TF(
M\99F("XLHB;BTL"W(YD8_0V%"8X4(4'#P9,/C*,+LZW0:9=>N;-63=K%(/G*
MAKN_:B:G$@6\U,3S!*"%7D6Q+XJ-CZ*ZN,5B5H:**BN8P'2Q)**D,M6$H:>"
M-:*WS;T@ T_D12R>(FO2%RW:J&2]M56RBX._F"!$S%A%BC7@$>_#G#;K=RJD
M77/40TX#OX%:A-J6^:B/B .@W$NB"'71O.,'35MJ^O>K/^N5I>=O82I<-0]R
M"]J.=/EL"-(B0HC5->M^Y1!U OF 5W"-?!3"@RQH9#P '8>'\#B&UQ5R5>O5
M ']?)SN&'PH@Y,"6T6GPG\TJ"Q&;L1W9+*#($3U_!WA1H+F^80C_!,\,[*FE
M?EB7Z3)50%4.^_N6 E_L6.?R.A!P#)R05_TDQ!W*R(T-Q^1FZD 'ZVM/J>(O
M%<&<Z.D/)N"0Z=$8LU;?K%7.UHJ1FU&7,:-!)H>^BO@]9N:9D.X3_#%'9:Y1
M#,>SK:V#3HV<0*Z0 6VPL+Y\8ZM#*VM7Y@F3G?B(*J@R."P07>468$8(7[!T
M2C!S)W(D$@S^E2_&<B^&DHM)4R,?%I,-C7S&]]\!NH&R2$F@/T=<WDESQ:1F
M.ED;F\-$NFG!A!%]-A7HUY)(QPG"K\WB+XLX!MT@+MH7ED+/DQRAZ3-.<KT
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M_5/?TK72*_WQ^,BL)^12_1!*5-RVS&:'Q33CJ-X7WA2NC.*Q?_S_4$L#!!0
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M^?;6,Q@3"/*W138'=P8D^/.R.*U3?N2S0_[OCP?[CQ[>GYOTO&S5MC[.IA_
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M#MWD8K)11)GL]3>SWKT_^N,8[L8)1B@\CNL8[HF=,((NYFWR'X_VGCQY]#!
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M1L-NNHJA'K@7H\"TSR4N,H]24JKWZ-;J:+>WCN$<7=X>LN^'^S-)BP/;WG)
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M<T!MJ(:\GY#@RF)8+]4@9P7#8'@9!M8@E06 ,Q.";7.0J)G4G\,?+78H.\_
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MLR8L^S\NY'!-._F "0OISDCN\O,'B<#$0G-]!,=(9D"R4_PS+99DN&$- 9?
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MCU8;W3WL60/_ V>#D<_3SNA47PH9Q5VC)M+!"]FJ<IQZ6>M+,66OUS**D4G
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M+V;UA4CBU(?#=%DW*9P=<$'C6S)^_E-Q665OR='!8G&I[KP,3SEO_U47MQ>
M\%+2D60'9X>FGWE"I##Q7T?M+># N$_3XI^!9?2 H@4HC6HD&J#0085609';
MG+"!6,>'G],U?8'./> 9\1SP1(@E^J&D4E'N,Y(R9()<@;R/5VT""T"?W/*7
MHGWT!E"PD52BXL13, &Y+S 2GG"PC$X!@26IA@D::C!HD%LC),.C;YJM>=/G
M-UJ6DLG("^I@@ZQ4[%)F2B\$%DM3M1T?S__,%LNGR;_@ Z?)JU?'J6-U;Y6S
MJ^ K52_+RJ4PPEY6PVZP].BFXPA/6SEC*% .8G1J'3;K$+@IA<N-[HZ3$;$N
ML+6\(\;-4*N!03NK;$V%9T772)?1F-7+%<CXJ?750>XN+-.]GJ<8ZQ*'TU(W
M"D8H*/B"7Z"G\="_""/D+>4PN>[8!P&.GQV^^370^ZCWB".*PWRC$,\@YA?'
M@ /B!#K\_CB)6[%99/+@P<-]#4HB98G#86R2*?S?*[.3<=P7;_<&&Z8!5B5[
MPT64/DV!2Q8(\* ]5%.<UQ\THWY6NT\*B6DAF*/@:8P^P+W(F^SB"Z:)VS_X
M&LZ\*TG^M]30J&QUXLSDHX<#D(&\#-JP;2HP-TQU"F$EP8/G?(."Y) ?WA+L
MT:%\[I I;C',KT'./"OF8 R^K*9[NQ&I*16'4[UH[@4I>VD*PP 3V;IS4\D^
M(L.UX6.0PG@)JA"Z,VO/T'J^4"B;TLBWGD=^#X9-M2 #FV :="J0,L1(8M"6
MI3"GB3-EN\8%G63P+WAI4Z].R2^P[R^K<P2SYWWX.](4*-&F8)M<3[,!U<IG
MB#R+S(42,H)C_R\,HR4XPZ_J8+AL;/(*UG#%'&<2,N+PT3!-X15,,W)VY"BQ
M(1"PX8/U7_AJA<'T'9FOSG"U"SZ$"??W02.0'AYXNBJQ JLJVB#3I>OUNM9R
ML*$]%V"6K%([/2MR?G"_0N@&D .M>_+WD/<1M/R$=-G(%;0#W> 2^OLT<')N
M/OXKQ,A@/P1Q41#.-7R]AD_'#8^!^HCR-I0F_KP6KLOVA"BJ/$V7&ZHN)*:?
MV-NPUG"84^J4^:2QF2O&!-,S?.UUHO@7CHHT!=/Z+9N2@C0U5T!*#8H8<X%#
M2U(N0,#9:(L\^!Z@31K2@Z;YWL]LXW[W5'YHK8%\0GGW/F)K+8&<5(7FR8>B
M6":3NOX@,J4I\-RT ;ID.+EO;$N'.&E7,\Z1=5=F)#'Z82LU@XUJ"D^M,W"8
M89G@7N&AT(.L%4(HD)2;)0N)L4P99_0NG36'2P) [!+) KJ-LJ #!0&L\8@U
MRRRFN!,20)LY;H.G@3D_Q5$0]37'7D$[\F#X!LX'^7LV6AC?1,FMS+F)B?JU
M&!LHESDM6 AQ$P-'+\@?R#J[Z71DL,XR$6(@=VD]Y50'![+O:U,,O9R)7M58
MDQWMAKI\>^MNE/FF=N,MZ7PZ!=<3_Z:5T W,@,\=Y&E9)'+DR;)I<NI1_L#E
M0-M;?R":LC%>@^T]9B#C8&<Z_HLH#!G:"R5EFX(FX#<_$[9I%^<(7<I+Z6]:
MJNT@1)I%R6+NH;XL4$-7X,Z#?)IG6#/;H\S\%0-_4>O#'M:>>%<H2_1/T4Q+
M#N_:I:E%A]>.H+\-&PE_#%?GFI79=8K,EWCMA%5.7"BYJQ*7@CYKT?P\PF5@
M<]BV4X/+U1_:7G+H^\./G*1@W..$?4/UTJCXUA7CA;89S-J5@L81+RKJN8HT
M!,W[RE4?C<[!%%K FWIT*DL,;2Z9]HPRW*EAVYF5#<$L9JO6LD?T\_QX^ND,
MT5W %)H&KLV@M:#&X32_V##2HZ]AI%M#Q5T;9Q&@4LR5Q(/7EWNID7H?<];]
M&=<C3>D9AV=!N1T"6J@ 'XP5,9ZHBKZ0(+IV7!=A33_.,-=$.9IU2BQH[%G?
MNM1FAV/#K0"KQ.^%%<ZQJQYPB<J.I/+3I*X(*D(_.''AJ2-=1E&6&C&"%>T=
MZ4MF7&MP497;2UGKO,(+MO 43X'ZH$)LMJE1L&%&QI5#"/O!589C7-]WAC#T
MV(SFGE(XYS2:L<Z4"D5IDGN)A_?<P@&Q49N4M-)ZY1F?X#3BT+QDB[]HR<Z5
M3I^&LLKCL3=0MV#61=KVRLP,J.,'7A_;L@AX&*S]$&DN0R'FDHBF".= MK=7
M!#Q0=X\)<!83?AV(HZ,[I:8F2RHG3I,YN.!(-C)=+2:"8)C.LW+A+\,]"'-T
M4CF%&^U2A*_8D0S"&;;0/\Q*CA Y[1]@CV68*_SC5%O)!FE(#C"A!A"N;S&!
M7V=MGOV=_#:O)^A.4 M9Y5^2S"-_Q.4<]0H'%-ODS*)N8?_6U*2D#*)2+"U)
M1;*].6R%!]X1%#JTMD5*^@INMRK#%0\,-5&N*/\E+,'&;Q&>A2>#Y9Z-(P?W
M+.K3@HJXE%1L%O1LB#+3\ !9O-("I.C=9D+]U""M1RM X,'Z&5<GGPI5:&CO
MKF^]EF&3-LN)*PL2UWWPX#^_I[O:K!4-&.X/J(@L.^>Z09-I/I)HS/;62\<6
M*<[PZZ(4*\#O<[4&^V'A ;'M3Y51EL T(BUE D(B"]IQ0MSL1$1AJKREDL<?
M=#70BQ&P%?[HF1J9NY'B&0)T<<GV]>2,ITB1Q(2<.;%?X-D(.U^<1^NU#BIC
M_U0V(<:R">F>'>.J1L4-]1VAZI Q12C ^*D&9V<)0V& 559Q'T:'"@V=6Z:6
MPA.Y:@JK,')L$(?#;5:H2>8U=O+VSZ8V%%X#9Q;B:)A(1^C4+0%EV9G%B;J
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M^ODL+C@RL=D@P0!743<P"B3Y(,EVE5"[0G)1WG^#Q:@TU&G.2)]*;Y"Y7'0
M4VW< RO^'ZEJZ KBL8:5PXO"ARDJL%V/:JLOP'1?4E65%/"!5,4P>0ZF/RZ]
M3T^@J4KA$A=*0?+P @F$,,R.; /3(I$?Z4])E2U0I>4UPEOX)QN )^*?A&JO
M$#_:B%&.X1KDVR53$^Y%/:4*=X]4<XX>ZD,)<&#V!3>QHP*GY:6F%C! JC^2
M^7)1TP!EHOA*WRBB*Z9G53VO3S%W>'4O6CQ;#\[JBU2C*SSK%DN8.CO35<5C
MXT SDKOK;Z0W%B)>BHYZ%9+Y.^-%"?EH4L%9J=4LS#VI>5%I3X03+[(6QO7
M);9AMJ IEQ"JS^IF,+AH5C^S<)#=F%;=E6)<=4[5MQ 48 H^VYS1+BLN[:HM
M$:'"C[4SJ#/*3 FPEI^QQT0UBA6&V.4[R@G(<093EXQ H!L -SG+XE[B(I9C
M5)X_)3O[8AQ6UPR]1?P#<$RP-AW3%HNR-2"J/*CZU;Y$+ GLOE FQFZ,VM?@
MNS>Y-E\B$_9@8,@@EE9(1;@B6@:.&#O_ME%O-K73Z7=!BB<I*'28"VWT%)-
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MWBB57+Q&]R1$'3.0(,'&U&5J%[ /AHZ$R8 W@:EZB)Q&+ZG7)SL.S#SF#])
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MFX!,$!E0/5@M776<:BKFNU!Z%[I)5QT"5>MK#QCGS]E=)0J)!D&DU O+S8C
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MYWD5(94U8$XW"%ZX/FXFMH?Q X-SXYZ+RA-TM0[&LZY40I__\M:UP+L<RB.
MP=R:*Q1V>(F/W&CIC=8XXW7W5'U7YAS ''_@/N[R#D%!M)8_>S:&J$1ZC,4N
M)$JW)UN:U4R$( TE%T95<^)+!*4PG6>69D^Q,%1OJ[?: 3&'Z[H,O""X"K6C
M1*8";4-72:Y4T&E9<?B&7$$K">N ==_5JWP$Q1XW&?!0T8TCGU%WO4WPX%=D
MM9S?]W[O9 _L)2G0?=ZL3I/#?%%6?AR1F?2\;R4=K7!MLBKY T35E#IA'C+'
M] Z)<_?EHS_LEPFO*)!<E^F6G?49[LVVU(;%\0+Y;R4+'!22<1=$PAG7[$L
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M[>)IL4K5,=GC4%2/:!?;5&R:KL=@FN4)0YQB(?)[^Y?AS,W?G&VWGE?!8PJ
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M^M9^70BF/%X^F1(E*]P*6EK22(++"+H@37:D==%X<&_SR')6=.P\3Z6TKMN
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MYF-#2C"5$V-^Y2]:?"O_H5DMEW-S!;/DP@%8FJO>SG%W9RN92*XH$K G>$/
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MX>!B8MZ 7+AIEQ*_#BPZ?73#R89H'[T]&VPDIK@,9[&=@)P7& I/.%A&9V>
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M62K.2>!*476Q'T!3$4="Y9AE.,X1!(S4F72L D2GH(6?DSGUD\"UH=2"=&V
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M"*Y3A5MP@1&ND9TD6D,_@RNL8^3[^/B=I%$JVCK7-\26J%T+\,!AATLFEIA
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MGH16OY)VB%/E8KP@:HEY1@67@* 4Y4SL@;C3!U!S@"/D 'O=:@1E^4Z1&=1
M84CM$&-E9(&*=\)$AA*XY5 '->T)[,E!G.&5E,T-2U)!%)0;A,:%5L4A-[XN
M7']D?7L\4GRI!UU25?SF%[L[&K%AFU/L,'F5HZLB6DB?59>+C@-F04-P&8>6
ME%G.%[++X)LGJPR#;WF7W6S-F!DA8?.N IK8LKYY=V?-1]!<IO)F:@N4UU%]
M,\M>4,*>.>C<HB)V^6*U2"K+DIZ,L_(C!==\SZMX?M-\,L^$!,=8OF;5Z7;W
MS6&%<_?,AP.=R/2(RZHE18VU 4F.B"OG4YY6V+;>(3>I^-WI'Z],>.+^(_"$
MA0 7)V"#8RY8,#920XRFR:K%IH:TKT'O&^W8)>=0S_J Y]ZU5$13TK]5E41Z
M@J2"C$51&]()Q.9@E?-((O[K ^Z:*+<NQ&5T#LEW)[L4*L<[L'5F!!4) K$F
M*D[.S@N#'ZM[/GON/AO?&V(T.U(KX^RC!<R8#>*9)C0V6K93_K7$*;SK]D);
M&B4?E..BZZLB4]6,^Q]7I>LQDR=[V@N=_00.1:^="/<AFTYK# F"[%&HOBKG
M%S*D3#JXK2BA0\![P2UC<YGN]#*/@L9/2SM ZGG10Q;*IK2LF5]$-LJEBY/'
M;DA KG-C<U;4A:@''C=;S<')FVO4Q<;9(I4\''/AT]!1::OYA1]M&KP)IVU>
M=?L>]0EXU.*VX5IM;D-^,+[W2&^!]]9UH]ZYQ[W)JEZ/-HA3.'YY,IY^+^;8
M!.\]]JPIB^3GJIK6X"&QAO^O;+%\"N/'6&>:O-T_WD^'<F0L:/)'S4FA0]["
MME1FVB7VI*'*>[B2:XIZ<%XJ%6X_/@&.);BW3F6J3F(H#@4QFRPX<X66([E^
M%@KIHK85^Y.#4=M;AN:*8# /=!]KL]MN=?/[]UN",\G@?O^KF"^S%K;X8_*A
M.D?<_=3N-5E:+6S5Z]=OT^1U?C$MX*[Z[ZIH[:=^R2YPOUZW4Q"(UZM)U@1_
M!1,$=1H_ R9*C-&O\'G(R_X>,5W3K$2Y:D2H?EN,\_KDV_];+!NXQ.![?"-L
M+9M@S--S2((*NWY+7;\X3'(9P;U9T4RN)YFW#6W^C#JK,[_A:!R*,C(:65E&
M@0!/A-(;+<M-1S]U#+N_@)Y*+RT-0G5SUXKJ#^K:A6XVJ 9<BTT[YI1/RCOV
MHBZ;0)/\&S;BA#?.H1,R[J+GF_-I1R3+"&W,Y+=2)M=CYT:V&MGQ&[8-[17J
M!8@11]RDYI*G5,//.A]>#:I<&>YF?Y;52/:\N^/=']^QJ#$6U-H4YZ!]_R7&
M#N\??(T=WB Z__CEF^38@[+VDS=E=*@ZGF*/_QD@]@.S,H"V]^I#BPE+C6HT
M73BG!!>#T3BO6',DVYS=%+^)0</):9'/3"0!O.YB(G$"2[6D76G,H4/<>>>T
M;==()>5:.%.@Y(.DZ.:@WI02I7@@="D9X,/E;XB_B+TP'R&N"Q=;H[Z!S&UY
M6_1&/@+YZ>3T8]GH)W4=NH^EBDJ]3Q(?<?_/<IU1@"7%1NKS)"@?043]2IBG
MY!N1BZQE$5PM[,O1\>VU=]?M/&E=)EF=@RN+7<X_P<J7,H<!G$MO=3F./6I,
MP#6QOE#?9G =63E%.,YS+ ULV/#)?95&766(<:W.F49\8W>%_AJ:WAA5UEX)
MY77C*99\.!*5VNA-%$CI8B*C65+R<2 D98CO770JZ_OXI6)5?\&0E&.2\QTJ
ML0->&!(B4GV_LDP$P!7(''"B5*_!199T!U"(RB67>['VG>!6;9^\/O1TI3+3
MFT_;W!C*4-D1<=4,+F$(L, .R=:<A*:W2DI5L&:D(1,J/L&P]!F5U0^U<7W>
MUH++>N&*VBTZ:)P^#&%,E*V$40]50!"+X":6YLO[9#<M%2 6U.^VXS,MJJ:E
M.[9L^ZOY8B"E98]&[3%?-7@?.L;&&+,R6MMZ7E,HG.M)OY1D,YAZG&WN5!EE
MF(7"8@#*0MOJ'&U>48.PH1^).#(6:C]!W_0[R%W'0,1N.GNKG;@#VV^A+2JE
MJ5=?Y6%8(VF.M+ @3:74=)  *#GF/J12;8S:_B7:R5OD69_<^Y=&IF+[FU)J
M&\JKM%2 [AQG$=#]$MSY/6ALOJ%]??L=;$ZYJ2K=[ 4<@P4&Q& S]+,XN2./
MT9;*%239=^J?M@'6DM/RO4O,7V/?*2R"N?U85C6R$WJNW7CZ<?U=WS>YC.O+
MW+;:&SCP\X(ZJ; OT!7Z:-WF BY'ZX-P%&% 2Z'/AKKZ6N9DZ>91'ZT-\4"*
MS) R19OOHJ/\7[FB(DT/6!BN'T(@K%]B3.WP:TSM!HN;;&O3H691@L$(R^R\
M06HHWT[K:G5RRNZ0<;(]ZFAFE0.Z043 1P%B)O/R%%;D,(6MDLE5RX6RP?I!
M5RIKN];:'>$-*AE/%_A/8=;(58&6*SF-5C/B..'3>"4A!2+.-Y\WN;"1=;QK
ML[Q*;T%U0N):>M8##N<X!BOU;]#%+>CP,W'%I:-Q&T#9M]J\EF7N\3YHN6F^
M*/V-C;,YAF<HI<X^5P[>06U=/+*A>BIKL$B/6^0[DV^S+D<_ .Z2>C%'K[<?
MW(4'R'$N*=-213(HH3NI<05IJ2YRC511Y7&#WH  WFKZ-U'0S.?YB2%2X<!(
ML;0V_'KZ(CS ?3%+BD"!Z](0^Q[UU ;-,.\W#DPW#6S.)Y:;H:+J=J@C?1.P
M+V4G6'; ;,>*ZH%KN\%EF,RS8H%+EBU@-?#T%D0;Y<!\$XF-_5$54@@"OGV-
ME0.VI.-"@PN\# OAZ\3F/ZX"=+@7;VQ/>WZ?3@4/ESCAJ41*9^^T<TTBL651
MYW'YJ]>@#MQJZ!%2Y_)A#H\C) -!3R$R;$QXR9:WA?HJC1V07O^C7Y4D=37/
MHU&T6K'\-%$"H!3.Q7E..4AF";,FD&/N&G,V!@$7"&'4-D$#FX\CLMN/?*ZN
M*MPOFWBD-@8'#UK9->9 (S$$<=SSC]6TF!!$&%0X$W"8P\5.O<( <"8X@]EJ
MCD4<& I<H92,,^'2(=@O^,_@>93Y"5@,VI2F;SE#[F#?_IRBEI=8"!,*<%X0
M7R\CDJ+<R!#.?)QA")V8&?I9NFNG8[9A\(YS6)=J-.OQS9W87RI_Q*5[AD9V
MW% F[L>SN2?@14]^+>50VVVWCY+QW&"*8]U:]A=^D<^T04+HG38N*9)1F:XX
MK/]:;2$;R<>-E5U%M5-Z4>K=#!]9$'<%WV.2Z)3;'I4BW).8OFNH:P#!QU.O
M=_(3P\QF=8LSO!S=!7MUB[X=8LH(HB'@T.\TG\4M7?!DR[G68^WOM@M_LXD6
M8P76> TF:F-0X28#^A8K( @N;DEJJ8FSO2Z<OHS:+3N"->E-,#05JZ N6/TT
M]@YKME$_?0*W]G.4O"+])R:W/'ZJ#!MX,>* W#F*E?$KPP70;<Z,]B#VU&%Q
M:B]\FLC1V^&J2I1'*4#\.O@"4]T8M$*\"8!WS=W4\ _8P^LPOI>PAUW27).;
M: ][&]C^VMC#:'LJV^AP\CDV63U)3L=V]:?A*C9K8 "F-V&SRC%2S8M33[NZ
M-[V=\Y'$QX/3R/XXQ!TA8W'H!-),+EHYM_H;3!.;&:9\YP2 8ZK24A*Y6^+0
M_KI&Q3:9@O^/K(KH/D98Y987<O)%W,?K+UR)>>WNB&DEGA0M!W\J1EZYQPT<
M#J(++) #JP&_:^[*MDK8AT&7HA2,PIF'!-E\WJ0BN+I!NC)\;,UMR#BRT1<<
MB;[_-1)]@V0PTNY:4%["+8NY+.Y<+53VIA]E5G9/O?'003T&P4,46]>04Z09
MVQ5/O /J^+[3 :4BE+AH#_#![O&-B6^3/!)&/LFMCB]T5@VQ14;C#>/KCU/;
MAJ?GB^8.Y.EP',C-1T;SE(CE\!FSK)CC38)M5ZH-#W<^@3/S\8+/SZAM!D4L
MO![C&9A./YGQ)\ 0Y&CWJB3;33KT&,,?'C@MXBX<<^S;X(!6XK9PY!I^UID(
M, +=+IYA5<_ YA(VG(&IT4,I_-VB)UDCVX:D+5&%-Y+#]'Y*T";'=45+W8H,
MO(=6B<*#ACY.[/>N7%5B*69E\#QG/+MG>.6.#LB&56<KNV=P+KF .8E6R&JR
MY9("GAKXEU/2_;K6G$Q.*SJQ0\*MGY-+EGUI0>N%TW3KH!8![_BL4K:3:$&0
MKPD$>85,*7MX$NA#Y',.;(>G!:"#P<JD)U9(<C3$W]DPF6SNEH@)KOU-V[.Q
MM<M:]:%EV L<M@!LJ0_/87=GG/<BISOO1GJC%JT5Y:K?M$USC;UV96';K7/Z
ML_\S)DM.V!.BNH%G<Y*BN[Z>G'9W9UY-J-$._66DN-NUXIUIEWI'X\.DI_T,
MH+36G2& K@\8A079IW^>( BU7*-OME@YQZ;5*-+"/1ZW#]%;Z$K-BPE=4P4A
M 9K6-B3"!V=<+H@25Q&?.Q8#D%F:,3*.?)06J6()ZI-Z4U7.F_98A'O]=&"L
M:U8]_E/OMAL[&^8D6#TU=HG,B)I]D)F.),6JDL/F0/BN;YT1'[\0#QMK!/1[
MI\6,NJO)Q14R-=+907AE\(+^"79X?M>J&9JM)-^F_@AO<W#%R=D@-!QRR*QT
M4U]/5FVAI8,6"%R,&HBQ>Q[S80S/2F@T_I,/CGKP',L5H1?!X,WRE/@F>C6A
ML?9ZUQN%AL.0:]7XHJISOF>K,A\X\GM1R"W4/'WN8!:V&Z]J1]IK?ELH8?4B
M#RCX]I,CO-"VGQQ?16T[#RQ7\R9&30O^$&.D5%$D+<KVY+*4'X>(Y5C"3O/Y
M=-1_D7B"<GP.VIUL&)L6L[T6>E@,2\@OPDP.*D]U]ONE#A>D=Z>=[$502%#5
MH:5-';[(:N)?:$!G2,U)((*Z5!B<QB4V:'>G=X>TAE>WQEX](JGNF6#_!(@P
M+]>/#Y(I>(U=?REP:4*+F*X/W- F*Z:*Q[/WR]!W^RJ?0M7#-"^B='9WS!1<
MT[,',F+V>I--4Q7S?+NA.57LY&CHDNII*"(-9)CCMZ(>B,N5H"%\GY/^YXE5
M!5O-)K:6:\@S93#TVP!=J&CW:!502?3-TGLG*DD4-*(GQO)T^9,?:VISPZ8R
M."5 J3$F+#_1\W=WU-$K6^8&PD/@6(MB<"V=D%XF9HF@><^\D+H6JUGU2=6L
MWV-04+H#KXBA(4Z$)_#>Z^G#T6=@$&*F:W&13Z8@-3;E*$[@HGTC=86C#4[[
M5]%0E(EUAIH.GN'*A=")S?$@Y:[_0X^6)&\4$PI!"LW@0/Q8URYUZ!M/JYSZ
M]%#F4]ISP]7IL@A(T0DN^A<<XWOP-<9W@W2\(53O%1M$2B(<QA':"QOJ6!-?
M8E+U3OP,KXU5&9CUE'%H5I@-+$0;AYG%7GM%+W36CR'JVU50QVAY!HS-79R^
M\LK'>1C9"?P-^X,FKRG+%Q(&;WH%ZR_B".*FL4+=A45'5<T!,R0-1%<>?E47
M62L1F-E<HI62@*-JM#*?<2\_N<0CA+D"-DI,*9=<XC*07="/DA)UZ*;A1!#(
M@1@@<S2T>S,8ICLY>@@PR*DU/..]OMZ6*=N%VZ_++BW%,A%_*W=]O,@8D<WF
M317N 6G*N*S+K_ONCEOX]3D:]8E[\W$.VVA0,":?JWZS0Z?IU$5"32&U)R#'
MV^<,41Y4L$8;0!FFJ=:J[2?/-LE7/]HYQ^I,9T>T%;*Q]S=U=9U8]L2(!.%9
M<4V>^@2CX.6%I!4');^_QK]WA-W\]<N<BP/I-J:P9!#U"[)IR\SS^QO2$T2[
M!9)A!N#0A,8VX">*%6#R^UH!>PG@G?C/VZ&SXB^'[>P1;[K 1IH:X,:J.E^%
MR#:001;L[K@WL <M:)#AY.:0AAJ FMI#HBY>*^M@TJVJ)HK:'U!39 N. B%1
MPJ'1:Y>H(E9T?Y'6Y[)Q7R',<^X!5?BI/XVLK)[-Y>7T(9S*-2GI$Y/+[TGW
MR<EYI@6E_-NV=:> ?QUO2#UTE%S%O"RVU+NZA>8=23_/RG=G%F'R!^X'DW /
M6L>/,9C3",[=*<!B%GH;Q)7@=V1W9TSF35(C68NY^/9PI%*WT47&,^%"3F$,
MQ*>4DL!A(X7O*"X7'SEP.NWI K96.HW[=[&J5Q->6AXS 8B>AB&-SN(DV$M)
M-?7%B,+.ZIR5-9;<=$1:LJS$!I0X8V?B8U>F.HU,*8:/T)!1W7Z:&)H ^?WX
MHK<- ZCH0.?3ZO75(L05H&L@+?A^O);,V_F\[NXHS-IG=3H]I(+J)RH]MY/&
MCHUC-6F<PV:4_#9PK1Y-ONW&)5?:-P[QW<#&\>5_R>T;W(_D<V_'[LYU]D-K
M94Y6Q9P#=+,Z6TU7<S+\BR;D/$GV^N&'@3]T>(BDQ;WUW:/^='"@OUPVVU3Q
MX(6 BL./4HJ$UXQU'VNL54EYV8JA#[=0,!16WSC(IV)(4R5 2ET%5>H+KGPI
ME0-?K.&$<E%_ 1O$B]M?)=W!H7YF^*E 9GM9GP@X:ZKK'89VN"8C7M#XD9=?
M'T-WZEQ>;V"K4[U<SK7I@2,8GP0M![O:[&ZZI?0QB!]YEB#L(+:JS]#^>2Y4
M<FRI]/0CU$4=1!/Y(]Z%DS-^_S)X\@]!F$91M7Z_.B12:E5'X-ON,-7Z<O3>
M'8:JF.]ID#Q]J*26F9W VF8NE;-<X<I(3X:&E(#0A.(,0S3U="[7TY[M_J==
ME1V\/2R("UL%&L2HXJ:Y( Y^&N<PLMF 7Y^*'])?[9E<OM@32W,V5WM^L1';
MAU\CME>LM^:*RK]LB6]T7[%_&1V@H"@T#:M"Z+-Z6L0]NI6;-4I84M!!V^4Q
M\'"H?\8E7%-"3C!2UL,[^4[G=-8PYM6F=P2MRA ;UVM$0P_!XMIZE?!OKE6\
M66V_#0.AR6!)^EL(:I%%]'7>]&V[V-UU"^3O8%/]Q7%W;8V[ 7 I]_:Y4,F1
MZCVGA%95[9+-$RKJ&XKS!% 0CW6P-1!41-<6Y8J.EH>Y#I0$51'SO6 J->!/
M/2[+AA^!&.+A>&Z4;K=WN?90<5:/341UK9;O)(/13]]A%D_;RL9#&6P:^\BQ
M>709?<+VXO@;SP!4L&.&,9O58L'OSGFKY,@+A!IC;+-5PSEL&*5NRW"+%++-
MP<HP%8^"\*B5)R!QU!8^LNDWMF,HZ>36TA^E%B$=^-T98API0-Z_T6FDSPF_
M']K X,MKW(.C!.OZRS^TS>49\>1<CE1B)Y*?0K2+(J-"&%.GTHT# 5K(Z"%]
MJ>/+$5XY@1Q<OZH<#N*]:G9O64T^YFU4^@4F@$.G- :$.]2E/H#84N<2,VH'
MS@J?*E/5;E>*KKM])I\X_+6%92\"T22'>^-1FCQ,D\=\RS_!JX@YD Z?Z.&5
MZ%C+3*_T^K%A-N7[CC[3B+]'L20SAKN^LI[L2W5.<^7KRC*$7HELR2<L4X5D
M-:E@S7J;0/$59OU>5R]#EN,LFS0@Q7/NJG EJN9KDP9AH'^HR4>77HN8:#@P
M"BXLTM'D\_P3_MK-A1E8?)+N1ABH+S6M?^84'X=?OGY]O$9NM^TP>JF7/[I_
MD/R2@:*!R1^=Y>4J1R?P5H>@O0=3WX40G#^I%1S8B,\RD*.6(&E5^4/RL[1:
MU-XUT9+XQS[V?OV@FQ^X]3"A#T?/7K_01SU[\^[YBW?WP E^??3V_8L?]!]K
MQQI/[)N$'_/W;PZ^28Y?O'[]]NCY\U>__NQ^?O_VZ%A_M@XVC^<=N^+)WY-O
MC/->4/[JA^RL*J;RP>?ZY8=_\Y/Z\#SZXR-PW/];/'=8%.?%LT,.%X#]COU;
M\"V[WDFXQ,EUU??3)!J45RL]^(KK:!,^331A^)]W^#^X^]=DB[Z46+^BJO3V
MXED!IL>K<K+V-OHL!^O!HP<'R3^KTS+Y1[7\"'*%YPHLY5M6-.^S$MLDY">P
M#L='R??W#Y4:\TYTS#_)(']=S/^ FQFS1;>]+2]0BF4<^WX<_T<%9EQ4^Y/U
MX_HLQ@L7B"#7ZX4BL#WR&ETTJLS)Q909N4O[BPR^/OH:?+TA<;YD5\M;/VZ'
M]^\_>)2\ *,"V[E4R;L\ZQ@6MZ "$]: NSNL A\<W*$*_ 53*&7RS_V$"57(
M*_EP"I]KX*H@+IN[THJ+<QK1_SEO3FK4@N"[G/*(W*^NQ.=Z/0Y=+3^5BB$/
M0W"^,<%HB5-("IFP#N;"5X=%H20,6$KDG<%>TOAE5M7.542PB'88J0(<6L\#
MM83&US1E20DSL ^VN*N[]M2_WT_>4DJC25X8+(?@;V'\\FE4S_0/-U7OV=\B
M _N'OJ!I42*#@QBP8S=R$R<!$1D7O(6.2W!MV,^A.6U/1MPXA!U5<E*S!G$-
M#OJI":$Y%5OQHD;I5I_3(  B12A5EBQ"+HXA/I;0$(553EUM:+ 6Q H'HC<5
M4UTG3A9#O>('G^ TI'A*7B^49;.B7DAX'02S%K;8B&;"S0H_W7#5D?NT9:R6
M-% 7>9^&I$H>+X@=):;<Z)[JGS@:P^D;4ZL51]8T+:?PLT[_;<Z(86Q,&(;"
M3=S=D5V4+G69Z^!-+%7>\/+U2A=X=BG<7/?$UGVL>0'/F3N8D_O279_XPX/]
MW9V?$4E.V<G7V?E?X21K<S8I*..CA+US+DP=I2M!<\*A5=-=1>SD_X2F2MD4
M[L+A#T1/!2?NYCP[]ST66LGW^#"-9J7@+/G::54_RKM #Z '&61DJZ?X%IG0
M>T7@D$"#+XOI:E(@W2E7#L 03XOEW248G?*=./RV"=0*]K(O&R(!<^ZV)C59
M6!J:ETP*7&>,T..V6?PI4&$R^]0)WW3%1'.SWM[#'7"O;WW)6!WZZ#@K/[+"
MD^QHW#3>)4<V@8/[^+!]:J4O*ZYX<7VX*Z5N3<7+* WN!EH<S! AQ(E;*Q 3
MGN=#]&4HK!G3\&*MSE%/,C%<.-?]Y 6!/,CV$C8ZZO"+U)3":R2V,%UZ"^I;
M1ME&)YEXDV%H"9OMK3C3:.XN\^1]T]I&*>7Z(+JT_Q,!Q&>V^7 VA7.*8H+-
MVO"C] MA<92?.FU< M2\@$,RQ]M$]QQ\(?N4&AE)@[:904\U;3@HM$:6]>%*
M#9SZ^AU1EG?>[NXP,2&JJO-29T]/F<C=0/>6#BG8])@%:9&1T.O#[ $,<6QT
MU);+.BLHB3S;:A:>NV<-:+:L_*@<8:)'#JCI;H$Z(1,;R1 5 9X5H)B&JA4C
M4,LVX_?TD;J8ELF4DW?V$:Z5'(,@M(V?DNK+85/:$F/Q]H(JD \7N::Y^$2>
M&M3RFW:0,;9PC9SO)Z]:+J3$'G0MTAL,:FAW\G1"CGD?O\Q95->*/@I%9TZ'
MSK*BMGT=>_5;ISX!;_V+(:O97]NP _5%Y 78BVAP;NA#<A\GITJ4<<EUQ1.C
M,QYKK["XQ@!AWCQZ]\L\#P^W?/L\ Q-?3%LI\V]2MX"K^1RI*81*;XFW12M(
M$S!64F^"F?E:8"_-TS(4;KHC\8L8CYN<VMH%_<W,:'I4[U]PW?_CKX',&^K:
M<WA_/_D',^LW=].>YP,;8BW[DSR2'MUA^K*68.ZI32%*GBF%X/(K"^V]X6LJ
MM;TQZ42#F^KVJ+I+-^$!7(@+UQT;QBQ_3N2_OZ.NJ:^.\;@F#">@?%Y4TX"[
MA?1@W8,>ZT:$F%[%-=GKDH6[Z"%^"PPW:1HAYA78D,(O6FE[:.8V^Y37DT(L
M6F8N)&./XAS!_2L5XD+B(NF=S$R!>0&B1RB)Z0IM=G+H_!<,Q+:G,F^X:9@+
M' T,Q-D PKOF0BY8ZA!6/KCR8#;?1]($F5TU#>3*DX.W&7RG_%EVR.,KO7.B
M2,N[/RP/]Y/WV$14<]_16?FG,>6?)K^[%87?7R0?L!S^;HX1HHJ"<2?_#*CF
M>DP,[I7JK#+?FC=P5T3\?MM_O^]:5*':<R@7I@/ -L'.3MK=>58Q&@Z^_4M6
M@@G2DC_/PRBX:M ]P?4/Z;(.=7I6A;T#^O"DE_.EG)V%A+U_J!?.3%)L$X+I
MB(_V[+%<NU9)C.E"O'Y!'2EC+!$<]#)6*<]GW<8P?Q,>H692GC3+=EC!IZ:F
MG-T\?5PSJU7PEB!,H%M,%!AQ*-U&S04"GI=4&#75$? 39?)63FCFO&ZN6T/C
M*O:0M9N7@UY&@]/)W7[[U_&H]^!*G",J70OI]XVX*(GM[DY++!AC\O,O;DB:
M[SR\_&@_>9O!S.!J.YJT=Z/47O4'=OM:5__V_LB.-]G[@$FPY-6K5_B)MZOQ
M?O)Z?S-\^O#@NWN/'BL>>D\*7I%^<'<'^^R]F;35.*]YC>X_3I/[!P>'HU%_
MG*H(FZM68TQEI* I:FUP4^<XNX#2@IDF<+V0C*J1(D"3O9K,"T;#AA%(%\E0
M&CS_2#S+FO? CU+#!S)=)9O):SCP&HPY*/F/<@Q%PZ50 #),G ^57"!?4EYC
MDPV>V<7@"^]<\!^#I*"W+H3C,,?G3!IP)_D5) 6P@=?>T%TEEU(6](@*\X,!
MIQEJ?DQAI@DN?\%)/&(>_'.5"Y^A4B5$;5&"YVW94_(JUW2:*"6*B]^*8JX:
M%QILM=F!J]0A>2RC[*HZ@3U<3I;-7XZ0N\1-]8K8 F%!M.2OHA1OU,7*U1JN
M30RC^>889/%VU-7/&G%)N?'%JG3EP#C7HG:<[W=M-W^W3S!C,)!P0'?D3'[H
MPD+0B#$N(7+G8* ;N<(F9KRNJL=^."2--A]/Q6)V_=S-@UC(,#!&E/T!;1@^
M29I+)=KJR_&^1T]HJQ/VO(Q7A</0&#HQ)Q24 V6#H4NK2-*DG;;Q.@J:>_?#
M?5/;[(D!PAKV9D:4H!N4_:9 [K_$J-]W7Z-^5ZX=-[G,J%68%STN':10@!IQ
M@4/YXCU,D@NI9VA2'8 4[I_L@S%S?KZ/-67X* 2KC1)IM"ZY!B%Q:[F_7P=6
M(FUC-LGY[@X*NND.UB_@&E,A)BYP:,Y@F:>!*Q77.\H5(6:D[[",1[?#.('<
MDLK_[%:.N+^,V@ GA;2.)N'"&O) ^VUUQ+>=.CQ9LJ#=66L5H]+[W+D)]V0_
M>8[M-@NAH<2_*GR('>S=G5F%]BK1WY6NE5U'?D*R&J$"H+Z=&*/4>-5MEBTR
M^BEJ-2BH)QXNCI(SBAG7,,N',)$D)LC6S1 Y.^1%#H=S5W,>@Q:@M.$TN^A.
MF-F]@HY*V>[.>SQ%\&MP8Y+W<!8S3H$*<NVT E'67]$_-/:C\ _30(-P<G#9
M-BVI,Y $90/7_A@4=Q45X))QW .WXD:4+N2%,;"KV6PWL)#8X9&/=;_<6-8/
M..:.U,)_[\Z&WNV,V9U"T+:GTY/3WU9:JTPNCN ?.Z29BI4)6NX@[;EW@0MM
M9P/_?O'I%'R3-GDF_EJ'!,1[9 ,=0).X V3H^?DPI ^>,T6ER7=@- DO*;Q2
M;#%_=_7N;"-?.*CW<UCU[B8RAYA2KA&5A%N8-=1CY&]53?O_VKN^GC2"(/[>
MI-]A8]LW0.  @1B20K%>4] (MC%-'Y" 7D0P!Z3EVW=G9O]S!T'$*T0?##E@
MF9F=G9F=G?U-VKAFK;J,PC)7YV!8&X:"!8B$1]P5\%<3H%9].2E39^+(K%VC
M%J =G^E<Q2M@[1<R"QUUY)8AG(^@HRAEGK!8R8'2DMX>(&7FHSO=6!W#F.2D
M8;J?:'E$JHI36 W=@<6.S0B==&;#7G!)<1MC%R(\'AO"1^6B?S*;".M^XU /
M>,7GG16R1843Y^(7)<7KN@B&CD$T9\91L3R$< R\F5*G\D\3,$4E*V\'HK6S
MB<%"8LH7L(\BVMCEX">E]^4JG'=(2$J8IEGDD8^TB]&2=1";0M.D&IBE8\#M
M?%R?-^^D/94TM\SSVF^V)QGRC)[GI?.E2BE;3LFAM*\>D%^E@$07:!EH]L+Z
MXX%VA+:X/<==K>"F@A1"S:II#F.4)&XY"?."B1_I?T5/@$@Q+X_O9>NQHYNV
MG4W&(M5D.U0+Q8LR0BM=H^$+;0]H-REJ\.@!A @_(7='V-$ ]6H5BX"#/Y%4
M)Q9UV()<ZUFU0_56.%2VD3\5<8?I4/<Q8U8^[(S9AE<UMU+-[3&=2+F[4)\]
MODMS_4K3150'W@D4<CX6Q55"^4'MIV0X^^;;9 =U0]% @8RAYA+R/][I&@5X
M.CMQCC2*T/>'6PZT9[F25X\&H=YYKLC5W%^G?JVCTFN7<,CR_MT9)H-.C_W:
M[_U=DI7#7I*OV+)*-";2G2Z#:=0EL\5D'LJR>0$B)I'L=1)V,/L#I:76I868
M:Q I]L I'BU4>I%^ 5I?/,WP9V49.JQ^?>9)-PAZ,YF I>[22RO+$$'^:3.\
M'YPC,8E8]W)D0 "YR#PN<H\$VP%%, !^7A0Y"$TVH0#5Q L%Y)/+?3HB[!KU
MCD3H(6ZULLH/V@.4R_(Y@M_HGY(\Q, -L0UY<(A#T"$N#B[;-BRTV@_(\\]X
MS+% Q9BF-$TV/<; QKCG3?_K>9=S6;*'C1OEE;@2R!9+__U6Z[KM=V_J_D6*
M^>U&YMG<6G,:*85\$E*(Y;R^J)H4.\H:@5@5!SBUVD[FX-$MMVB#4#_Z"]>2
M.'L?LOBWH>$\GA[SO0&W2JR181V^+YG:N%&O)MHMY-?F47YUB8M]X@!+WZJL
M<1\,ANQ,;98O",+ -&02QXOBA42C,-ABVOZPOV &2H4,S0XTN-D;;WJRI3.M
MY/\/9_H9HRK14&NH<\C#( 1L<^AM)5%@J@?A9[\US\Z:5WZS P"=!^=+]]MG
MMH+^?6\P8O4P&#_PI\EX34M=R TN$Y8H4<*SM7KCWAWF(0403Y1/>_-F>[)5
MWT;RI_6:/'+_O.Z.Z4ZFGA. )R34=RT>R-XD[FW&7V;&Z^PR#+ 2T#?*,9YY
MTWBSJOSYXRU='^K<]\+!M,IRA53V))\JY8H[+WY3J / /:(^$!4"!ZM/U4E8
M;?F3>FA5V4<O4RRN!$E\&=JT8*8H&'@%:6<LU)CT']@UI,M&)G'+PMMI&7M3
M7N<EZ7'ZM) *F7S)*ZTPS%RW+K[<\(?GW=;WVC]02P,$%     @ G$I/5JU'
M_?KM0   B$$! !    !D-C0T.38X9&5X-#$N:'1M[7UY<]M8DN?_C.!W0+B[
M)L0-6.6SNDIV*4)7M;5C2UY++G?OQ$8'2#Q**(, !P ELS_]YO5. "1ER5>-
M:V+:$@7B7?GR_&7F\Q?GKU[N/G]QM'>X.QP\/S\^?WFT>_2/^T^V'S[_D7^#
MCW^4OT?/]T\/_QGM__W@].7IFU_OO7MQ?'YT;S<:#N"A U4TJMI]?GC\>W1V
M_L^71[_>N\[2YG+GY^VG67$O2O+LHOCU7JZFS3UZUVO]V"RI+K+B?E/.=Q[,
MFV>1_#XNFZ:<\4?3LFCNU]F_U<Y#^_LTF67Y<N<\FZDZ.E'7T9MREL!(>R^/
M_W[RZ[TJN[B$H9[O[QY]N,S&61/!JJ+G/^[O/O_Q-2ZK:P(/']WA#":T)32%
M@]-7KTY/8,#3@_^,7K]]<_!B[^PH>K?WYLW>R?FZ2?WT:>9T_.K5VY/C\W_N
M'Y_&T?')P;:9AW,XSABX-<%9M29U;_<_BG$]?T9O08K:VW]Y%!T<O7QY]GKO
MX/CD[[_>>W"/?G^]=WBH?W]W?'C^XM=[#Q\\^.%>M'_ZYO#H#7TN<^!/[@/5
MO=Q[?7:THW]8N>)P>UH[@%1+4WRS*S\<ZHD\??@#[-"/YX?V+[_+MWFI=LKZ
M0?\%3W[6G\/_O'&&TDN:)Q?J_KA2R?O[65%GJ=I)KLHLC6ZVI-U@<G L]W;?
M)565%$UT=IE4JMYQ9Q<L0LY*GUC[.7Q?<)V.ZWJAHL.D43O1;VI<+9)J&?WK
M7W'TZ,&CQ^Z*X1\\^]WNB]Y'THWZT,".I'!&.[_\<#,2WSU_<7P6K;YI6\VE
MBO[C+P^?_.W9\[=ZJY[_^'87/_OYV2B:J*K)IAF\N+E,FA@&K**K)(<U5VJB
MLBN5QL/!O[K_B^#9K*FCI*Z!U]7!8"_*/%65.U961[#.K,GAI=%B7A81?@&(
M<P;O*-*H7HS_4),F:DKZ0Y[-LB9ILA)>#<^J#ZJ:9+6B1_'OD[)(,_[SI:I4
M5B13>%=4JP97T5S&4=+ P\NH@8W#-\!T^1'\MCU8>B'_>5YE\+\P_M.=!P^&
M@_GV;#O:PAW_9UF]CPZRAE\VPL=#:OA7L/YS6!?,"2=(P[@[,5XT45$V.!&X
M$SBG&$>%#:@G5396= PXK?FBFEPFL.AI5<ZBX]EL4< D]K,2.%@QV88E1H<J
M3ZZ!]&$_JGE9\8#^5 [*V1PVPID![C^.V#K2FF[1<+"5U.YY).D?B[J9P?'1
M7B^ 8G'*'<0E]]!=;3F-8 8SF-994T[>;T?G\#VS,MCSB<)GRD+Q\.$7(AH.
M1@,"TJ/ @WD>P4ZI_UXDN2:9(TTCK_&EL#MUE*II5J@TRN!EL!C8'+[_C[;&
M(Y0 -Q>-[IU]<M,["QLET\ =@M_D'Y[40_P-9O5V]Q"GS=0MG]U<7LI'J(+0
M1&\U\8-D#K<QAZ=3N;*+&GY$(D5*+I&4KW'K]8;SG92#NDRN%)W03"5%5ES4
M]IKBR2#O(5:4\#$M*E@ZC/]:B&0XV+NHE"+Z\TE;/Q&9!SPJ3^'BI7!%)FHV
M5A5OLKFX#Y\R&P<Z 5J[H/G)53%,1I-I!3,&)I<T)7R1KFU3?G7D\\B0C[X(
M7P?M)"-W3GB]'4FT';E_</<\(AE<@R2: T=!-2:-QDN?#\R2)7*!69+"=0?B
MN;XL<T6"J8CF2=6@$!@.K!2HZ-]Z,W$P5D"A3+<A-\>)I"H' 8GT4'JT \M(
MHG21+U%F318X[=>'OP%_GB^1IX)4DY4\_^T49+2V'BZS1MVOY\E$[13E=96
M;J/NSY(L?_XC/K<;;<&4;O856'G3))-+O!<CO;TG92,<UVQ\QJ(85CN#Y1<P
M;;Z_L##_NK6_ZURW[>A=!H?#[U))E6>PN?#H5C9B^FRNX7V/1M%YE:3 !& C
MERSYMS+S"'RU6.!EQ6]Z#TY@>ZNLSN2FGC7PS:1*@5\TH%(0;WBM0(##ZQ*0
M8/V,/QW!C(0_C6#1>5Y>Z[<BP\"1K;8!,T0JJ),L98G'BHTP-J$!^D-R 3SH
M E_@RR&2YOB +R*C>JXFJ'NE>O^3^3S/)LDX[SPD()CK#,D1WE%/<8.J:)+4
ME[#+>  _/8,MNE23][#T*KDND(:3Z"T($1@ -JN!$<=)@=(T5W7-*A1\G7XQ
MRYU7Y42E"QC&FUVP@Q-0813L&JIT-UO%-AAB9'>=E.MI.2O>WR^!"<#%,Y>@
M8V.T+C <5* -P!;!016E/B&\D3.5PH]X=R^ \\,1*$6WB:16U"SG]$+[-_@3
M"+6DROY--YZN#KZGZU104^91M_'OUW %:B1-I"CX#EZ("RT,A5& Y@J'6"T[
MZ EEJ?-*_,;\<EG#?N8Y<H^J4FUEJ"F' Y<!+4#+SMUW S<U7!5D-HPCO""@
MR.0*> >=G-'RC"34C^*[QDI9A9P.?KK(<V' V>02"4MUK*YW_A[_G!)A%Q.5
MY\QPKS5;J?#<'@NK$.8P'!!WD 7Q_=73(*:&U-/)]&I]>WF?G2EL1Z]!=F3P
M/;U(&<"9-.S7(F_P<%'4R.;6S/Q!#Z>)RZ0:H*7<86L;['J@-JGI%#5Q^"[<
M.F!RS*V&@W+1&&+K?;],+A@!9IT4J/D M?A:M'.!U[T3B?[<GK*F%7V2O H0
M2 5I=F!2EE4*+./2,MSU(YBW:MY<+R:78)SI+><9^$-JMDSBF*P8/ XT9+IO
ML5 8FB!;#X6^]A<@:Y Y GWAPV00SQL] [RJ\!K0KO9W@RT@!9*,8@6W /AV
M,IFH>8,D'9(1Z">3]\#OP":^8-4C0456K''X*MB'M:$D6'557H$,))M8W@1J
M#GPGF5_&@2PS>E0730:['5AU&] JWE(S@L,NV.:^@.TO6.<2%4V$3B)"@NFN
M;DA!%U? %)@_O:J<;J.,B,2M%CV?]SA/6YIKY*JF/P<.ND_N@]6^MH=ZYN@7
M.CS^'=1T\1>38PS=3G-8^S)7OLV@9JVIX$>.]XQ5TITDOP:FATZ]YR_>1&?'
M_Q?6]/B>?B7YJW?^\@O]%[@;9:8'1R?G1V\^BS/[3DV)L6]*D'[%5@3>04>-
MP1L^9T;:YU% H=GE4H +_=<G2'_;CWYZ_%.\S@\2J,CMN1GUN)\(/XL9-AG!
M4;\%2UZ4/M](/)[BW25Q19:2HP/SE62S%\5F48I @DL.#.HBJQOQ.]%]INWA
MCTE4Q9'HO\"\4%ML%C6I0 GIYXWH1O3>)F P^*T,3#/+.EN<2X06LU_B7D7+
M1 0[**]+<A=II:776F3F3GLP7I*_0H0ZGW!+9>;3M:I/2^G!4<7MB9,5ORJ\
ML)?)>M+XOQ<@9W!'R['L&)J>V57&RL]:)?J_MO;N[X^,#?F/T?_#%VSMC6*8
M,&S]SBW)\L9N:Q@Z^I7L*J-G[#@V(BSY]W=[K[5,<$S *)N!(I\!A>5+E(2P
MD6EHMZTWHS(1W]T:H9'^L-Q+:[^C8+;*(H@])$GB"(%EE(ST;2'S*TV6[-S2
MU.VM!P@/S.$;C3<<K![0?;WQ9N.FE'.%CC=<+Q,R7-!%GE1H3M(W+DL818AY
MRW><OEG 5O[TX,'6F"RA-_1-NN\GK\[P5L\6^04)<NVIA=NKX">@XMIZ\_+D
MNB;7.>V_,]/8<0 (#RKGCK(R'.C;K3*RV+:6-Z.6Z&.)!4_HW\Y8^UDJ-KU\
MW9,J,@G8]V*2S6'Q>CJODNJ]:I#F*X5Z&%_B_;PLD0-<1"^W7V_C7[6]( S8
M6;JV\)E"'#WN-L1NR T,?ISF>L)HT1@2JF=(:5N-73V\<_0&)]@!QUU,\@6]
M1&S5UN/ LHUS;I*7K,7>?(*CC2YK++S;'J]AW6BK%$RT<U*AX;UI.5F@D*LC
M4L=3[9<TC#\P:)T]\3Q:L"+C0]3'W3XI$I]P0?HXY(U87VA']5!&^Y!7/'QK
M5DDGS2Z,FQUUR$B>?799MH^RK!UZZC#S:E$>Q;5*G/(9[A;:")]WTO_0D^[5
M0$AF79>+/,4[0!H8TA0%;97GKG<4+?0H3-#")VT-B=X)\+8>G@X'='SF==>H
M7?HJ%RI;]@'0,<E=AS9DTO9=WH5^?:-]/&Y;QQ5O%HM-6E['1&,F=50X42SV
M.P"Z=M2[1(_A$FW]8CS[3N1L;]+$G3YGXFM-\EYI]J$5=9@SV/)5,D&EO89[
M;L21O +=?GC/C KM.UYHVJSE(/O#$?#C>5E3&',XT%Y/YHY "BVG\O8W:_ _
M^F[P?R*C-26#_Y4"VBR$)N\TN'EC[IE)?-[*[>"*O44FZ<^Q[:"<)(M:=5U0
MZ_:T#H:&3%>*^]C@(6D+YSH6M'>AK"-=M!!X: +7.FNTWHN\!+UN<J]]S5+
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MLEY'>!L&4DWM4 +81& B*"DMV":(F'PH7)J$5^2N+G8[IM.<&UW<;<H'K31
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MI#5R&\H77\8F <YK5J=MI9LFL<7K4XATHDFX1BJA'28+-9OE!AUM2&979;X
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M:D"=?_OA'@,AS1\T6I,7:VE//Q@@1A_ISPE):4?22^A!GD8W7$(P.<*?PF[
MUI[@O;DQK-2+)6X_H$OJDOE]_>'-DHWV=X]?O7I[<GS^S_WCTS@Z/CG8?O[C
M_JX/-_4WR!G 6>B+H^._OSB';?_)WW;G<[O^1_=ZW_[IMO\KV?+]Y8[9W1X*
MUI.4V[1_>GY^^@IV^T-$\*;H+P_HOR[HLT=O_J7<Z#6?]T16;,*:M7TEAWD"
MUL_.JLOR??-6 ,C1817L'FHOC&UG+>:;U,7^]ET7NR-M?7_WY/3\^. H.OTM
M.OK'T9N#X[.C2 NH'J_ G=@-N^>G.U%+-'Z$47DK573KX8B,1C+-N2B%\;Y1
M!\C:B^3\2_X+T0QABFM_:QME:S29GF)D;6*C45/Z1,JI2+8<^=&JVF"]P_Z:
M0<,K4V F*.G!96RU[\$OXH21<$J_OW4-LYL?P:,1F(F\($E912R?8!.I3-P6
M[!>FH=C9C\L/HYT[P7S?:*[_\9=?_O;DR3-*^DNN89?)=6^PE&\+\OJ<(73D
M]OB0CY\>PY<[\BG["\775*M78[_BOE@PGL@B3WPH*M8CD[+;F.,<$U"B.RQ*
M+]* ?[D=L^1#-EO,^B<GUR\H%2*5'4*<#V,/4G0^K)KDRM/Y1(3^& @]9Q0K
M84BI'$\[NZ,)*GDXO$E@$$[K6WJ03\_6\AJKO+QN7X];6+0W-E]9&'XJ^S44
M8RO,V<=/;VG//GYTVQ<\7&,0N_;>AT^KM][4\KE[^V>E/KU&J^[28C^A:Y,2
M,(/[V0&;$4YD6](?OML[B/:DC>8)<;7OE_'[9?S37L:;>*]^[G9>_=SAN]K@
MD37#?S^_[^?W/^#\/H\P_*\S&'OO_.T;\A6\.'T)J_Q_'V&OW]C]1TC&X^)*
M<349[N>Y8VSQV_[WJ9?P_'C7QD-!I7?K3]#G)0/.PA5BL'1G./CJUB-'TKF.
M.SF5C[&;;^X6_:1+^/1K.$P:=7=WH&OJW_VJ'^%7E6CO\_W=HW^\.-X_/H_V
M/XLW-=3!]\Z06[^"S8I^.WWSZE,C40CU<:[+>/MYQ09Z$YO:N>02<KHJS^?Y
M,G(:N9G.,]O18<EI7;7[+=<ERT5HMAUPR6?LOP![BT+Y[5'TYNC@Z/CWH\.8
M459F]7T=#&P[ZD8#;BMEL+>F<'AYAZB$;]=L?/KPEE;?DY^_&"9!1S _@Q8:
MO/"KC$JOCY]NJ@3KY[;$I_JZRHIF],FMFL\;@M[C7H3?Z>>&@?GUBSPY??=F
M[_6&U/,)U_+ZLBR4]A)^@\?\C5ZL(VKU^?UZ=>T-VA;ICKN<P$* __M7+,;'
M7;#P+[!&/^7<&.@[4?^R_T3KU72_;K%WO5S'4]5M88*M='KX3_CPQ?FKE[O_
M'U!+ P04    " "<2D]6;H!>90P.  "O/@  $    &0V-#0Y-CAD97@U,2YH
M=&WM6VES&S<2_<XJ_@<4LTG)511%4H=E2F*5#EKBKB*I1,;>[#=P!B1A#P>3
M.21K?_V^QC$SO!0?DNUDG:HD&A #-!K=KU\W,(<7PU\ONX<7O>.S;K5R..P/
M+WO=WK\W=QNMPRWSA.8M^SL[/+D^^YV=G)]>7U[?'M7>7O2'O5J752OH="K"
M5,3=P[/^&S88_G[9.ZK=2S^==O8;NS*L,1[(27A4"\0XK>FQ;ERW&8\G,MQ,
M5=1I1ND!L\\CE:9J9IK&*DPW$_E?T6D5SV,^D\%#9RAG(F%7XI[=JAG'3,>7
M_?.KHUHL)U-,=7C2[7V8RI%,&5;%#K=.NH=;-]W2_*7!VQA\09PE:6K=7\)1
M$AWH44AIQR>7/7;:N[P<W!R?]J_.CVK-FGZ^.3X[<\]O^V?#BZ-:J]G\N<9.
MKF_/>K>ZW<I@6C:AV,OCFT&OX_YX=*F+>LF7[NF](#5#T23B;=?^<>8$V6W]
M#-UL#<^*7][8M\U2"Y%=Q_D!=O9=._YS6YK*+2GB$[$YB@5_ORG#1/JBP^^4
M]-FG+:F[(!RVQ:P+S?U?S]G@]O2H-MG;V7FUMS_9W0G;K<:[:$*:&![5+J_/
MKVO:@@OQ%U9I-]-MZ=I^"U;UU<SWK0P2%;*!@@I#R<Z5\F/I3:W4?!8=X+V$
MI_+PY+9[$ZNQ2!*I0AZP4Q5'*L8O*B13Q:J^DLBM=GM[E_4@ ;J'BMT*'I!T
M QZR,RDFJHY? CE6<2@Y>]5N;3<WMYO-]J=)V?I"*56'';Z^OAKF8#65J=A,
M(NZ)3JCN8PX[V]MM-K9WFYMMB'>X1;V[M)!QA]$O.Z^V&WO[K1;)778$_(\@
M88V-:(QY*HT[1W\M1G'&XP=C%JW=.FLWV]OL$8T^B1C=_FR6A3)].)'8U'[H
M-=@"MCZQI76W=[>;[)]J&K(+%;T'KL#,LSA];*5/,N]:VVVW%I?\).'D:<-"
M*=XLQJ7%N%6.4UT+Z$GZ$ AVQ-9!>FTQ-"#$E?':6:N)_0C(MZ)CXG !M^4N
M\V!?4BV;5R;[TGT]8,NR'?X&\28R20UTLD'*4S&#GS$\O%;Q[,]A8["Y[=!B
MZ[=N3CD*C' (\:R^><E]B18>^NP<X@>TB,XC_KFW9M)4?$BQW3[&Z.S\_(E"
MO!5LRN\$XUXJ?,83YJDL3$10K:2*+:%'G7%V)@)^SV.!GGG\8AOI5+!??FKM
MO#R@+>IW3]4LXN'#X5:_2^JEG_8/7M29#/%>& I/OW8OTRFC5^/RCJJQ;E/C
ML8BU>A(>T"/;X"]8:Z?>?-FN[[5V63*%&,GRW /=OC"U&]4*1JU[![3<V0Q3
M)JGRWM>KE7\T&\UFL\4B'K,['F2"19!!3\0V%M8WT\:']Y86N3%ZP:"BF(=I
MPJ#'*(N]*4_$"N$A57FHY<6\M>,L+H?TLN&],-A$+ZT94"9)QD?07Q:A37P0
ML2<3X;3A1J]6UDW,5FF39J]C91.!M^)B&TU?+5MY]#I;VB+A9;%,Y=(VU4E9
MD!@30W$K-NSI?)]MO);0BWFC6GGDG2O5,'K>WM[>;.^]VFONOZB[4?""-\5V
M)\P77H#U^TS <F'@<*O1@]%+OERMF]X'F$,XT6N;2<T'5WJ0_6W)DK'6.3[Q
MRM*)I3'*RL(*G;86!GR,%*R%NB]"G:%S;QE.YCQ\45EPNY&@3C/NBR73*/6\
M<2YV/(F%,0G21K6RVNI6])]72IWYW"(BQ%J@;SM:W^TZ;2])S^%ND[*QYA[@
M/#].F"15R3%-#A#4'HN$FZ<9UDAQ.Z&V6*2J\5FT\$FB@/A &0&6[:E(&C#Y
M4ST;YQZ3\Z&[=7G3N-I7S6\C&B2*51+!53):/$_U*, B3OB;&GT0["^:]0F]
M>Y._NP2-"4NR*-(!E?;0.F%ILN)GN\VK^7G=[91>W1AHX1=85_+=LEW>9K#D
MG?8.Q0"K/FHRC@^%9(%61[("/JL57WD9207-QPS!5??,]2!#%W+-HF(!#Q*A
M)TP/&=9IZ3/EDY7Y- 36"=,3OC%D7R1>+$?"=_V7-5LHE0UR'7T<]B]LRC+F
MK]VP1K62TQ DTX45@L.FL5$(_#'7#6DR%M"%;\WF7F!M$)6: W%'.T%]P#*0
M;&-7:?^<T4EMU<A)&$P\I-TSNN!C)&J8.D( @\:^@1/V04,RA!*S?&TE=5J:
M40S"."UP0Y9"/L_P7X"*!XZF5X7465)I85Y7U'4BP@PZ#;$XZLF#H( ?*'=#
MEL:M5D#1R.1I6 NU;NC\[6**)!NA)]DD^L)P-(DD^-##EN7%9J93&*D'..'>
M0UU+!P8&.TMST:BCU--;%<2"]@13&<?1+UEV18@$65-NS<5R26T:)8NIERW)
M3"IBPF(/KI0X'5<KL;B3XE[X!X9=R;N2[(&80+$>!S&PVB8M: 6BG=P,LC78
ML29\% +&H-3P1LP02_1P>C1&EQ269NW/63*B0:A21D84"6U)P0,320H.)Y.I
M<>L[#$DN7I@'[)Y<7G,\10*AUWU,NT+<U@*O\YQY=:IQM8)8+#T*4M1!:;\N
M=[LK0H$-< VD UC;>PK-Y$LEFZ6>A7& <'I9:L2&"D8B;UFV;:T!FH1R$*B-
M@H LXF(=KWI!YLOY6%LW@XP$ENIG4-8<3&):%4]X"!_T3:R.A;&[>QD$VM)3
M&8+G:^'J1/JE3QK_@,CEV EV9Z*43YH,:7HS@)Z6](R!S(.QOC\RF8!#6HLA
M[6=&L0LFE&%W#2PAH7(*EJ1Y#9-$']\A[":^]-Q.E=:F-1T[E-HZZ[\!I-H:
MOZ[T4MX>F=+ /'B)V1)V45.I=C 2<#_1X<$]?TAT??;BE@WZ_P$*;M?<D/J,
MH?/3*_W/0OW<YNRGO:MA[_8S#R">\PAB35WL.0M4CF&PN>+?,RZ1W6!#R0[:
MI$D]5[1FKJ6I6'FN_?D:V+/N"Z#(>*LQ<.-F_K*710I(6<]+$-H/-6X1,V':
MT. K&HE] F=-X BP%6!TPDN\RGAA[L^:@!2 !&*1F3B+ &B%(M*/D0I'Y]H_
MZP0FR^+0R ;RW()\8#40_($&T@'?X1S\6S_/16^->@);PO.8 7A*A";+H%XV
MZ&$,/D&R.DT 8X&Z-_1+HQEA#<T[DAJ\;'::LTH5SDGQ#8@/,4<;NW0NF(W>
M:0&5X]YBHDCP/S*J[%+0-@1:;U-4D() @H>42()^.XMU."O_1LI36>H4A3!$
M>:;!7QB@I844C9;*<<6Z]OYO2\?=Y;,X=V;Y:%VYU?C^ZLG#HFBUP"*<SQ?Y
M8RFWA]& >.O:FJ45UJE7])YP(I_52L0?=,*I_8X2$G@NF#"H*J<4+L^C %TS
MP[+#G-)"]!!&3&1%@"WS4E;[)[FYALV1R'F-$;D.OPCP%'%IQ ]5"&^B;&D4
M" ,!CU?#?SC"YSM"^SMU!%>N_?Y<X6,-'0X"UIXBO3 &/Q?WRJ%_/IM!C*6$
MTQ.Z4&[%G!-]M8 @ZUI$DR_^<)KG=)KM[]MIGC>*5"O.*)WK6 /.SW.B6+HZ
MX,<Z5'XZ8W:D(-A:_*<.&%^CAFWY,83+BWL\<3S2)=FD?%/B*&?7M@FDSU9\
M!=("9.NEU)S]AHP16Z,+V;KQ>":@=IZ3S7,1TDO52NEJ#[OD]SF$I3HW&!=G
MJ-H*$A4(LI5<U!R(<SPC_/HT1%NH*Q1SD\I^5_'[;T#TKTM55UWLH;UPV0XL
MS51(;!&FGB]3IU E@$9'FPJ8NG:J.DMK^0&UGP^U&_S%]X>UY01.SB*5&) <
M\?!]G$4I59.A#A7<B9#^1FI;*B0@5R2/FEBN,(YY!GC6% 3-R9@2]1DY++ Z
MFR%[1QJH\2#!K &/C2?%@LYNJ/JH*,'GYI375B/UK37M;1[P6V*DA(KNA ?!
MP\$:@/R163Z-P8Z^0X.U!@%;(;B<A7GEPIYZA&DL1YD]Y=%W"&;\@5(U;>G&
MNGD4!7B+0"^@,!(S*CJEN@$1/_1D% A#/ZD(_,/$GL_$O._0Q#0#--4\X(Y%
MFY)A4*LV& V.[NR$V""5OPI$)6ND&J-^P9U8T5MT),834#T8')W/U<TYR)@3
MH20SQE\Q6"MZNU,14YU-$JGO'(7\C@- 1S*PAV9TM$&>X(JRFI]JPOHN"\VA
MAS[+&B]4].C= F+!;44@XOR <,)C/[#GA^#4!KKU6:JC#48 :2@5#"0VYX6<
M;@5X0FC%X-EH2P< T!/XW#IJ^S5OR_0AIX^0X@Z$U])<MW1NSOSH'"W6I4Y:
M\5HBJ&.9([Q4Q-8OK:*\]RH+?#:A37)%9$-8O:FB]*,\*.$5='LGZ?*!34G*
MW+9!][7HY@2%\J4S>73.*]JLO>JH4+">RWUN=.ZSH6\XC,LGP6ZN%Z8Z0.>J
MP%?NO\L2>UP-ML]G=-I8K>AJL*NE+UW^*^AU?K7NZU^;HEL2L%P$!K)B45R$
MRMR-/KK=4)@$IPM_YM.:E9?ID*AD<4SCW JZ;?+QM^CV-__E[K^9:S'F-)*/
M"%CTL0D9F3EAJ-OM+Y]<SMU>T0<UZ^\+-7X<<O[5#CE7?.;P-4XZM_]2)YV
M=4"IR1]L8#*53'B/TF#%_1FYKKWB1#!D@8WNK4Q4K".JO7H"\ >0YL @$W-
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M.H95&$)HP>71 <-:]3/V\(\!R&_6MPD(^A:J4#:.Q^,N'- =FINN.(HA9&Z
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M-F5V!'*-"5X5X8)PE1H2OX_R4.@[P]M6RV5R&_7MANV-('H^B,(B?1Q,?T5
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MAZV0Z^B@- _88)^=W!RQ_^R3@-CR-U!+ 0(4 Q0    ( )Q*3U94%A7'3A8
M ,"(   .              "  0    !D-C0T.38X9#AK+FAT;5!+ 0(4 Q0
M   ( )Q*3U9NMR[; Y   ).W @ 1              "  7H6  !D-C0T.38X
M9&5X,3 Q+FAT;5!+ 0(4 Q0    ( )Q*3U;.70$&M7P  #AD @ 0
M      "  :RF  !D-C0T.38X9&5X,3$N:'1M4$L! A0#%     @ G$I/5JU'
M_?KM0   B$$! !               ( !CR,! &0V-#0Y-CAD97@T,2YH=&U0
M2P$"% ,4    " "<2D]6;H!>90P.  "O/@  $               @ &J9 $
M9#8T-#DV.&1E>#4Q+FAT;5!+ 0(4 Q0    ( )Q*3U;!/94@E@\    P   1
M              "  >1R 0!D-C0T.38X9&5X.3DQ+FAT;5!+ 0(4 Q0    (
M )Q*3U;E?IDO0@,  %4+   1              "  :F" 0!I8G)X+3(P,C,P
M,C$U+GAS9%!+ 0(4 Q0    ( )Q*3U9!)SA=7 8  +Y#   5
M  "  1J& 0!I8G)X+3(P,C,P,C$U7VQA8BYX;6Q02P$"% ,4    " "<2D]6
M=QJVC+8$  ""*@  %0              @ &IC $ :6)R>"TR,#(S,#(Q-5]P
<<F4N>&UL4$L%!@     )  D .0(  )*1 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
